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ABSTRACT 
 
Alzheimer’s disease (AD) is a highly complex and rapidly progressive neurodegenerative disorder 
characterized by the systemic collapse of cognitive function and formation of dense amyloid-β (Aβ) 
plaques and neurofibrillary tangles (NFTs). AD pathology is derived from the cholinergic, amyloid and tau 
hypotheses, respectively. Current pharmacotherapy with known anti-cholinesterases, such as Aricept ® and 
Exelon ®, only offer symptomatic relief without any disease-modifying effects (DMEs). It is now clear that 
in order to prevent the rapid progression of AD, new therapeutic treatments should target multiple AD 
pathways as opposed to the traditional “one drug, one target” approach. This research project employed 
medicinal chemistry tools to develop multifunctional small organic molecules against three key targets of 
AD pathology – the cholinesterases (AChE and BuChE), AChE-induced and self-induced Aβ1-40 
aggregation and generation (β-secretase). A chemical library composed of 112 derivatives was generated to 
gather structure-activity relationship (SAR) data. The derivatives were based on a novel, non-fused, 2,4-
disubstituted pyrimidine ring (2,4-DPR) template with substituents at the C-2 and C-4 position varying in 
size, steric and electronic properties. Molecular modeling was utilized to investigate their binding modes 
within the target enzymes and along with the acquired SAR, the chemical library was screened to identify 
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CHAPTER I 
  Introduction   
 
1.1. Background on Alzheimer’s Disease 
Neurodegenerative diseases have a large socioeconomic impact on healthcare costs, patients and 
their care-providers. Alzheimer’s disease (AD) is a rapidly progressive, neurodegenerative disease first 
described by Alois Alzheimer in 1907 [1-3]. Its demoralizing pathophysiology primarily affects elderly 
populations; however, genetic predispositions associated with the apolipoprotein ε4 (Apo ε4) allele are 
linked to its prevalence in middle-aged patients [4,5]. According to the Alzheimer’s Association, the 
epidemiology of AD shows a doubling in the rate of disease development by 2050 with a current patient 
load of 5.4 million in the United States alone. Along with an estimated care cost of $202 billion in 2010, 
these factors collectively build on the unmet need to develop a safe and effective cure to AD [6].  
Ever since the manifestation of Mrs. Auguste Deter’s case in 1901 and the subsequent 
characterization of AD pathology in 1906, various hypotheses outlining its pathogenesis have been 
described [7]. These hypotheses branch off of the common physical and behavioral observations seen in 
AD patients such as cognitive impairment, dense amyloid-β (Aβ) plaques and neurofibrillary tangles 
(NFTs) leading to memory loss, depression, loss of independence and eventually death [6,8]. Although AD 
pathogenesis is mainly described by the cholinergic, Aβ and tau (τ) protein hypotheses, other subsequent 
mechanisms have emerged over the past few years expanding on its complex pathology (Fig. 1). Of those 
mechanisms, pathways generating reactive oxygen species (ROS), neuroinflammatory responses and 
complications of diabetes mellitus (DM) have sparked keen interests in multi-disciplinary areas of AD 
research [1,9-17].  
Most of the current AD pharmacotherapies on the market (Fig. 2) are considered examples of a 
mono-targeted approach, where the end result is mild symptom relief and cognitive improvement, but lack 
an overall disease-modifying effect (DME). Galantamine (Fig. 2) on the other hand, is an example of a 
disease-modifying agent (DMA) as it is a dual cholinesterase inhibitor (ChEI) and an allosteric enhancer of 
nicotinic acetylcholine receptors (nAChR) – collectively improving cholinergic neurotransmission [2,18]. 
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Fig. (1): Outline of AD pathophysiology. 
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A recent study also demonstrated galantamine’s ability to inhibit self-induced aggregation of Aβ-fibrils and 
its respective cytotoxicity [19]. Supported by recent studies, current research efforts are abstaining from the 
“one drug, one target” approach in favour of generating multifunctional candidates in order to attain 
DMAs: a key step in halting the rapid progression of AD [20-24]. 
The thesis presented here is aimed at examining the potential of a novel class of small organic 
molecules, based on a 2,4-disubstituted pyrimidine ring (2,4-DPR) template, to act as DMAs for the 
treatment of AD: primarily evaluating anti-cholinesterase (ChE) and anti-Aβ dual activities. The template 














Fig. (2): Marketed AD pharmacotherapies. 
 
1.2. The Cholinergic Hypothesis 
This is one of the oldest and most studied hypotheses outlining the pathogenesis of AD. The 
hypothesis suggests that impairments in cholinergic neurotransmission, dependent on the neurotransmitter 
acetylcholine (ACh), are to blame for the rapid decline in cognitive ability of AD patients. The cholinergic 
branch of the CNS, primarily allocated within the cerebrum and cerebellum, is associated with cognitive 
function and overall physical awareness. Besides ACh, other key players in the cholinergic hypothesis are 
the ChE enzymes: Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) – ACh degrading 
enzymes [1,3,8]. 
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1.2.1. Cholinergic Neurotransmission 
The cholinergic branches of the nervous system rely on ACh to initiate and transmit a neuronal 
impulse. This neurotransmitter is synthesized by choline acetyltransferase (ChAT) within cholinergic 
neurons by coupling choline and acetyl-CoA using an active site histidine residue [25]. Once released from 
storage vesicles into the synapse, ACh binds to nAChR or muscarinic G-protein coupled receptors 
(mAChR) to initiate a neurotransmission cascade [8,9,26]. Nicotinic receptors are mostly associated with 
the CNS, PNS and neuromuscular junctions, while mAChRs are mostly associated with the PNS but are 
also more widely distributed throughout the body [9]. Degradative ChE enzymes hydrolyze ACh to acetate 
and choline where the latter enters a high affinity re-uptake mechanism to be re-used for ACh synthesis in 
the presynaptic neuron [27].  
With AD, the concentration of ACh is significantly reduced compared to that of non-AD patients 
due to the ChEs’ rapid hydrolysis rate and impairments in ChAT’s activity [26-28]. Without swift 
intervention, AD patients start to encounter difficulties with learning, memory recall and self-care. This 
ultimately leads to the systemic collapse of cognitive function within the CNS. Thus, pharmacotherapy 
targets to improve cognitive function in AD patients would include AChR agonists or ChEIs, where the 
majority of currently marketed therapies are derived from the latter class of agents (Table 1, Fig. 2). 
 
Table (1): Comparison of currently marketed cholinergic pharmacotherapies. 
Therapeutic  
Agent 
























Short half-life and 
moderate side effects 
[2] 




DMA (AChEI + 
nAChR agonist) 




On the other hand, a number of nAChR agonists are enrolled in clinical trials to assess their efficacy 
on improving cognitive function including the FDA-approved treatment for smoking addiction, varenicline 
(Chantex ®) [29,30]. Positive outcomes from those trials would be beneficial considering that the risk of 
developing AD amongst current smokers is higher than that of past and non-smokers [31]. 
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1.2.2. The Cholinesterase (ChE) Enzymes 
Classified as α/β hydrolase enzymes, the ChEs’ primary role is to terminate the stimulatory action of 
ACh in the synapse; however, they are also involved in other cellular functions including cell-adhesion and 
embryonic development [32-35]. The two isoforms (AChE and BuChE) share a high degree of structural 
homology and around 51-54% sequence identity [32]. Once ACh binds within the enzyme catalytic site 
(CT), active site residues rapidly degrade the neurotransmitter to release choline and acetate (Fig. 3).  
 
Fig. (3): ACh hydrolysis by the ChEs. 
 
Due to the dynamic imbalance between the generation and degradation of ACh, the ChE isoforms 
are well-known targets for AD pharmacotherapies as they play a vital role in the pathology of AD. In fact, 
early marketed therapeutic agents against AD (e.g. Tacrine, Cognex ®) were derived from research into 
anti-cholinesterases [2].  
The development of safe and effective ChEIs requires employing the key architectural differences 
and similarities associated with AChE and BuChE leading to their ligand specificity (Fig. 4) [36]. Because 
AChE is primarily synthesized and localized within the cholinergic regions of the CNS, its concentration 
and actions there quickly dissipate after the onset of AD. On the other hand, BuChE is more widely 
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distributed within the body and with disease progression, the ratio of BuChE to AChE increases aiding in 
the transfer of AChE’s degradative duties to the secondary/pseudocholinesterase [37-39]. This shift in the 
ChE ratio with disease progression constitutes the urgency in developing dual ChEIs in an effort to better 








1.2.2.1. Acetylcholinesterase (AChE) 
With ACh as its natural substrate, AChE (EC 3.1.1.7) is widely recognized as the primary ChE 
enzyme, thus main inhibitory target of the cholinergic hypothesis [40,41]. As a serine hydrolase enzyme, 
AChE utilizes the commonly associated CT residues, histidine and serine, with the typical aspartic acid 
residue substituted for a glutamic acid [33,41]. These triad residues work systematically to activate the side 
chain hydroxyl group of serine to initiate the degradation of ACh (Fig. 3). 
This ChE isoform predominately exists in the CNS but is also found on the surface of erythrocytes 
and muscle tissue. Although the enzyme is encoded from a single gene on chromosome 7 in humans, 
Fig. (4): Active site comparison between hAChE (PDB:1B41) and hBuChE (PDB:1P0I). Green: CT; Red: Acyl pocket; Blue: 
Hydrophobic stabilizing residues; Yellow: gorge entry (PAS – AChE).	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alternative mRNA splicing yields a variety of physiological forms ranging from monomers to sets of 
tetramers [41,42]. The more prominent form within the CNS is the amphiphilic membrane-bound tetramer 
[32]. The molecular architecture of AChE is unique in that its active site is located at the bottom of a 20 Å 
gorge with a secondary “back-door” channel believed to aid in the displacement of water molecules. The 
entry to the main gorge resembles a bottleneck, where aromatic residues (like tryptophan and tyrosine) line 
up the entry and contribute to its specificity [42]. Other important features of AChE include: i) the key 
stabilizing aromatic residues (Trp86 and Phe338 – human enzyme numbering) as part of the hydrophobic 
pocket; ii) Phe295 and Phe297 that form the acyl pocket that stabilizes the acetyl end of ACh and iii) 
Gly120, Gly121 and Ala204 that form the oxyanion hole used to stabilize the transition-state intermediate 
[43]. In addition, a peripheral anionic site (PAS) is located near the entry to the active site gorge and it is 
mainly marked with Tyr72, Tyr124 and more importantly, Trp286. Numerous studies implicate the PAS 
with AChE-induced aggregation of the Aβ fibrils, thus creating a highly neurotoxic AChE-Aβ complex 
[3,9,33, 44-48]. Highlights of human AChE’s key features are presented in (Fig. 4, left panel). 
 
1.2.2.2. Butyrylcholinesterase (BuChE) 
This secondary/pseudocholinesterase (BuChE, EC 3.1.1.8) is capable of hydrolyzing the cholinergic 
neurotransmitter ACh, although it is not its natural substrate. While it attains similar properties of the 
primary isoform, BuChE is unique in its ability to hydrolyze various types of natural and toxic esters such 
as the recreational alkaloid cocaine [49]. As a serine hydrolase, BuChE utilizes the same CT elements 
found in AChE – serine, histidine and glutamic acid – and follows the same hydrolysis mechanism 
described above (Fig. 3) with varying kinetic parameters based on the concentration of ACh [50]. In 
contrast to AChE’s localization, BuChE is more widely distributed throughout the body and is associated 
with the plasma, liver and various components of the nervous system [36,51]. The pseudocholinesterase is 
encoded from a single gene on chromosome 3 in humans and, as with AChE, variable splicing yields 
different physiological forms ranging from monomers to sets of tetramers [32,52]. In human plasma, the 
most prominent form is the soluble G4 tetramer, while variable dimers and tetramers occur within glial 
cells and the CNS [53].  
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The architecture of BuChE attains certain aspects seen in AChE; however, it is unique in other key 
areas as well. Although the active site gorge is also 20 Å below the enzyme surface, the entry to that gorge 
is far less restrictive as the number of aromatic residues in that region is lower than that found in AChE’s 
gorge entry [51]. The key ligand-stabilizing aromatic residues found in the primary ChE are also present 
here (Trp82 and Phe329); however, smaller residues (Leu286 and Val288) replace Phe288 and Phe290 in 
the acyl pocket accounting for BuChE’s wider substrate pool [54]. Since the gorge of BuChE contains 
fewer aromatic residues at both the entry and the active sites, the overall volume capacity of BuChE is 
approximately 200 Å3 larger than that of AChE [55]. Another key feature of BuChE is the lack of a PAS at 
its gorge entry – Nonetheless, various studies suggested its association with neurotoxic aggregates in the 
brain via an undetermined mechanism [50,51]. Highlights of human BuChE’s key features are presented in 
(Fig. 4, right panel). 
 
1.2.3. Summary 
The cholinergic hypothesis is centered around ACh and its perspective neurotransmission cascades. 
Key aspects include the generation and degradation of ACh (ChAT and the ChEs, respectively) and the 
cascade receptors (nAChRs and mAChRs). Of all the hypotheses that describe AD pathogenesis, 
cholinergic dysfunction is the core physiological failure that occurs within the CNS. That said, it has been 
linked to the amyloid hypothesis (discussed next, Section 1.3) and that in itself, strengthens recent 
ideologies that AD is a highly complex neurodegenerative disease that can’t be defined by nor limited to a 
single pathological mechanism. As discussed above, most of the currently marketed pharmacotherapies 
were derived from cholinergic research – specifically, anti-ChEs. Although those agents offer symptomatic 
relief, they lack DMEs to stop and reverse the progression of AD. Current research efforts are attempting to 
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1.3. The Amyloid-β Hypothesis 
Medical complications involving the misfolding and aggregation of amyloid peptides have sparked 
exponential interest over the past few years. Several studies have implicated these insoluble aggregates in 
the direct and indirect pathologies of neurodegenerative diseases, various cancers and organ failures [9,56-
60]. 
With respect to AD, the amyloid-β hypothesis is centered around the pathology of notorious 
amyloid-β aggregates. These insoluble plaques wreak havoc on internal and external cellular mechanisms 
leading to neuronal cell death and corroborating cognitive dysfunction. Key aspects here include the 
amyloid precursor protein (APP), the APP processing secretase enzymes and the aggregation mechanisms 
that produce these neurotoxic proteinaceous Aβ-plaques (Fig. 1).  
 
1.3.1. Amyloid Precursor Protein  
As its name suggests, APP is the precursor substrate to amyloid-β peptides. The APP is a large, 
integral membrane protein (IMP) that is ubiquitously expressed in mammalian cells and concentrated in the 
CNS [61-63]. Although it plays a fundamental role in the amyloid-β hypothesis, various studies report 
putative physiological roles for APP including: i) cell adhesion; ii) metal-ion homeostasis; iii) cell signaling 
and iv) synapse formation, function and elasticity [61,64,65]. A single gene (~ 240 kbps) on chromosome 
21 encodes human APP. Alternative splicing generates various isoforms of APP ranging from 365-770 
amino acids in length. Isoforms encoding the Aβ-peptide are dubbed APP695, APP751 and APP770, where 
the foremost is mainly expressed in neuronal tissues [61].   
The architecture of APP is quite interesting (Fig. 5). Its extracellular domain accounts for the bulk 
(~90%) of this IMP and is comprised of the E1 and E2 domains, where the former contains a conserved 
metal binding motif and a growth factor-like domain. A Kunitz-type serine protease inhibitor (KPI) domain 
divides the E1 and E2 domains but it is only present in the APP751 and APP770 isoforms and two key 
glycosylation sites are located downstream of the E2 domain. With respect to the embedded Aβ-peptide, 
the bulk of its sequence (~70%) is part of extracellular domain with the remaining 30% belonging to the 
transmembrane domain [1,61-63,66,67]. The intracellular domain (AICD) is highly conserved and is 
believed to act as a transcriptional regulator as it is translocated to the nucleus after APP has been 
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processed by the secretase enzymes [68]. The AICD also contains a key Thr668 residue that is susceptible 
to phosphorylation by various kinases that allow for APP to interact with different adaptor proteins and the 
phosphorylation state of this residue also plays an important role in APP localization. Recent studies also 
discovered high levels of phosphorylated Thr668-APP compared to healthy/control groups suggesting a 
role for this residue in AD pathology [61]. 
 
 
Fig. (5): APP architecture and processing. * Numbering based on the APP770 isoform 
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Mutations in the critical regions of the APP gene can potentiate the development of AD by 
increasing the overall production of Aβ-peptides. Some mutations occur within and some occur outside the 
Aβ-peptide sequence. The most studied mutations of the APP gene are the Swedish, Flemish, Dutch, 
Florida and London (Table 2). These mutations don’t include other factors such as Down’s syndrome and 
Presenilin-1 and -2 (PS1, PS2) mutations that are also linked to disrupting the APP processing balance [69].  
 
Table (2): APP mutations leading to the overall increase in Aβ-peptide liberation. 



















Glu693Gln Enhanced  
fibrillogenesis  





Ile716Val Alter γ-secretase 
 cleavage 






Gly or Ile 
Alter γ-secretase 
 cleavage 





1.3.2. APP Metabolism and Processing Pathways 
Although APP is involved in many cellular functions, it exhibits a short half-life and thus, is under a 
constitutive secretory pathway [61]. Its processing is governed by the activity of the secretase enzymes (α-, 
β- and γ-secretases) and interestingly, is influenced by AChRs – a link between the cholinergic and amyloid 
hypotheses. [70]. The proteolytic cleavage of APP can be divided into two main branches based on the 
secretases involved: amyloidogenic and non-amyloidogenic.  
The amyloidogenic pathway is of greater interest with respect to AD pathology as the resulting APP 
products include the Aβ1-40 or Aβ1-42 peptide that constitutes a major role in the amyloid hypothesis. In this 
metabolic pathway, β-secretase or β-site APP cleaving enzyme (BACE) is the primary protease acting on 
APP. The cleavage between Met671 and Asp672 generates a large soluble peptide (sAPPβ) and a 99-amino 
acid C-terminal fragment (CTF99) carrying the Aβ-fragment. γ-secretase cleaves the CTF99 between Ala713 
and Trp714 or Val711 and Ile712 to release the Aβ1-42 or Aβ1-40 peptide, respectively along with the AICD 
[62,71-73] (Fig. 5). In contrast, the non-amyloidogenic pathway is initiated by α-secretase. The cleavage 
between Lys687 and Leu688 generates a larger soluble peptide (sAPPα) with neuroprotective properties and 
an 83-amino acid C-terminal fragment (CTF83) [74,75]. Because α-secretase’s cleavage pattern occurs 
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within the Aβ-fragment, the resulting CTF83 does not carry a complete and functional Aβ-fragment. γ-
secretase cleaves the CTF83 to release a small p3 peptide and the AICD [61-63] (Fig. 5). 
It is noteworthy that both metabolic pathways occur in healthy individuals and that suggests that the 
liberation of Aβ-peptides itself is not an AD characteristic. The non-amyloidogenic branch is the most 
common metabolic pathway but when the amyloidogenic pathway does occur, efficient clearance 
mechanisms are in place to remove the Aβ-peptides [63,76]. In the amyloid hypothesis, AD pathogenesis 
emerges when the balance between the APP metabolism and processing pathways, in addition to the 
generation and clearance of Aβ-peptides, is disrupted resulting in the rapid accumulation of Aβ-peptides 
that aggregate to form insoluble and neurotoxic species in the CNS.  
 
1.3.3. The Secretase Enzymes 
These are transmembrane protease enzymes involved in the metabolism and processing of APP via 
the amyloidogenic pathway to generate either Aβ1-40 or Aβ1-42 peptides (BACE-1 and γ-secretase metabolic 
pathway) or the non-amyloidogenic pathway to generate a neuroprotective soluble peptide (α- and γ-
secretase metabolic pathway) (Fig. 5). Key features of the secretases will be briefly discussed below.  
As the initiator of the amyloidogenic metabolic pathway of APP, BACE-1 (EC 3.4.23.66) is a key 
pharmacotherapy target in an effort to reduce the overall generation of the pro-Aβ-peptide CTF99. This is a 
membrane bound, aspartic protease where optimal activity is observed in acidic environments – a typical 
protease property [77,78]. Interestingly, two BACE homologues exist sharing ~ 45% sequence identity and 
~ 75% structural homology. The key isoform, BACE-1, is encoded by a single gene on chromosome 11 and 
is mainly expressed in neuronal tissue – more notably the hippocampus, cortex and cerebellum [79]. On the 
other hand the secondary isoform, BACE-2, is mapped on chromosome 21 and, unlike BACE-1, is 
expressed in various tissues but is barely detectable in the brain and recent studies suggest BACE-2 acting 
as an antagonist to BACE-1 or an alternative α-secretase [62,78,80,81]. In terms of its architecture, the 
narrow cleft-like active site is located in the center of the enzyme between the extracellular N-terminal and 
intracellular C-terminal lobes. The active site is sealable with a flexible, 10-residue hairpin loop or ‘flap’ 
with Tyr71 playing a key role in controlling the dynamics and conformations of that flap [82,83]. Upon 
substrate binding, the flap closes down on the active site entry and re-opens to release hydrolysis products; 
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the overall variance in the position of the flap ranges between 5-7 Å [83,84]. The catalytic residues, Asp32 
and Asp228 are part of a large hydrogen-bond network mainly comprised of polar residues (e.g. Thr232, 




Fig. (6): BACE-1 proteolytic mechanism of APP. *Substrate shown reflects the peptide bond between Met671 and Asp672 of APP770 
isoform 
 
In its unbound form, studies suggest that the protonation state of the aspartic acids is di-deprotonated (not 
depicted above), while it maintains a mono-protonated state with a bound substrate; these conformations 
are affected by pH and water networks within the enzyme [82]. Besides the catalytic site, several sub-site 
pockets have been identified and their primary goal is to stabilize and orient incoming substrates. Some of 
these sub-site pockets include: i) S1 and S3 – mainly consist of hydrophobic residues; ii) S2 and S4 – mainly 
consist of hydrophilic residues and iii) S5 to S7 – localize near the insertion helix and are primarily used for 
substrate recognition [84,86]. Highlights of human BACE-1’s key features are presented in (Fig. 7). 
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Fig. (7): Active site of hBACE-1 (PDB:1FKN). Green: Catalytic site; Red: Flap; Purple, Turquoise and Blue: Some hydrophobic and 
hydrophilic residues of the various sub-site pockets in BACE-1; Yellow: Other key residues - part of the hydrogen-bond network. 
  
In contrast, α-secretase is the initiator of the more dominant, non-amyloidogenic pathway of APP. 
Classified as a disintegrin and metalloprotease (ADAM – EC 3.4.24.81), α-secretase isoforms include 
ADAM10 and ADAM17/TACE, with the latter being involved in the processing of a variety of type-1 
membrane glycoproteins such as pro-tumor necrosis factor-α (pro-TNF-α). The more prominent zinc-
metalloprotease isoform, ADAM10, is encoded on chromosome 15 and its activity is regulated through 
constitutive and inducible components, where the latter is under the control of protein kinase C (PKC) 
[62,74,87]. As discussed earlier, the non-amyloidogenic metabolic pathway disrupts the Aβ-fragment and 
generates s-APPα with neurotrophic and neuroprotective properties, which supports the hypothesis that 
over-activation/stimulation of α-secretase should reduce amyloidogenesis [74,75,87] (Fig. 5).  
As the final protease involved in APP processing, the end products of γ-secretase’s activity depends 
on the competition between BACE-1 and α-secretase for the APP substrate and the resulting CTF: 
amyloidogenic CTF99 or non-amyloidogenic CTF83 (Fig. 5).  Compared to the preceding proteases, γ-
secretase is a larger, multi-complex aspartyl protease comprised of PS1, nicastrin, anterior pharynx-
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defective 1 (Aph-1) and PS2 with numerous studies linking certain mutations in the presenilin genes 
(PSEN1 on chromosome 14 and PSEN2 on chromosome 1) to early on-set and familial Alzheimer’s disease 
(FAD) cases [62,69,88]. Similar to α- and β-secretases’ range of substrates, γ-secretase is known to act on a 
wide range of glycoproteins and other substrates, including the Notch protein – a vital component in the 
cell signaling pathway [89-94]. In most cases, γ-secretase generates the Aβ1-40 fragment with the generation 
of the Aβ1-42 being less frequent. However, it is noteworthy that the Aβ1-42 peptide is more hydrophobic and 
is more susceptible to aggregation leading to the insoluble neurotoxic plaques [62]. On the other hand, 
some studies suggest that the AChE-Aβ1-40 complexes are more neurotoxic compared to other aggregates 
[95]. 
 
1.3.4. Aggregation and Toxicity Mechanisms 
As Aβ elimination mechanisms start to deteriorate, Aβ-peptides accumulate in the CNS where their 
neurotoxic properties take affect. Aβ-peptides can take on many forms – oligomers, fibrils and 
aggregates/plaques –, each having a unique biochemical formation mechanism but all start with the 
monomeric Aβ-fragment released by γ-secretase (Fig. 8). Factors implicated in turning monomeric Aβ to 







Fig. (8): Transformation of Aβ-monomers into various soluble and insoluble forms. 
 
The biophysical properties of Aβ allow it to self assemble at high concentrations (µM range) and 
acidic conditions. With disease progression, the transport of Aβ monomers to the lysosome for degradation 
is hindered thus the extracellular concentration of Aβ increases facilitating self-assembly and 
oligomerization [96].  As this patterns continues, these small oligomers grow in size, taking on a cross-β-
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sheet assembly conformation, to generate Aβ-protofilaments and two protofilaments intertwine to form an 
Aβ-fibril. These structures can continue to grow in size, aggregate and form dense, insoluble plaques [97]. 
In connection to the cholinergic hypothesis, numerous studies have demonstrated the role of the PAS of 
AChE in promoting Aβ aggregation. The architecture of the PAS (mainly aromatic residues) is believed to 
provide suitable conditions for monomeric or small oligomeric forms of Aβ to assemble into larger, 
insoluble aggregates [3,9,33, 44-48]. Similarly, metal ions, especially copper (Cu2+), iron (Fe3+) and zinc 
(Zn2+), are known to facilitate the aggregation of Aβ-peptides through the metal-ion coordinating domain at 
the N-terminal end. Three conserved histidine residues (His6, His13 and His14) play an essential role in the 
coordination of the bound metal-ion and it is noteworthy that APP itself has a highly conserved metal-ion 
binding domain at its N-terminal end [98-105]. In its interactions with the above metal species, these Aβ-




The amyloid-β hypothesis is mainly centered around Aβ-peptides. It is evident that the mechanisms 
involved are very complex with numerous factors leading to the disruption in the balance between the 
generation and clearance of Aβ-peptides. Various studies have demonstrated the impact of Aβ-species on 
cellular structure and function; these impacts include the disruption of membrane integrity, transport and 
ion channels and the decrease in cholinergic efficiency, among others.  As mentioned earlier, the 
cholinergic and amyloid hypotheses cross paths with AChE implicated in the facilitation of Aβ aggregates 
as well as AChRs influencing APP processing mechanisms.  
Anti-amyloid strategies are directed at reducing the generation or aggregation of Aβ-peptides – those 
include the development of: i) BACE-1 inhibitors; ii) γ-secretase inhibitors; iii) metal-ion chelators; iv) 
AChE-PAS blockers and v) Aβ anti-bodies. Although, there has yet to be an approved treatment option 
listed under one of the above strategies, a number are undergoing clinical trials to assess safety and 
efficacy. It is noteworthy that developing an agent capable of blocking the generation and/or aggregation of 
Aβ-peptides possesses a DME and along with an anti-cholinesterase profile, a candidate multifunctional 
pharmacotherapy option is within reach. 
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1.4. Other Factors in AD Pathology 
The cholinergic and amyloid hypotheses govern this research project; however, it is important to 
address other key factors in AD pathology. Of those, the pathological mechanism involving tau (τ) is of 
great interest in AD research. Unlike extracellular amyloid plaques, neurofibrillary tangles (NFTs) cause 
significant internal damage to the neuron. Complications involving tau (τ) protein arise when the balance 
between tau (τ) kinases and phosphatases are disrupted resulting in hyperphosphorylation of the tau (τ) 
protein. In such a state, tau (τ) protein dissociates from microtubules, in turn distorting cellular integrity, 
and aggregate to form NFTs. Targeting tau abnormalities is challenging considering its regulatory 
mechanism involves a wide range of protein kinases (including Cdk5 and GSK-3β) and phosphatases that 
are crucial to other biological pathways [107-111]. Secondary hypotheses involve N-methly-D-aspartate 
(NMDA) excitotoxicty, monoamine oxidase (MAO) enzymes and neuroinflammatory pathways (Fig. 1). 
With NMDA excitotoxicty, the elevated levels of glutamate result in over-activation of NMDA receptors 
leading to a large influx of Ca2+ ions and this leads to excitotoxicity and neuronal degeneration [112]. 
Along with the generation of peroxides as part of its oxidation mechanism, recent studies have reported 
elevated levels of MAO activity in AD patients, sparking a potentially new pathological hypothesis for AD. 
Neuroinflammatory responses have been linked with the formation of Aβ-plaques and NFTs and recent 
studies have implicated the COX-1 isoform of the cyclooxygenases, the 12-/15-LOX isoforms of the 
lipooxygenases as well as the pro-inflammatory cytokine TNF-α [113-117]. Interestingly, promising results 
were observed with the long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) – selective 
COX-1 inhibitors – but not with the use of coxibs – selective COX-2 inhibitors –, suggesting the 
localization of those isoforms is important to the pathology of AD [2,113,117]. 
 
1.5. Chapter Conclusion 
It is evident that AD pathology is complex. Numerous factors are involved and the end result is 
systemic collapse of cholinergic neurotransmission along with neuronal cell death, collectively leading to 
dementia symptoms (Fig. 1 and 9). With the majority of current pharmacotherapy options only offering 
symptomatic relief, it is crucial to enroll more candidate agents in clinical trials to assess their safety and 
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CHAPTER II 
  Hypothesis and Design Rationale   
 
2.1. Template Design 
 
Fig. (10): 2,4-DPR template design concept based on key functional groups of marketed pharmacotherapies and other research 
candidates. 
 
The goal of this research project was to develop a novel template that can be used to generate a 
chemical library capable of targeting multiple pathological mechanisms leading to AD. The novel template 
T. Mohamed 2011 
	   20	  
design concept was attained by assessing recent research efforts, current therapeutic agents and molecular 
modeling studies. Key functional groups were identified (red, Fig. 10) and collectively, a 2,4-DPR was 
hypothesized to serve as a suitable template to generate a chemical library capable of targeting the ChEs 
and amyloid-β parameters.  
 
2.2. Target Derivatives 
The basis of the chemical library is based on generating compounds with varying steric and 
electronic properties to assess those impacts on the biological profile of the derivative and aquire SAR data 
(Fig. 11). Examples of such comparisons include evaluating: i) bioisosteres (e.g. piperidine vs. piperazine); 
ii) steric effects (e.g.: iPr vs. nPr); iii) positional isomers (para- vs. meta- vs. ortho) and iv) effect of 
electron-donating and withdrawing groups (EDGs and EWGs; respectively). 
 
 
Fig. (11): Overview of the synthetic routes to target derivatives. 
T. Mohamed 2011 
	   21	  
CHAPTER III 
  Setup and Methodology   
 
3.1. Synthetic Chemistry 
The synthetic routes to target derivatives were relatively simple and efficient, requiring a maximum 
of three steps to achieve the required coupling or modification.  
 
3.1.1. Intermediate Product Synthesis – Step A  
Necessary intermediates were synthesized via a nucleophilic aromatic substitution (NAS) reaction at 
the C-4 position of the ring system as shown in Fig. 12.  
 
 
Fig. (12): NAS mechanism used to generate target intermediates with primary amines at C-4 position. 
The 2,4-dichloropyrimidine starting material (1, Fig. 11) was converted to the 2-chloro-4-
substituted-pyrimidine intermediates (2-15, Fig. 11) in the presence of diisopropylethylamine (DIPEA, a 
base) to activate the respective primary amine used (R1 = benzylamine, 2-, 3-, 4-chloro, 4-bromo, 4-fluoro, 
4-methyl, 4-methoxy, 3,4-dimethoxy, 3,4,5-trimethoxybenzylamines, benzo[d][1,3]dioxol-5-methylamine, 
naphthalen-1ylmethylamine, diphenylmethylamine or phenylethylamine; respectively).  
This reaction (Step A, Fig. 11) was run in ethanol (EtOH) and typically refluxed for 4-5 hrs with 
stirring. The resulting solution is evaporated in vacuo, re-dissolved in ethyl acetate (EtOAc), neutralized 
using 0.5M hydrochloric acid solution and washed with concentrated brine solution (3x15 mL). Collected 
organic fractions were dehydrated using anhydrous magnesium sulfate (MgSO4), filtered and re-evaporated 
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in vacuo to afford a crude solid or semi-solid intermediate. Purification was performed using a differential 
melting point (DMP) technique and/or silica gel column chromatography (SGCC) with a suitable carrier 
solvent (Fig. 13). Intermediate product yields ranged from 55-75% [120-122]. 
 
Fig. (13): Overview of –Step A– setup 
 
3.1.2. Final Product Synthesis – Step B + C  
To obtain the desired final products, intermediates 2-15 were coupled with the respective secondary 
cyclic amines (Step B, R2 = pyrrolidine, morpholine, thiomorpholine, methylpiperazine, methylpiperidine, 
isopropylpiperazine, isopropylpiperidine, propyl-, hydroxyethyl-, methoxyethyl-, cyclohexyl-, acetyl-, Boc- 
piperazine, 4-chloro, 4-bromo, 4-fluoro or 4-trifluoromethylbenzylpiperazine; respectively) or 4-
aminobenzylpiperidine (Step C). These were also NAS reactions that occur at the C-2 position of the ring 
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Fig. (14): NAS mechanism used to generate target products with secondary cyclic amines or 4-aminobenzylpiperidine at C-2 position. 
 
Step B (Fig. 11) was setup in a sealed pressure vial (PV) with butanol (BuOH) as the solvent and 
immersed in an oil bath (150-155 °C) for 1 hr. with stirring. Step C (Fig. 11) was also setup in a sealed PV 
with DIPEA and BuOH as the solvent and immersed in an oil bath (190-195 °C) for 14-16 hrs. with 
stirring. The resulting solutions were evaporated in vacuo, re-dissolved in EtOAc, neutralized using 0.5M 
hydrochloric acid solution (Step C only) and washed with concentrated brine solution (3x15 mL). Collected 
organic fractions were dehydrated using anhydrous MgSO4, filtered and re-evaporated in vacuo to afford a 
crude solid or semi-solid product. Purification was performed using SGCC or high-performance liquid 
chromatography (HPLC) with a suitable carrier solvent to achieve a final compound purity of 95% or 
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Fig. (15): Overview of –Step B/C– setup 
 
3.1.3. Post-Synthesis Modifications – Step D + E + F 
The thiomorpholine ring (grp C, Fig. 11) is susceptible to oxidation by liver cytochrome enzymes. 
Therefore, to replicate this modification, peroxide reagents were used to oxidize grp C to the sulfoxide 
(SO) and sulfone (SO2) analogs (Step D + E) (Fig. 16). The conversion of grp C to grp D was 
accomplished using meta-chloroperoxybenzoic acid (mCPBA) in methanol (MeOH) and the reaction was 
run at room temperature (r.t) for 3 hrs. Conversely, the conversion of grp C to grp E was accomplished 
using potassium peroxymonosulfate (Oxone®) in a MeOH/water/dioxane cocktail and the reaction was 
refluxed for 1 hr. then moved to r.t for 4 hrs. The resulting solutions were diluted with EtOAc and washed 
with concentrated brine solution (3x15 mL). Collected organic fractions were dehydrated using anhydrous 
MgSO4, filtered and re-evaporated in vacuo to afford a crude solid product. Purification was performed 
using SGCC with a suitable carrier solvent to achieve a final compound purity of 95% or higher for 
biological screening. Oxidized analogs were generated with yields of ~ 75% [120-122]. 
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Fig. (16): Oxidation mechanisms used to generate the sulfoxide and sulfone analogs using peroxide reagents. 
 
The t-butoxycarbonyl (Boc) functionality present in grp O (Fig. 11) is susceptible to in vivo 
hydrolysis. Therefore, to replicate this modification, trifluoroacetic acid (TFA) was used to hydrolyze the 
Boc functionality present in grp O to generate the free-piperazine analog (Step F) (Fig. 17). 
 
 
Fig. (17): Hydrolysis mechanisms used to generate free-piperazine analogs using TFA. 
 
The reaction was setup using dichloromethane (DCM) and run at r.t for 2 hrs. The resulting solution was 
evaporated in vacuo with the aid of toluene then re-dissolved in EtOAc and DCM and washed with 
concentrated brine solution (3x15 mL). Collected organic fractions were dehydrated using anhydrous 
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MgSO4, filtered and re-evaporated in vacuo to afford a solid product. Purification was usually not required 
for this hydrolysis reaction and yields were ~ 70-75% [120-122]. 
 
3.2. Biological Assays 
Establishing a biological profile for the synthesized derivatives constitutes a large aspect of this 
research project. Derivative screening was coincident on the following parameters: i) ChEs; ii) AChE-
induced Aβ1-40 aggregation; iii) Self-induced Aβ1-40 aggregation; iv) BACE-1 and v) cell toxicity of select 
derivatives (Fig. 18).  
 
 
Fig. (18): Using SAR data to identify lead/top multifunctional derivatives. 
 
3.2.1. Cholinesterase 
 The ChE screening assay is based on the Ellman method described in 1961 [123]. Thio-analogs of 
ACh (ATCh) and BuCh (BuTCh) are used as enzyme substrates and once degraded by the respective ChE, 
the thiocholine product reacts, non-enzymatically, with a pro-chromophore (dithiobis-(2-nitrobenzoic acid) 
or DTNB) to release 2-nitro-5-thiobenzoic acid (NTB – a yellow chromophore detected at wavelengths of 
405-412 nm). With derivative screening, the ChE inhibition profile is obtained by monitoring the 
generation of NTB – as its concentration increases, the ability of the derivative to inhibit the ChEs 
decreases (Fig. 19).   
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Fig. (19): The ChE biological assay based on the Ellman method.  
 
3.2.2. AChE-induced and Self-induced Aβ1-40 Aggregation 
The Aβ1-40 aggregation screening assay is based on the biophysical properties of Aβ-peptides and the 
significant change in thioflavin T (ThT) fluorescence in the presence of Aβ-oligomers and fibrils 
(excitation-emission from 385-445 nm to 450-482 nm). This is a linear relationship that can be applied to 
quantify self-induced and AChE-induced aggregation of Aβ1-40 monomers. The mechanism involves the 
cross-β-sheets of oligomerizing Aβ-monomers and the ThT conformational changes upon binding to those 
secondary structures [118,124-126]. With derivative screening, the Aβ1-40 aggregation inhibition profile is 
obtained by monitoring the change in relative fluorescence units (RFUs) after a 24 hrs incubation period 
and ThT addition – higher RFUs indicate the inability of the derivative to slow and/or halt the 
oligomerization and fibril-formation process (Fig. 20).   
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Fig. (20): The ThT Aβ-oligomers/fibrils quantification assay.  
 
3.2.3. β-secretase  
The BACE-1 screening assay is based on the fluorescence resonance energy transfer (FRET) 
method developed by PanVera ®. The peptide sequence uses the APP Swedish mutation (Table 2) linked to 
enhanced BACE-1 cleavage and is capped by a fluorescence donor (Rhodamine derivative) and 
fluorescence quencher on either end. Upon cleavage of the labeled peptide, fluorescence is restored and 
detectable at 530-590 nm (excitation-emission). This relationship can be applied to quantify the rate of 
peptide cleavage by BACE-1. With derivative screening, the BACE-1 inhibition profile is obtained by 
monitoring the change in relative fluorescence units (RFUs) – higher RFUs indicate the inability of the 
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Fig. (21): PanVera® BACE-1 FRET assay.  
 
3.2.4. Cell Viability 
The cell viability screening assay is based on the MTT assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT reagent). This yellow tetrazole is reduced by the mitochondrial 
reductase enzymes of metabolically active cells to a purple formazan whose absorbance is detected 
between 500-600 nm [127]. This relationship can be applied to quantify the cytotoxic effects of a test 
sample. With derivative screening, the toxicity profile is obtained by monitoring the absorbance at 570 nm 
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CHAPTER IV 
  Results and Discussion   
 
4.1. Structure-Activity Relationship (SAR) Studies 
Obtaining SAR data is an essential component of medicinal chemistry research. On the 2,4-DPR 
template, SAR studies investigate the role of the substituents at the C-2 and C-4 positions in mediating each 
derivative’s biological profile (Fig. 23). The breakdown of the synthesized small molecule chemical library 






Fig. (23): Investigating the role of the substituents at the C-2 and C-4 positions through SAR studies.  
 
 
Table (3): Breakdown of the small molecule chemical library. 
Series Benzylamine and substituted benzylamines 
C-4 group * 2 3 4 5 6 7 8 9 10 11 12 
21 6 6 6 6 6 6 6 6 6 6  
# of derivatives 81 
Series Naphthalen-1-methylamine Diphenylmethylamine Phenylethylamine 
C-4 group * 13 14 15 
# of derivatives 14 11 6 
 
* refer to Fig. 11 (R1) 
 
4.1.1. Anti-cholinesterase Evaluation  
Anti-ChE SAR studies encompass the largest of the biological parameters assessed. This section is 
divided into four main classes: i) benzylamine and substituted benzylamines; ii) naphthalen-1-methyl-
amine; iii) diphenylmethylamine and iv) phenylethylamine series. 
T. Mohamed 2011 
	   32	  
4.1.1.1. Benzylamine and Substituted Benzylamine Series 
The anti-ChE values for series 2–12 derivatives are expressed as the concentration required to 
inhibit 50% of this activity (IC50) a, along with the selectivity index (SI) b, partition coefficient (ClogP) c 
and  molecular volume (M.V - Å3) d in Table 4.  
 









ChE IC50 (µM) Cpd. R’ X R” AChE BuChE SI ClogP MV (Å
3) 
2a n/a n/a n/a 8.70 26.40 0.3 2.97 174.9 
2b n/a O n/a 14.00 68.30 0.2 2.14 183.8 
2c n/a S n/a 23.20 6.10 3.8 2.98 193.5 
2d n/a S O 12.60 > 100 / 1.26 197.9 
2e n/a S O2 24.20 > 100 / 1.18 202.4 
2f n/a N Me 24.90 > 100 / 2.71 199.6 
2g n/a CH Me 18.40 3.40 5.4 4.05 202.4 
2h n/a N iPr 25.00 3.40 7.4 3.54 225.7 
2i n/a CH iPr 14.20 6.50 2.2 4.97 225.7 
2j n/a N nPr 15.30 59.90 0.3 3.76 224.7 
2k n/a N EtOH 26.40 > 100 / 2.13 217.5 
2l n/a N EtOMe 26.70 > 100 / 2.89 232.9 
2m n/a N Cyclohexyl 22.90 7.60 3.0 4.65 252.8 
2n n/a N Ac 16.60 > 100 / 1.73 211.3 
2o n/a N Boc 18.80 > 100 / 4.12 258.6 
2p n/a N H 15.50 > 100 / 2.13 185.6 
2q n/a N p-Cl-Bn 20.20 10.70 1.9 5.14 262.0 
2r n/a N p-Br-Bn 25.50 14.30 1.8 5.29 277.1 
2s n/a N p-F-Bn 21.60 7.30 3.0 4.57 250.7 
2t n/a N p-CF3-Bn 28.80 >100 / 5.31 276.5 
2u n/a n/a n/a 12.40 8.20 1.5 4.60 261.0 
 
3a 2-Cl n/a n/a 14.50 14.30 1.0 3.68 193.8 
3f 2-Cl N Me 17.10 16.70 1.0 3.42 213.3 
3g 2-Cl CH Me 13.20 8.80 1.5 4.75 216.1 
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ChE IC50 (µM) Derv R’ X R” AChE BuChE SI ClogP MV (Å
3) 
3h 2-Cl N iPr 14.60 4.70 3.1 4.26 239.4 
3m 2-Cl N Cyclohexyl 14.00 3.00 4.7 5.24 266.9 
3u 2-Cl n/a n/a 7.70 2.40 3.2 5.32 276.5 
 
4a 3-Cl n/a n/a 15.20 12.80 1.2 3.68 195.2 
4f 3-Cl N Me 16.80 11.30 1.5 3.42 216.4 
4g 3-Cl CH Me 22.80 12.00 1.9 4.75 218.1 
4h 3-Cl N iPr 25.60 5.90 4.3 4.26 241.5 
4m 3-Cl N Cyclohexyl 19.20 3.60 5.3 5.24 271.0 
4u 3-Cl n/a n/a 7.70 2.50 3.1 5.32 271.7 
 
5a 4-Cl n/a n/a 18.90 21.40 0.9 3.68 193.5 
5f 4-Cl N Me 18.80 10.70 1.8 3.42 214.7 
5g 4-Cl CH Me 16.00 9.20 1.7 4.75 218.5 
5h 4-Cl N iPr 25.20 6.70 3.8 4.26 241.5 
5m 4-Cl N Cyclohexyl 20.70 3.00 6.9 5.24 270.5 
5u 4-Cl n/a n/a 8.80 2.80 3.1 5.32 277.8 
 
6a 4-Br n/a n/a 13.70 16.50 0.8 3.83 203.4 
6f 4-Br N Me 14.70 15.50 0.9 3.57 223.3 
6g 4-Br CH Me 10.10 8.10 1.3 4.91 225.7 
6h 4-Br N iPr 29.50 4.70 6.3 4.41 250.4 
6m 4-Br N Cyclohexyl 22.70 3.70 6.1 5.39 277.8 
6u 4-Br n/a n/a 9.90 4.10 2.4 5.48 287.1 
 
7a 4-F n/a n/a 24.50 36.00 0.7 3.11 184.9 
7f 4-F N Me 21.50 25.20 0.9 2.85 203.1 
7g 4-F CH Me 27.30 14.30 1.9 4.18 207.5 
7h 4-F N iPr 33.40 11.80 2.8 3.69 229.5 
7m 4-F N Cyclohexyl 23.20 4.10 5.7 4.67 257.2 
7u 4-F n/a n/a 7.70 2.20 3.5 4.74 263.1 
 
8a 4-Me n/a n/a 18.70 16.40 1.1 3.42 194.5 
8f 4-Me N Me 30.10 25.40 1.2 3.20 213.7 
8g 4-Me CH Me 27.20 12.10 2.2 4.54 214.0 
8h 4-Me N iPr 35.40 10.0 3.5 4.04 233.2 
8m 4-Me N Cyclohexyl 16.80 1.70 9.9 5.03 264.1 
8u 4-Me n/a n/a 12.90 2.50 5.2 5.10 272.7 
 
9a 4-OMe n/a n/a 21.70 24.00 0.9 2.89 198.9 
9f 4-OMe N Me 44.10 92.10 0.5 2.51 220.5 
9g 4-OMe CH Me 21.00 7.10 3.0 3.96 224.0 
9h 4-OMe N iPr 29.70 20.70 1.4 3.34 249.4 
9m 4-OMe N Cyclohexyl 17.70 3.10 5.7 4.45 274.7 
9u 4-OMe n/a n/a 9.40 4.90 1.9 4.52 281.3 
 
10a 3,4-OMe n/a n/a 18.10 71.70 0.3 2.62 217.5 
10f 3,4-OMe N Me 21.50 > 100 / 3.70 240.1 
10g 3,4-OMe CH Me 28.40 7.80 3.6 2.24 242.5 
10h 3,4-OMe N iPr 26.00 11.40 2.3 3.08 266.9 
10m 3,4-OMe N Cyclohexyl 19.80 15.40 1.3 4.19 295.0 
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ChE IC50 (µM) Derv R’ X R” AChE BuChE SI ClogP MV (Å
3) 
10u 3,4-OMe n/a n/a 9.90 11.40 0.9 4.26 240.1 
 
11a 3,4,5-OMe n/a n/a 9.40 > 100 / 2.26 238.0 
11f 3,4,5-OMe N Me 43.10 > 100 / 1.89 262.4 
11g 3,4,5-OMe CH Me 26.70 28.30 0.9 3.35 260.7 
11h 3,4,5-OMe N iPr 28.40 80.20 0.4 2.72 283.3 
11m 3,4,5-OMe N Cyclohexyl 25.90 13.00 2.0 3.83 319.3 
11u 3,4,5-OMe n/a n/a 10.30 7.70 1.3 3.90 319.3 
 
12a [3,4]dioxole n/a n/a 21.80 25.70 0.9 2.93 200.0 
12f [3,4]dioxole N Me 31.10 22.20 1.4 2.67 219.5 
12g [3,4]dioxole CH Me 22.30 6.90 3.2 4.01 222.6 
12h [3,4]dioxole N iPr 17.80 7.80 2.3 3.51 247.0 
12m [3,4]dioxole N Cyclohexyl 16.30 7.30 2.2 4.61 275.4 
12u [3,4]dioxole n/a n/a 12.60 3.90 3.2 4.57 280.9 
 
Donepezil – Aricept ® (Fig.1) 0.03 3.60 0.009 4.60 271.0 
Galantamine – Reminyl ® (Fig. 1) 3.20 12.60 0.3 1.00 179.2 
 
a The result (IC50) is the mean of two separate experiments (n = 4) and the deviation from the mean is < 10% of the mean value. b SI = 
hAChE IC50/BuChE IC50. c ClogP was determined using ChemDraw Ultra 12.0. CambridgeSoft Company. d MV was calculated after a 
minimization protocol using the molecular properties calculator in the Discovery Studio program from Accelrys Inc (San Diego, CA). 
 
This class of derivatives offered a wide range of anti-ChE activity ranging from 7.70 to 44.10 µM 
(AChE) and 1.70 to >100 µM (BuChE) (Table 4). The presence of the smaller, 5-membered pyrrolidine 
ring (group a, Fig. 11) generally led to non-selective ChE inhibition, with the exception of 10a and 11a 
whose activity toward BuChE was or near non-existent (BuChE IC50 >100 or 71.70 µM; respectively). Of 
the 11 derivatives featuring this group at the C-2 position, 2a, with the unsubstituted C-4 benzylamine, was 
the most potent AChEI (IC50 = 8.70 µM) while 11a, with the tri-OMe-benzylamine C-4, was a close second 
(IC50 = 9.40 µM). In contrast, BuChE inhibition was directed by more hydrophobic C-4 substituted 
benzylamines like 3a (2-Cl, IC50 = 14.30 µM) and 4a (3-Cl, IC50 = 12.80 µM). Interestingly, the 4-Cl 
substituted C-4 benzylamine derivative (5a, IC50 = 21.40 µM) was ~ 1.6-fold less potent compared to its 
regioisomers. It is also noteworthy that the 4-F substituted C-4 benzylamine derivative (7a, BuChE IC50 = 
36.00 µM) exhibited anti-BuChE activity similar to moderately hydrophilic C-4 derivatives (9 and 12a) and 
was a less potent BuChEI when compared to other halogen-substituted bioisosteres (3-6a).  
The effects of increasing the ring size at the C-2 position were investigated by using piperazine-
based substituents. Starting with alkyl piperazines, the smaller Me-piperazine substituent (group f, Fig. 11) 
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generally led to non-selective ChE inhibition, with the exception of the unsubstituted benzylamine 
derivative (2f) and the OMe-substituted derivatives 9f and 11f whose activities toward BuChE were non-
existent (BuChE IC50 ~ 92 to >100 µM). The common factor leading to this observation is likely the 
hydrophilic properties of these derivatives, leading to the suggestion that more hydrophobic substituents are 
required to target BuChE. In terms of AChE inhibition, the C-4 halogen-based benzylamine derivatives (3f-
7f) exhibited activity in the range of ~ 15 to 22 µM, compared to the more hydrophilic C-4 substituted 
derivatives (8f, 9f, 11f and 12f; ~ 30 to 45 µM). Interestingly, the di-OMe-benzylamine derivative (10f) 
exhibited similar activity to the 4-F substituted C-4 benzylamine derivative (7f, AChE IC50 = 21.50 µM) 
and the unsubstituted benzylamine derivative (2f) exhibited intermediate activity (AChE IC50 = 24.90 µM). 
The bioisosteric Me-piperidine substituent (group g, Fig. 11) showcased a more unanimous inhibitory 
pattern. Due to its hydrophobic properties, derivatives with that C-2 group tend to be selective BuChEIs as 
seen with all the derivatives here (2g-10g and 12g) with the exception of 11g (AChE IC50 = 26.70 µM, 
BuChE IC50 = 28.30 µM) that exhibited a non-selective inhibitory profile. Of those derivatives, 2g was the 
most potent (BuChE IC50 = 3.40 µM) while the others exhibited anti-BuChE activity within the range of ~ 
7 to 14 µM and the anti-AChE range (~ 10 to 28 µM) is not far from that of the Me-piperazine substituent. 
With the larger/branched iPr-piperazine (group h, Fig. 11), selective BuChE inhibition was observed with 
all the derivatives except for 9h (AChE IC50 = 29.70 µM, BuChE IC50 = 20.70 µM), showing non-selective 
inhibiton, and 11h (AChE IC50 = 28.40 µM, BuChE IC50 = 80.20 µM) exhibiting selective AChEI with near 
loss of BuChEI. Interestingly, derivative 2h demonstrated equipotent anti-BuChE activity to 2g (IC50 = 
3.40 µM). The halogen-based derivatives (3h-7h) were in second place in terms of BuChE inhibition (IC50 
ranges from ~ 5 to 12 µM). With the bioisosteric iPr-piperidine substituent (group i, Fig. 11), 2i exhibited 
an ~ 1.8-fold increase in AChEI and decrease in BuChEI (IC50 = 14.20 and 6.50 µM; respectively). The less 
sterically hindered, nPr-piperazine isomer in 2j exhibited an ~ 1.6-fold increase in AChE potency compared 
to 2f and 2h; however, it demonstrated weak BuChEI compared to its branched isomer (AChE IC50 = 15.30 
µM, BuChE IC50 = 59.90 µM). This observation suggests the requirement for hydrophobic and 
branched/hindered substituents to target BuChE and additional support to that observation is seen with the 
derivatives featuring the cyclohexylpiperazine C-2 substituent (group m, Fig. 11). Derivative 8m exhibited 
superior BuChEI (AChE IC50 = 16.80 µM, BuChE IC50 = 1.70 µM), while the other derivatives ranged 
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from ~ 3 to 15 µM and considering the size and hydrophobic properties of group m, AChE activity ranges 
from ~ 14 to 23 µM. 
With alkoxyl piperazines, the lack of steric hindrance and presence of polar moieties led to a 
complete loss of BuChEI regardless of the substituent (group k with a terminal OH or l with a terminal 
OMe). These derivatives (2k and 2l) also exhibited an ~ 1.7-fold decrease in AChEI (IC50 ~ 26 µM) 
compared to the hydrophobic nPr substituent in 2j. A similar pattern was observed with carbonyl-based 
piperazines where the presence of an Ac-piperazine (group n) or a Boc-piperazine (group o) substituent at 
C-2 also led to a complete loss of BuChEI regardless of varying sterics. These derivatives (2n and 2o) 
exhibited better (~ 1.6-fold) anti-AChE activity (IC50 = 16.60 and 18.80 µM; respectively) compared to 2k 
and 2l. The potential in vivo hydrolysis of 2o to generate 2p had no significant effect on the anti-ChE 
profile, which is surprising considering the 28% reduction in molecular volume and the overall variances in 
steric and electronic properties. 
When a morpholine substituent (group b) is attached at C-2, derivative (2b) demonstrated moderate 
anti-AChE and weak anti-BuChE activity (IC50 = 14.00 and 68.30 µM). Interestingly, the thiomorpholine 
bioisostere (group c) had the opposite effect suggesting that the small differences between oxygen and 
sulfur atoms greatly influence anti-ChE activity (2c, AChE IC50 = 23.20 µM, BuChE IC50 = 6.10 µM). The 
potential in vivo oxidation of 2c to generate 2d (sulfoxide) or 2e (sulfone) had significant effects on the 
anti-BuChE profile (IC50 > 100 µM), which correlates to the hypothesis that polar groups are not suitable to 
target BuChE. 
Larger benzylpiperazine substituents (groups q-t) were investigated in an attempt to selectively 
target BuChE. Those attempts proved successful for derivatives 2q-s as they selectively inhibited BuChE 
(IC50 ranges from ~ 7 to 11 µM) with moderate anti-AChE activity (IC50 ranges from ~ 20 to 26 µM). The 
trifluoromethyl group in 2t didn’t generate anti-BuChE activity and its AChE IC50 is inline with its 
bioisosteric derivatives. These observations denote the role of electronegativity in dictating anti-ChE 
activity. When the benzylpiperidine pharmacophore of donepezil (group u) is incorporated in a diamine 
template, dual anti-ChE activity is observed which can be attributed to the secondary amine found at C-2 
that offers a degree of flexibility not present in derivatives 2q-t. When compared to the unsubstituted 
benzylamine derivative (2u, AChE IC50 = 12.40 µM, BuChE IC50 = 8.20 µM), the majority of the 
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substituted derivatives enhanced BuChE inhibition (IC50 ranges from ~ 2 to 5 µM) except for 10u offering 
non-selective inhibition (AChE IC50 = 9.90 µM, BuChE IC50 = 11.40 µM) and 11u offering near equipotent 
activity (AChE IC50 = 10.40 µM, BuChE IC50 = 7.70 µM). In terms of AChE inhibition, most exhibited 
slight improvements (IC50 ranges from ~ 8 to 10 µM) while 8u and 12u offered equipotent activities 
compared to 2u (IC50 = 12.90 and 12.60 µM; respectively). 
The anti-ChE SAR data for derivatives 2-12a, f, g, h, m and u are graphically summarized below 
(Fig. 24 – Panel A + B) by examining each C-2 group independently and comparing the activity across the 
11 C-4 groups. 
 














PANEL (A) – AChE Inhibitory SAR 
Unsubstituted 2-Cl 3-Cl 4-Cl 4-Br 4-F 4-Me 4-OMe 3,4-OMe 3,4,5-OMe [3,4]dioxole 
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Fig. (24): Graphical summarization of anti-ChE SAR data from the benzylamine and related benzylamine series of derivatives. Panel 
(A): Anti-AChE; Panel (B): Anti-BuChE 
 
Amongst the derivatives of these series, lead candidates were identified as follows: i) 11a (AChE 
IC50 = 9.40 µM, BuChE IC50 > 100 µM) as the most potent, fully selective AChEI; ii) 7u (AChE IC50 = 
7.70 µM, BuChE IC50 = 2.20 µM) as the most potent, dual ChEI and iii) 8m (AChE IC50 = 16.80 µM, 
BuChE IC50 = 1.70 µM) as the most potent, selective BuChEI (Fig. 25).  
 














PANEL (B) – BuChE Inhibitory SAR 
Unsubstituted 2-Cl 3-Cl 4-Cl 4-Br 4-F 4-Me 4-OMe 3,4-OMe 3,4,5-OMe [3,4]dioxole 
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Fig. (25): Top candidates from the benzylamine and substituted benzylamine class of derivatives. 
 
4.1.1.2. Naphthalen-1-ylmethylamine Series 
The anti-ChE values for series 13 derivatives are expressed as IC50 a, along with the selectivity index 
(SI) b, partition coefficient (ClogP) c and molecular volume (M.V - Å3) d in Table 5. These derivatives were 
compared to the original, unsubstituted benzylamine series of derivatives to assess the impact of this planar, 
bulkier C-4 group (noted as Cprd).  
This class of derivatives offered a wide range of anti-ChE activity ranging from 5.80 to 50.80 µM 
(AChE) and 2.20 to >100 µM (BuChE) (Table 5). 
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ChE IC50 (µM) Cpd. X R” AChE BuChE SI ClogP MV (Å
3) Cprd. to 2x 
13a n/a n/a 5.80 8.90 0.7 4.14 210.6 √ both ChEs 
13b O n/a 14.70 28.00 0.5 3.32 218.5 √ BuChE  
13c S n/a 12.80 34.70 0.4 4.15 227.4 √ AChE 
13f N Me 17.50 2.60 6.7 3.88 229.8 √ both ChEs 
13g CH Me 25.80 2.20 11.7 5.22 231.9 √ BuChE 
13h N iPr 15.80 7.60 2.1 4.70 255.1 √ AChE 
13i CH iPr 16.70 9.10 1.8 6.20 257.8 not imprvt. 
13j N nPr 19.00 18.10 1.1 4.91 256.2 √ BuChE 
13k N EtOH 9.80 17.90 0.5 3.28 247.1 √ both ChEs 
13l N EtOMe 11.70 26.50 0.4 4.11 260.2 √ both ChEs 
13m N Cyclohexyl 8.00 3.90 2.1 5.76 284.0 √ both ChEs 
13n N Ac 13.80 32.90 0.4 2.89 244.1 √ both ChEs 
13o N Boc 50.80 >100 / 5.31 292.7 not imprvt. 
13p N H 17.50 25.40 0.7 3.30 216.2 √ BuChE 
 
Donepezil – Aricept ® 0.03 3.60 0.009 4.60 271.0 – 
Galantamine – Reminyl ®  3.20 12.60 0.3 1.00 179.2 – 
 
a The result (IC50) is the mean of two separate experiments (n = 4) and the deviation from the mean is < 10% of the mean value. b SI = 
hAChE IC50/BuChE IC50. c ClogP was determined using ChemDraw Ultra 12.0. CambridgeSoft Company. d MV was calculated after a 
minimization protocol using the molecular properties calculator in the Discovery Studio program from Accelrys Inc (San Diego, CA). 
 
The presence of the smaller, 5-membered pyrrolidine ring (group a, Fig. 11) led to enhanced dual ChE 
inhibition, with the slight selectivity toward AChE (AChE IC50 = 5.80 µM, BuChE IC50 = 8.90 µM). The 
unsubstituted, polar 6-membered morpholine and thiomorpholine C-2 rings (group b and c, Fig. 11) 
exhibited improvements to the anti-BuChE (13b – AChE IC50 = 14.70 µM, BuChE IC50 = 28.00 µM) and 
anti-AChE (13c – AChE IC50 = 12.80 µM, BuChE IC50 = 34.70 µM) profiles, respectively. The Me-
piperazine, along with the piperidine bioisostere, derivatives were identified as near equipotent BuChEIs 
(BuChE IC50 = 2.60 and 2.20 µM; respectively) and 13f also exhibited slight improvements to AChE 
inhibition (AChE IC50 = 17.50 µM). The iPr bioisosteres and the nPr isomeric derivatives (13h, 13i and 
13j) exhibited similar anti-AChE activities (IC50 ranges from ~ 16 to 19 µM) and BuChE inhibition 
decreased sequentially from 7.60 µM to 18.10 µM. Derivative 13m (with the bulkier cyclohexylpiperazine 
group) exhibited potent, dual ChE inhibition (AChE IC50 = 8.00 µM, BuChE IC50 = 3.90 µM) surpassing 
that of 2m. The alkoxyl piperazine derivatives exhibited improvements to the anti-ChE profiles (13k – 
AChE IC50 = 9.80 µM, BuChE IC50 = 17.90 µM and 13l – AChE IC50 = 11.70 µM, BuChE IC50 = 26.50 
µM) suggesting a key role for the naphthalen-1-ylmethylamine C-4 group in balancing steric and 
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electrostatic properties of the less hindered and more polar C-2 groups. With the carbonyl-based 
piperazines, derivative 13n demonstrated minor improvements to the anti-AChE activity and significant 
improvements to the anti-BuChE activity (AChE IC50 = 13.80 µM, BuChE IC50 = 32.90 µM), while 13o 
didn’t showcase a similar patter (AChE IC50 = 50.80 µM, BuChE IC50 > 100 µM). Derivative 13p (with the 
free piperazine C-2 group) demonstrated similar anti-AChE activity to 2p but exhibited significant 
improvements to the anti-BuChE activity (AChE IC50 = 17.50 µM, BuChE IC50 = 25.40 µM). 
Overall, 12 of the 14 derivatives in this series exhibited some form of improvement in anti-ChE 
activity. Derivative 13a (AChE IC50 = 5.80 µM, BuChE IC50 = 8.90 µM) was identified as the most potent 
AChEI, 13m (AChE IC50 = 8.00 µM, BuChE IC50 = 3.90 µM) as the most potent dual ChEI and 13g (AChE 
IC50 = 25.80 µM, BuChE IC50 = 2.20 µM) as the most potent BuChEI (Fig. 26). This suggests that the 
bulkiness and hydrophobicity of this C-4 group is a key balancing factor and that is observed with both 
polar and non-polar C-2 groups.  
 
 
Fig. (26): Top candidates from the naphthalen-1ylmethylamine class of derivatives. 
 
4.1.1.3. Diphenylmethylamine Series 
The anti-ChE values for series 14 derivatives are expressed IC50 a, along with the selectivity index 
(SI) b, partition coefficient (ClogP) c and molecular volume (M.V - Å3) d in Table 6. These derivatives were 
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also compared to the original, unsubstituted benzylamine series of derivatives to assess the impact of this 
sterically hindered C-4 group (noted as Cprd).  
This class of derivatives offered a wide range of anti-ChE activity ranging from 10.00 to >100 µM 
(AChE) and 7.60 to >100 µM (BuChE) (Table 5). The Me-piperazine derivative (14f – AChE IC50 = 13.70 
µM, BuChE IC50 = 23.80 µM) enhanced BuChE inhibition compared to 2f but it was also 9-fold less potent 
compared to 13f. In terms of AChE, it exhibited better activity compared to 2f and 13f. The bioisosteric 
derivative (14g) exhibited moderate, non-selective ChE inhibition (AChE IC50 = 32.30 µM, BuChE IC50 = 
33.80 µM); however, it was far less potent compared to 2g and 13g. 
In contrast to the benzylamine and naphthalen-1-ylmethlyamine series, the iPr bioisosteric 
derivatives (14h and 14i) exhibited a significant degree of variance in their anti-ChE activity profiles. 
Although 14h exhibited selectivity toward BuChE (IC50 = 9.70 µM), it was ~ 2.9-fold less potent than 2h 
but it also exhibited slight improvements to AChE inhibition (IC50 = 20.30 µM). On the other hand, 14i 
exhibited weak anti-AChE activity (IC50 = 42.50 µM) and a near loss of BuChE inhibition (IC50 = 87.00 
µM) compared to 2i, 13i and 14h. Interestingly, 14m offered good, non-selective ChE inhibitory activity 
similar to that of 13m (AChE IC50 = 10.00 µM, BuChE IC50 = 7.60 µM) and its BuChE activity was near 
equipotent to that of 2m. A similar pattern emerged with 14j (with the nPr isomer) where its AChE 
inhibitory profile (IC50 = 14.60 µM) was similar to that of 2j and the BuChE inhibitory profile (IC50 = 
17.50 µM) was close to that of 13j. With the alkoxyl piperazines, the derivatives in this series (14k and 14l) 
were less potent compared to their C-4 naphthyl analogs but they did improve BuChEI when compared to 
2k and 2l. With the hydroxyethylpiperazine, derivative 14k (AChE IC50 = 21.60 µM, BuChE IC50 = 59.50 
µM) only improved BuChEI compared to 2k but it was ~ 3.3-fold less potent compared to 13k. In contrast, 
the methoxyethylpiperazine derivative (14l – AChE IC50 = 39.20 µM, BuChE IC50 = 28.40 µM) exhibited 
similar anti-BuChE activity similar to that of 13l but it was also the least potent AChEI compared to 2l and 
13l. The carbonyl-based and free piperazine group derivatives (14n-p) exhibited a complete loss of BuChE 
inhibition (IC50 >100 µM) and their anti-AChE activities (IC50 = 29.00, >100 and 31.30 µM; respectively) 
were also less potent compared to their benzylamine and naphthalen-1-ylmethylamine analogs. 
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ChE IC50 (µM) Cpd. X R” AChE BuChE SI ClogP MV (Å
3) Cprd. to 2x 
14f N Me 13.70 23.80 0.6 4.11 247.8 √ both ChEs 
14g CH Me 32.20 33.80 0.9 5.40 251.1 not imprvt. 
14h N iPr 20.30 9.70 2.1 4.92 279.2 √ AChE 
14i CH iPr 42.50 87.00 0.5 6.33 282.0 not imprvt. 
14j N nPr 14.60 17.50 0.8 5.09 271.8 √ BuChE 
14k N EtOH 21.60 59.50 0.4 3.47 264.9 √ both ChEs 
14l N EtOMe 39.20 28.40 1.4 4.23 285.0 √ BuChE 
14m N Cyclohexyl 10.00 7.60 1.3 6.01 303.2 √ AChE 
14n N Ac 29.00 > 100 / 3.13 260.1 not imprvt. 
14o N Boc >100 > 100 / 5.51 260.2 not imprvt. 
14p N H 31.30 > 100 / 3.52 235.3 not imprvt. 
 
Donepezil – Aricept ® 0.03 3.60 0.009 4.60 271.0 – 
Galantamine – Reminyl ®  3.20 12.60 0.3 1.00 179.2 – 
 
a The result (IC50) is the mean of two separate experiments (n = 4) and the deviation from the mean is < 10% of the mean value. b SI = 
hAChE IC50/BuChE IC50. c ClogP was determined using ChemDraw Ultra 12.0. CambridgeSoft Company. d MV was calculated after a 
minimization protocol using the molecular properties calculator in the Discovery Studio program from Accelrys Inc (San Diego, CA). 
 
Overall, 6 of the 11 derivatives here offered moderate anti-ChE activity improvements compared to 
the unsubstituted benzylamine series. Also, variances were observed when comparing these derivatives 
with those from the naphthalen-1ylmethylamine series, indicating a key role in the steric differences 
between the linear/planar naphthyl ring system and the bulkier/branched diphenyl ring systems. From this 
series, derivative 14m was identified as the most potent, dual ChEI with an IC50 value of 10.00 µM for 
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Fig. (27): Top candidate from the diphenylmethylamine class of derivatives. 
 
4.1.1.4. Phenylethylamine Series 
The anti-ChE values for series 15 derivatives are expressed as inhibition concentration 50 (IC50) a, 
along with the selectivity index (SI) b, partition coefficient (ClogP) c and molecular volume (M.V - Å3) d in 
Table 7. These derivatives were also compared to the unsubstituted benzylamine series of derivatives to 
assess the impact of the additional methylene (-CH2-) group on the anti-ChE activities. 
This was the least comprehensive series considering the preliminary results were not promising. 
Overall, anti-AChE activity (IC50) ranges from 8.80 to 26.40 µM and anti-BuChE activity (IC50) ranges 
from 13.80 to >100 µM. The presence of the smaller, 5-membered pyrrolidine ring (group a, Fig. 11) led to 
dual ChE inhibition, with the slight selectivity toward AChE (15a – AChE IC50 = 9.80 µM, BuChE IC50 = 
13.80 µM) and an improvement to BuChE inhibition compared to 2a. The unsubstituted, 6-membered 
morpholine and thiomorpholine C-2 rings (group b and c, Fig. 11) exhibited no improvements to the anti-
ChE activities (15b – AChE IC50 = 19.70 µM, BuChE IC50 >100 µM; 15c – AChE IC50 = 26.40 µM, 
BuChE IC50 >100 µM) compared to their benzylamine counterparts. The Me-piperazine derivative (15f) 
demonstrated slight improvements to the anti-AChE activity profile and a complete loss of BuChE 
inhibition (AChE IC50 = 20.40 µM, BuChE IC50 >100 µM). The piperidine bioisosteric derivative (15g) 
was identified as a selective AChEI (with improved activity compared to 2g) but suffered (~ 5-fold) in 
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terms of BuChE inhibition (AChE IC50 = 8.80 µM, BuChE IC50 = 17.70 µM). With the Ac-piperazine 
derivative (15n), a minor decline in the anti-AChE activity was observed with no changes to the anti-
BuChE activity (AChE IC50 = 19.90 µM, BuChE IC50 >100 µM). 
Overall, this series was not pursued further as the majority of the synthesized derivatives exhibited 
no BuChE inhibition. 
 








ChE IC50 (µM) Derv X R” AChE BuChE SI ClogP MV (Å
3) Cprd. to 2x 
15a n/a n/a 9.80 13.80 0.7 3.62 190.7 √ BuChE 
15b O n/a 19.70 > 100 / 2.79 193.8 n/a 
15c S n/a 26.40 > 100 / 3.63 206.5 n/a 
15f N Me 20.40 > 100 / 3.35 211.3 √ AChE 
15g CH Me 8.80 17.70 0.5 4.69 214.4 √ AChE 
15n N Ac 19.90 > 100 / 2.37 220.9 n/a 
 
Donepezil – Aricept ® 0.03 3.60 0.009 4.60 271.0 – 
Galantamine – Reminyl ®  3.20 12.60 0.3 1.00 179.2 – 
 
a The result (IC50) is the mean of two separate experiments (n = 4) and the deviation from the mean is < 10% of the mean value. b SI = 
hAChE IC50/BuChE IC50. c ClogP was determined using ChemDraw Ultra 12.0. CambridgeSoft Company. d MV was calculated after a 
minimization protocol using the molecular properties calculator in the Discovery Studio program from Accelrys Inc (San Diego, CA). 
 
4.1.1.5. Summary 
The anti-ChE SAR studies examined a chemical library comprised of 112 2,4-DPR derivatives with 
varying steric and electronic properties at both the C-4 and C-2 positions of the pyrimidine ring.  
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Table (8): Recap chart of the anti-ChE IC50 values (Red: AChE, Blue: BuChE). 
 
Table 8 summarizes all the anti-ChE IC50 values and the derivatives are graphically classified based on: i) 
their anti-ChE profile – selective AChEI (18), selective BuChEI (0), dual ChEI (86), and non-selective 
ChEI (18) – in Fig. 28a and ii) their IC50 ranges in Fig. 28b. 
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Fig. (28a): Derivative classification based on their anti-ChE activity profile allocated within one of the following categories: selective, 
non-selective, dual ChEI. 
 
 






Derivative Classification – Anti-ChE Profile 









0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
AChE  
BuChE  
Derivative Classification – IC50 Breakdown 
1–15 µM 16 – 30 µM 31 – 45 µM 46 – >100 µM 
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4.1.2. Anti-AChE-induced and Anti-Self-induced Aβ1-40 Aggregation 
Due to cost constraints, it was not feasible to screen all the derivatives for anti-Aβ1-40 aggregation 
properties. The selection process was dependent on the anti-ChE profiles and preliminary ligand-docking 
studies in hAChE. The SAR data (% inhibition) a of select derivatives is presented collectively in Table 9, 
along with the SI b value and mode of ChEI. 
 













Inhibition of Aβ1-40 Aggreg. (%) Derv X R” AChE-induced Self-induced SI Mode of ChEI 
2ac n/a n/a Not active n/d / Dual ChEI 
2cc S n/a Not active n/d / Dual ChEI 
2dc S O 56.00 ± 6.30 n/d / Selec. AChEI 
2ec S O2 44.00 ± 11.00 n/d / Selec. AChEI 
2fc N Me 59.00 ± 3.00 n/d / Selec. AChEI 
2oc N Boc 27.00 ± 17.00 n/d / Selec. AChEI 
 
3m N Cyclohexyl Not active 32.00 ± 3.20 / Dual ChEI 
3u n/a n/a Not active 42.20 ± 4.20 / Dual ChEI 
 
4m N Cyclohexyl Not active 39.30 ± 3.90 / Dual ChEI 
4u n/a n/a 27.20 ± 2.70 39.90 ± 4.00 0.70 Dual ChEI 
 
5m N Cyclohexyl Not active 36.30 ± 3.60 / Dual ChEI 
5u n/a n/a Not active 42.60 ± 4.30 / Dual ChEI 
 
6f N Me Not active 22.50 ± 2.30 / Dual ChEI 
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Mode of ChEI 
6m N Cyclohexyl Not active 35.00 ± 3.50 / Dual ChEI 
6u n/a n/a 53.90 ± 5.40 48.40 ± 4.80 1.1 Dual ChEI 
 
7f N Me Not active 21.00 ± 2.10 / Dual ChEI 
7h N iPr Not active Not active / Dual ChEI 
7m N Cyclohexyl Not active 35.80 ± 3.60 / Dual ChEI 
7u n/a n/a 38.10 ± 3.80 29.80 ± 3.00 1.3 Dual ChEI 
 
8f N Me Not active 21.60 ± 2.20 / Dual ChEI 
8g CH Me Not active 24.40 ± 2.40 / Dual ChEI 
8m N Cyclohexyl Not active 33.80 ± 3.40 / Dual ChEI 
8u n/a n/a 45.10 ± 4.50 21.90 ± 2.20 2.1 Dual ChEI 
 
9a n/a n/a Not active 39.40 ± 3.90 / Dual ChEI 
9g CH Me 20.70 ± 2.10 32.50 ± 3.30 0.6 Dual ChEI 
9h N iPr Not active Not active / Dual ChEI 
9m N Cyclohexyl Not active 38.40 ± 3.80 / Dual ChEI 
9u n/a n/a 36.20 ± 3.60 18.20 ± 1.80 2.0 Dual ChEI 
 
10a n/a n/a Not active 30.80 ± 3.10 / Dual ChEI 
10f N Me Not active 28.30 ± 2.80 / Selec. AChEI 
10g CH Me Not active 21.30 ± 2.10 / Dual ChEI 
10h N iPr Not active Not active / Dual ChEI 
10m N Cyclohexyl Not active 31.70 ± 3.20 / Dual ChEI 
10u n/a n/a 59.30 ± 5.90 17.40 ± 1.70 3.4 Dual ChEI 
 
11a n/a n/a 14.90 ± 1.50 35.40 ± 3.50 0.4 Selec. AChEI 
11f N Me Not active 32.60 ± 3.30 / Selec. AChEI 
11g CH Me 22.00 ± 2.20 37.40 ± 3.70 0.6 Dual ChEI 
11h N iPr Not active 19.60 ± 2.00 / Dual ChEI 
11m N Cyclohexyl Not active 36.40 ± 3.60 / Dual ChEI 
11u n/a n/a 32.70 ± 3.30 Not active / Dual ChEI 
 
12h N iPr Not active  12.80 ± 1.30 / Dual ChEI 
12m N Cyclohexyl Not active 36.70 ± 3.70 / Dual ChEI 
12u n/a n/a 50.20 ± 5.00 18.60 ± 1.90 2.7 Dual ChEI 
 
13cc S n/a 38.00 ± 25.00 n/d / Dual ChEI 
13f N Me Not active Not active / Dual ChEI 
13g CH Me Not active Not active / Dual ChEI 
13h N iPr 17.10 ± 1.70 12.10 ± 1.20 1.4 Dual ChEI 
13i CH iPr Not active Not active / Dual ChEI 
13j N nPr 22.00 ± 2.20 Not active / Non-selec. ChEI 
13k N EtOH 13.40 ± 1.30 Not active / Dual ChEI 
13l N EtOMe Not active Not active / Dual ChEI 
13m N Cyclohexyl 30.80 ± 3.10 Not active / Dual ChEI 
13n N Ac Not active Not active / Dual ChEI 
13o N Boc 11.10 ± 1.10 Not active / Selec. AChEI 
13p N H Not active Not active / Dual ChEI 
 
14f N Me 24.10 ± 2.40 24.80 ± 2.50 1.0 Dual ChEI 
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Inhibition of Aβ1-40 Aggreg. (%) Derv X R” AChE-induced Self-induced SI Mode of ChEI 
14g CH Me 14.80 ± 1.50 18.90 ± 1.90 0.8 Non-selec. ChEI 
14h N iPr 20.80 ± 2.10 21.80 ± 2.20 1.4 Dual ChEI 
14i CH iPr 31.80 ± 3.20 11.80 ± 1.20 2.7 Dual ChEI 
14j N nPr 23.10 ± 2.30 18.20 ± 1.80 1.3 Non-selec. ChEI 
14k N EtOH 18.80 ± 1.90 15.00 ± 1.50 1.3 Selec. AChEI 
14l N EtOMe 10.40 ± 1.00 16.30 ± 1.60 0.6 Dual ChEI 
14m N Cyclohexyl 32.00 ± 3.20 27.60 ± 2.80 1.2 Dual ChEI 
14n N Ac 10.30 ± 1.00 15.80 ± 1.60 0.7 Selec. AChEI 
14o N Boc 13.60 ± 1.40 11.40 ± 1.10 1.2 Not active 
14p N H Not active 20.80 ± 2.10 / Selec. AChEI 
 
15cc S n/a Not active n/d / Selec. AChEI 
15g CH Me Not active 26.30 ± 2.60 / Dual ChEI 
 
Propidium 82.00 ± 3.50 n/d / Not active 
Donepezil – Aricept ® 17.00 ± 8.10 n/d / Potent AChEI 
Galantamine – Reminyl ®  n/d 48 *  Dual ChEI 
 
a The result (% inhibition) is the mean of two separate experiments (n = 4) ± SD. b SI = hAChE-induced/self-induced. n/d = not 
determined. c Derivative’s anti-Aβ aggregation data obtained from the collaboration with Dr. Yang’s group; previously reported [Ref. 
121]. * Value retrieved from Ref. 128. 
 
With 2,4-DPR derivatives, anti-Aβ1-40 aggregation activity ranged from 0 up to 59% inhibition for 
hAChE-induced aggregation and from 0 up to 48% inhibition for self-induced aggregation. The benzyl 
derivative (2a) exhibited good AChE inhibition (IC50 = 8.90 µM); however, its smaller size (174.9 Å3) 
could not allow it to span both the CAS and PAS, thus its activity toward anti-hAChE-induced aggregation 
is non-existent. Similarly, the methoxy-based derivatives (9a-11a) featuring the 5-membered heterocyclic 
C-2 group were inactive toward hAChE-induced aggregation (with 11a showing very weak activity, ~ 
15%) but they inhibited self-induced aggregation by ~ 30-40%.  With the thiomorpholine analogs in the 
benzyl series (2c-e), an interesting pattern emerged, where the oxidation of the sulfur atom enabled 
derivatives 2d and 2e to exhibit good activity against hAChE-induced aggregation (56% and 44%; 
respectively) compared to the inactive parent derivative 2c. The phenylethylamine analog (15c) was also 
inactive toward anti-hAChE-induced aggregation, but the naphthalen-1ylmethylamine (13c) analog 
exhibited a wide activity range (38.00% ± 25.00). 
 The selective AChEI (2f with the Me-piperazine C-2 group) exhibited superior activity against 
hAChE-induced aggregation (59%) regardless of its molecular volume (199.6 Å3). Substituted variations of 
this derivative (bromo, fluoro, methyl, methoxy, dimethoxy or trimethoxy groups) were all inactive toward 
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hAChE-induced aggregation but they exhibited ~ 21-32% reduction in self-induced aggregation. Bulkier 
analogs, like the naphthalen-1ylmethylamine analog (13f) was inactive while the diphenylmethylamine 
analog (14f) was ~ 2.5-fold less active (24%). In terms of self-induced aggregation, 13f was also inactive 
while 14f exhibited comparable activity to hAChE-induced aggregation. The bioisosteric derivative (13g) 
was inactive on both fronts of Aβ1-40 aggregation, whereas 14g exhibited ~ 15% inhibition toward anti-
hAChE-induced and ~ 19% inhibition toward self-induced aggregation. When coupled to a C-4 
methylbenzylamine group, derivative (8g) exhibited activity toward self-induced aggregation only (~ 24%) 
and with stronger EDGs, the methoxy (9g) and trimethoxy (11g) derivatives were active toward both 
hAChE-induced and self-induced aggregation (~ 22% and 32-37%; respectively) while the dimethoxy 
derivative (10g) was only active toward self-induced aggregation (~ 21%). The iPr-piperazine derivatives 
(7h, 9h-12h) were all inactive toward hAChE-induced aggregation while 11h and 12h exhibited weak 
inhibition of self-induced aggregation (~ 20% and 12%; respectively). On the other hand, the bulkier 
derivatives (13h and 14h), were active against both hAChE-induced and self-induced aggregation but 14h 
exhibited better dual activity (17% and 12%, 21% and 22%; respectively). The bioisosteric derivative (13i) 
was inactive on both fronts of Aβ1-40 aggregation, whereas 14i exhibited ~ 32% inhibition toward hAChE-
induced and ~ 12% inhibition toward self-induced aggregation. The nPr-piperazine derivatives (13j and 
14j) exhibited comparable hAChE-induced inhibition (~ 22 to 23%); however, the latter also inhibited self-
induced aggregation by 18%. The cyclohexylpiperazine derivatives exhibited an interesting pattern, where 
the substituted benzylamine derivatives (3m-12m) were all inactive toward anti-hAChE-induced 
aggregation, while the naphthalen-1ylmethylamine and diphenylmethylamine derivatives (13m and 14m) 
exhibited comparable anti-hAChE-induced activity (~ 30-32%) corresponding to their overlapping binding 
modes in hAChE. On the other hand, derivatives 3m-12m exhibited better anti-self-induced aggregation 
activity (~ 32-39%) compared to 14m (~ 28%).  
With the alkoxyl piperazines, derivatives 13k and 14k (with the hydroxyethyl group) exhibited 13% 
and 19% inhibition of hAChE-induced aggregation, while derivatives 13l and 14l (with the methoxyethyl 
group) exhibited 0% and 10% inhibition of hAChE-induced aggregation; respectively. In terms of self-
induced aggregation, 14k and 14l provided 15% and 16% inhibition; respectively, while the naphthalen-
1ylmethylamine analogs (13k and 13l) were inactive. With an Ac-piperazine at C-2, 13n was still inactive 
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toward both hAChE-induced activity and self-induced aggregation, while 14n exhibited 10% and 16% 
inhibition; respectively. The bulkier C-2 group in 2o (Boc-piperazine) was hypothesized to provide good 
activity considering the proximiety of the Boc-group to Trp286; however, this derivative exhibited weak to 
moderate activity against hAChE-induced aggregation (27%) suggesting other factors in play besides just 
the proximity to the crucial PAS residue in AChE. The naphthalen-1ylmethylamine and 
diphenylmethylamine analogs provided weak, equipotent values (~ 11 to 14%) for hAChE-induced 
aggregation and the latter (14o), also exhibited weak self-induced activity (11%). The hydrolyzed products 
of 13o and 14o were inactive toward both hAChE- (13p and 14p) and self-induced (13p) aggregation but 
14p exhibited moderate activity against self-induced aggregation (21%).  
All derivatives featuring the donepezil pharmacophore (benzylpiperidine, 3u-12u) were able to 
reduce both hAChE-induced (except 3u and 5u) and self-induced aggregation of Aβ-peptides. 
Halogen/EWG-based derivatives exhibited a range of ~ 21-54% inhibition of hAChE-induced aggregation, 
while in self-induced aggregation, a range of ~ 22-48% was observed with the bromo bioisostere (6u) being 
the most active in both cases. This pattern is likely a result of the electron-withdrawing properties and 
sterics effects of the bromine atom. With regards to the EDG-based derivatives, anti-self-induced 
aggregation activity was lower than that observed with the EWG-based derivatives (range from 0-19%). 
With anti-hAChE-induced aggregation, activity ranged from ~ 33-59% with the methoxy (9u) and 
trimethoxy (11u) derivatives being less active than the similar dimethoxy (10u) and dioxolane (12u) 
derivatives, which correlates well with the molecular modeling studies.  
Overall, it is evident that anti-Aβ1-40 aggregation activity is mediated by the nature of the 
substituents at both the C-2 and C-4 positions of the 2,4-DPR template (Fig. 29). Electronic and steric 
properties are important factors along with the derivative’s proximity to the PAS of hAChE. In terms of 
self-induced aggregation, derivatives with the diphenylmethylamine C-4 group exhibited a broad range of 
activity where the majority of naphthalen-1ylmethylamine derivatives failed to do so. This observation is 
likely an effect of the aromatic structure at the C-4 position, where the branched diphenyl rings interact 
with Aβ1-40 peptides and prevent them from stacking and aggregating while the planar naphthyl ring can be 
stacked along the β-sheet formations (Fig. 30). The roles of EWGs and EDGs in the selectivity toward anti-
Aβ1-40 aggregation activity was evident in the profiles of derivatives 3u-7u and 8u-12u.  
T. Mohamed 2011 
	   53	  
 
 









T. Mohamed 2011 
	   54	  
 
 
Fig. (30): Illustration of how the diphenyl rings in series 14 may hinder the aggregation of Aβ-peptides when compared to the stacking 
ability of the naphthyl ring in series 13. 
 
4.1.3. Anti-β-Secretase Evaluation 
Due to cost constraints, it was not feasible to screen all the derivatives for anti-β-secretase activity. 
The selection process was dependent on the anti-ChE profiles, anti-Aβ-aggregation data (if applicable) and 
preliminary ligand-docking studies in hBACE-1. The SAR data (IC50) a of selective derivatives is presented 
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Cpd. X R” IC50 (µM) a Mode of ChEI Mode of Anti-Aβ-activity 
3m N Cyclohexyl 13.30 Dual ChEI Selec. self-induced 
3u n/a n/a 1.70 Dual ChEI Selec. self-induced 
 
4m N Cyclohexyl 2.60 Dual ChEI Selec. self-induced 
4u n/a n/a 0.60 Dual ChEI Dual hAChE-/self-induced 
 
5m N Cyclohexyl 1.30 Dual ChEI Selec. self-induced 
5u n/a n/a 3.20 Dual ChEI Selec. self-induced 
 
6f N Me 2.80 Dual ChEI Selec. self-induced 
6m N Cyclohexyl 2.40 Dual ChEI Selec. self-induced 
6u n/a n/a > 50 (33%*) Dual ChEI Dual hAChE-/self-induced 
 
7f N Me 2.60 Dual ChEI Selec. self-induced 
7h N iPr 11.70 Dual ChEI Not active 
7m N Cyclohexyl 12.20 Dual ChEI Selec. self-induced 
7u n/a n/a 0.70 Dual ChEI Dual hAChE-/self-induced 
 
8f N Me 1.50 Dual ChEI Selec. self-induced 
8g CH Me 4.10 Dual ChEI Selec. self-induced 
8m N Cyclohexyl 3.10 Dual ChEI Selec. self-induced 
8u n/a n/a 11.10 Dual ChEI Dual hAChE-/self-induced 
 
9a n/a n/a > 50 (34%*) Dual ChEI Selec. self-induced 
9g CH Me 9.20 Dual ChEI Dual hAChE-/self-induced 
9h N iPr 3.40 Dual ChEI Not active 
9m N Cyclohexyl 2.20 Dual ChEI Selec. self-induced 
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Cpd. X R” IC50 (µM) a Mode of ChEI Mode of Anti-Aβ-activity 
9u n/a n/a 0.60 Dual ChEI Dual hAChE-/self-induced 
 
10a n/a n/a 5.20 Dual ChEI Selec. self-induced 
10f N Me 24.50 Selec. AChEI Selec. self-induced 
10g CH Me 0.60 Dual ChEI Selec. self-induced 
10h N iPr 7.90 Dual ChEI Not active 
10m N Cyclohexyl 16.90 Dual ChEI Selec. self-induced 
10u n/a n/a > 50 (34%*) Dual ChEI Dual hAChE-/self-induced 
 
11a n/a n/a 1.30 Selec. AChEI Dual hAChE-/self-induced 
11f N Me 1.20 Selec. AChEI Selec. self-induced 
11g CH Me 2.90 Dual ChEI Dual hAChE-/self-induced 
11h N iPr 4.60 Dual ChEI Selec. self-induced 
11m N Cyclohexyl 5.50 Dual ChEI Selec. self-induced 
11u n/a n/a 8.90 Dual ChEI Selec. hAChE-induced 
 
12h N iPr > 50 (12%*) Dual ChEI Selec. self-induced 
12m N Cyclohexyl 0.70 Dual ChEI Selec. self-induced 
12u n/a n/a 1.40 Dual ChEI Dual hAChE-/self-induced 
 
15g CH Me 8.10 Dual ChEI Selec. self-induced 
 
Donepezil – Aricept ® 3.45 Potent AChEI – 
N-Benzyloxycarbonyl-Val- 
Leu-Leucinal 14.00 – – 
 
a The results (IC50) are the mean of duplicate readings (n = 2-4) with SD < 10%. n/d = Not determined. * % BACE-1 inhibition at the 
derivative’s ChE IC50 (µM). 
 
With 2,4-DPR derivatives, anti-β-secretase activity was relatively promising as it ranged from 0.60 to 24.50 
µM with some exhibiting weak inhibition (> 50 µM). The methoxy-based derivatives with a small 
pyrrolidine C-2 group demonstrated that the number of OMe substituents at the C-4 phenyl was modulating 
activity in the order of 9a < 10a < 11a. With a C-2 Me-piperazine, halogen-based derivatives (4-bromo and 
4-fluorobenzylamine at C-4) exhibited equipotent activity (IC50 values between 2.60 and 2.80 µM) making 
them ~ 1.3-fold more potent than donepezil and ~ 5-fold more potent than the peptide-like BACE-1 
inhibitor II (N-Benzyloxycarbonyl-Val-Leu-Leucinal). With EDGs at C-4, the methyl and tri-OMe 
derivatives (8f and 11f) exhibited equipotent activity (IC50 ~ 1.20-1.50 µM), whereas the di-OMe derivative 
(10f) was ~ 16-fold less potent. With a C-2 Me-piperidine bioisostere, derivatives 8g and 11g were ~ 2.5-
2.7-fold less potent compared to their piperazine relatives. This pattern was reversed for 10g, where the 
bioisosteric replacement improved BACE-1 inhibition by ~ 41-fold (IC50 = 0.60 µM) and when compared 
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to the di-and trimethoxy derivatives, 9g was the least active with an IC50 of 9.20 µM. Similarly, the 
phenylethylamine derivative also exhibited moderate activity (15g, IC50 = 8.10 µM) despite its extended C-
4 group. With the branched iPr-piperazine, the methoxy and tri-OMe derivatives (9h and 11h) exhibited 
comparable potencies, while the presence of a highly EWG resulted in decrease in activity (7h, IC50 = 
11.70 µM). Interestingly, the dioxolane derivative was not active (IC50 > 50 µM) despite it structural 
similarity to 10h.   
The SAR data involving the cyclohexylpiperazine C-2 group revealed an interesting pattern. With 
Cl-substituted benzylamine derivatives, the placement of the chlorine atom had a dramatic effect on BACE-
1 inhibition and the order of potency was p-Cl > m-Cl > o-Cl. The bromo-substituted derivative was 
equipotent to the m-Cl analog (IC50 ~ 2-3 µM), while the fluoro-substituted derivative exhibited similar 
activity to that of the o-Cl analog (IC50 ~ 12-13 µM). With EDG-based derivatives, activity ranged from 
0.70 µM (12m) to 16.90 µM (10m) with the methyl, methoxy and tri-OMe derivatives exhibiting low 
micromolar potency (IC50 ~ 2-5 µM).  
Derivatives featuring the donepezil pharmacophore (benzylpiperidine, 3u-12u) exhibited a wide 
range of inhibition (IC50 ~ 0.60 to > 50 µM). The EWG-based derivatives were potent inhibitors (IC50 ~ 
0.60-3.20 µM) with the exception of the bromo-substituted analog (6u, IC50 > 50 µM). The EDG-based 
derivatives were moderate inhibitors with the exception of 9u (IC50 = 0.60 µM, equipotent to 4u). The 
second most potent inhibitor within this sub-group was 12u (IC50 = 1.40 µM) and the methyl and tri-OMe 
analogs exhibited similar activities (IC50 = 8.90 and 11.10 µM; respectively). Surprisingly, the di-OMe 
analog (10u) was inactive up to 50 µM while 9u, 11u and 12u (with the same C-2 pharmacophore) 
exhibited activity below 12 µM. 
It is noteworthy that the 34 derivatives tested (~ 40% of the chemical library) generally exhibited 
potent BACE-1 inhibition with a few exceptions. Derivatives 4u, 7u, 9u, 10g and 12m were indentified as 
promising compounds as they exhibited potent anti-BACE-1 activity (IC50 = 0.60 to 0.70 µM). The activity 
profile is sensitive to the nature of the substituents at both the C-2 and C-4 positions of the 2,4-DPR 
template but the overall design of these derivatives seem to be suitable to target BACE-1. Where AChE and 
BuChE have U-shaped active sites, BACE-1 has a more linear, cylindrical-type active site, which 
recognizes the linear and potential V-shaped conformations of 2,4-DPR derivatives.  
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4.1.4. Cell Viability (data presented here is a result of collaborations with other groups) 
The results here represent the effects of select derivatives on the cell viability of neuroblastoma cells 
in the MTT assay. The SAR data (% cell viability at 40 µM) a of select derivatives is presented collectively 
in Table 11. 
 
Table (11): Percent SH-SY5Y neuroblastoma cell viability SAR data for select derivatives presented at 40 µM. 
 
Cpd. X R” Cell Viability (%) Cpd. X R” Cell Viability (%) 
2ab n/a n/a 101.70 ± 16.40 7uc n/a n/a 8.90 ± 8.10 
2bb O n/a 100.40 ± 6.00 8mc N Cyclohexyl 35.0 ± 1.00 
2cb S n/a 97.80 ± 11.50 8uc n/a n/a 5.30 ± 2.60 
2db S O 89.70 ± 11.50 9gc CH Me 8.60 ± 3.40 
2eb S O2 91.80 ± 2.20 9mc N Cyclohexyl 53.40 ± 7.70 
2fb N Me 98.30 ± 10.50 9uc n/a n/a 21.40 ± 18.00 
2gb CH Me 89.50 ± 6.60 10fc N Me 60.30 ± 0.40 
2hb N iPr 81.00 ± 10.30 10gc CH Me 59.50 ± 9.00 
2ib CH iPr 45.20 ± 4.30 10hc N iPr 61.90 ± 6.30 
2jb N nPr 87.90 ± 4.70 10mc N Cyclohexyl 67.10 ± 16.40 
2kb N EtOH 81.20 ± 8.90 10uc n/a n/a 81.00 ± 7.20 
2lb N EtOMe 78.60 ± 6.70 11fc N Me 60.50 ± 4.70 
2nb N Ac 109.10 ± 4.60 11gc CH Me 69.10 ± 10.00 
2ob N Boc 107.90 ± 0.50 11mc N Cyclohexyl 54.60 ± 7.20 
2qb N p-Cl-Bn 74.90 ± 4.00 11uc n/a n/a 36.90 ± 5.50 
2rb N p-Br-Bn 67.50 ± 3.40 12gc CH Me 42.00 ± 6.10 
2sb N p-F-Bn 39.10 ± 4.20 12hc N iPr 54.70 ± 6.50 
2tb N p-CF3-Bn - 0.90 ± 7.40 12mc N Cyclohexyl 51.40 ± 8.60 
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Cpd. X R” Cell Viability (%) Cpd. X R” Cell Viability (%) 
2uc n/a n/a 44.20 ± 14.80 12uc n/a n/a 45.80 ± 20.20 
3mc N Cyclohexyl 36.50 ± 4.70 13bb O n/a 95.00 ± 5.00 
3uc n/a n/a 0.60 ± 0.30  13cb S n/a 89.30 ± 2.90 
4fc N Me 72.00 ± 0.90 13hc N iPr 70.80 ± 2.60 
4uc n/a n/a 1.40 ± 1.00 13jc N nPr 85.30 ± 17.90 
5gc CH Me 0.20 ± 0.01 13mc N Cyclohexyl 30.80 ± 1.80 
5uc n/a n/a 1.50 ± 0.60 14hc N iPr 93.20 ± 6.30 
6gc CH Me 0.50 ± 0.20 14ic CH nPr 2.00 ± 0.50 
6hc N iPr 67.40 ± 8.20 14mc N Cyclohexyl 29.00 ± 5.30 
6uc n/a n/a 1.30 ± 0.30 15bb O n/a 90.20 ± 10.80 
7fc N Me 63.00 ± 6.70 15cb S n/a 116.10 ± 4.60 
7mc N Cyclohexyl 45.40 ± 7.60 15nb N Ac 82.60 ± 6.70 
 
a The results (% cell viability) are the mean of at least two separate experiments (n = 4) ± SD. b Derivative’s cell viability data obtained 
from the collaboration with Dr. Yang’s group. c Derivative’s cell viability data obtained from the collaboration with Dr. Beazely’s 
group. 
 
Through the efforts of the collaborating groups, cell viability profiles were obtained for 60 of the 
112 derivatives (~ 54% screened) and the results covered the entire spectrum ranging from 0 up to 100% 
cell viability. About 40% of the tested derivatives did not exhibit significant toxicity effects on 
neuroblastoma cell function (24 showed > 70% cell viability at 40 µM); however, an equal number were 
significantly harmful to the cells  (23 showed < 50% + cell viability at 40 µM). The observations presented 
here suggest that the impact of 2,4-DPR derivatives on cell viability is dependent on the nature of the 
substituents at the C-2 and C-4 positions (ranges from 0 to 100%) and that ClogP values alone could not be 
used to predict cell viability. The tendency is for hydrophobic compounds to be more toxic compared to 
their more hydrophilic relatives/bioisosteres and this pattern is observed when comparing derivatives with a 
Me-piperazine or iPr-piperazine C-2 group (f and h) with their respective bioisosteric relatives with a Me-
piperidine or iPr-piperidine C-2 group (g and i). 
 
4.2. Molecular modeling studies 
Computational chemistry plays an important role in understanding a derivative’s biological profile 
and corroborating the acquired SAR. The proceeding sub-sections describe the binding modes of the lead 
cholinesterase and β-secretase inhibitors within their respective enzymes. The docking images were 
oriented to correspond to those in Section 1.2.2 and 1.3.3 and only the key residues within the active site 
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are highlighted. Hydrogen atoms were also removed to improve clarity and hydrogen-bonding interactions 
are depicted in solid green lines.  
 
4.2.1. Lead acetylcholinesterase inhibitor 
 N-(Naphthalen-1-ylmethyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine 
Designation: 13a  
Cholinesterase Profile: AChE IC50 = 5.50 µM, BuChE IC50 = 8.90 µM; S.I = 0.62 
Amyloid Profile: β-secretase IC50 = n/d; Aβ1-40-aggreg. (%) = n/d 
SH-SY5Y Neuroblastoma Cell Viability (% at 40 µM): n/d 
Other Aspects: MW = 304.39 gmol-1; MV = 210.60 Å3; ClogP = 4.14 
______________________________________________________________________________________ 
 
Fig. (31): Docking of N-(Naphthalen-1-ylmethyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (13a, ball and stick) in the active site of 
hAChE. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown for clarity. Green: CT; Red: Acyl 
pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry (PAS – AChE); Turquoise: hydrogen bonding residues. 
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The binding mode of 13a in hAChE (PDB: 1B41) (Fig. 31) indicated that the 2,4-DPR template was 
located midway through the active site gorge (~ 6 Å away from the catalytic triad His447 residue at the 
bottom of the active site and ~ 7 Å away from the PAS Trp286). The ring was also equidistantly suspended 
between Tyr124 and Tyr337 allowing for two hydrogen bonding interactions between the tyrosine hydroxyl 
groups and the C-4 NH along with two additional interactions between the tyrosine hydroxyl groups and 
the pyrimidine N-3 (distances < 3.5 Å). Hydrophobic interactions with a nearby glycine pocket (Gly120-
122; ~ 5 Å away) assisted with template orientation. The naphthyl ring was tightly stacked between the 
aromatic segments of Tyr337 and Trp86 (distance ~ 3.5 Å) and the C-3/C-4 carbons of the naphthyl ring 
were in close proximity to His447 (distances 3.5-4 Å). The 5-membered pyrrolidine substituent was 
oriented toward an aromatic region close to the PAS and was ~ 4.5 Å away from Trp286 and ~ 3.5 Å from 
Tyr341. It is noteworthy that although the catalytic site is relatively exposed in this binding pattern (e.g. no 
close interactions with Ser203), the placement of the bulky, planar naphthyl ring at the C-4 position most 
likely attributed to this derivative’s potency considering its close proximity to Trp86 (a key element in 
stabilizing ACh binding). 
 
4.2.2. Lead butyrylcholinesterase inhibitor 
 2-(4-cyclohexylpiperazin-1-yl)-N-(4-methylbenzyl)pyrimidin-4-amine 
Designation: 8m  
Cholinesterase Profile: AChE IC50 = 16.80 µM, BuChE IC50 = 1.70 µM; 
S.I = 0.62 
Amyloid Profile: β-secretase IC50 = 3.10 µM; Aβ1-40-aggreg. (%) = Not 
active (hAChE-induced); 33.80 (self-induced) 
SH-SY5Y Neuroblastoma Cell Viability (% at 40 µM): 35.00 
Other Aspects: MW = 365.52 gmol-1; MV = 264.10 Å3; ClogP = 5.03 
______________________________________________________________________________________ 
 
The binding mode of 8m in hBuChE (PDB: 1P0I) (Fig. 32) indicated that the 2,4-DPR template was 
immersed closer to the active site (~ 7.5 Å away from the catalytic triad His438 residue at the bottom of the 
active site and ~ 17 Å away from the entry residue, Ala277). The ring stacked between Trp82 (~ 4.5 Å 
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away) and the tri-glycine pocket comprised of Gly115-117 (~ 3.8 Å away). The 4-methylphenyl ring at C-4 
is perpendicularly stacked atop His438 (distance ~ 4.5 Å) with the methyl group pointed at Ala328, Met437 
and Trp430 (distances ~ 3.8, 4.2 and 4.8 Å; respectively). The only hydrogen bonding interaction observed 
in this binding mode is that of the C-4 NH with the side chain of Glu197 (distance = 3.3 Å). Interestingly, 
the entire C-4 group (4-methylbenzylamine) and the 2,4-DPR template form a V-shaped conformation over 
Trp82, which is likely to hinder any interaction with ACh. The bulky and sterically demanding 
cyclohexylpiperazine C-2 substituent was oriented toward the entry site of BuChE and it exhibited an 
interesting Z-shaped conformation. The piperazine ring runs parallel along side a Thr120 residue (distance 
~ 3-4 Å), while the cyclohexyl ring is hydrophobically interacting with Tyr332 and Asp70 (distances ~ 4-5 
Å) and is ~ 10 Å away from Ala277. Although this binding mode doesn’t offer much in terms of hydrogen 
bonding interactions, its orientation and proximity to the active site allowed for a great deal of hydrophobic 
interactions at either side of the ligand. The sterics and interactions offered by the C-2 
cyclohexylpiperazine group and the V-shaped conformation atop Trp82 likely attributed to this derivative’s 
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Fig. (32): Docking of 2-(4-cyclohexylpiperazin-1-yl)-N-(4-methylbenzyl)pyrimidin-4-amine (8m, ball and stick) in the active site of 
hBuChE. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown for clarity. Green: CT; Red: 
Acyl pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry; Turquoise: hydrogen bonding residues. 
 
4.2.3. Lead dual cholinesterase inhibitor 
 N2-(1-Benzylpiperidin-4-yl)-N4-(4-fluorobenzyl)pyrimidine-2,4-diamine 
Designation: 7u  
Cholinesterase Profile: AChE IC50 = 7.70 µM, BuChE IC50 = 2.20 µM; S.I = 
3.50 
Amyloid Profile: β-secretase IC50 = 0.70 µM; Aβ1-40-aggreg. (%) = 38.10 
(hAChE-induced); 29.80 (self-induced) 
SH-SY5Y Neuroblastoma Cell Viability (% at 40 µM): 8.90 
Other Aspects: MW = 391.48 gmol-1; MV = 263.10 Å3; ClogP = 4.75 
______________________________________________________________________________________ 
 
Fig. (33): Docking of N2-(1-Benzylpiperidin-4-yl)-N4-(4-fluorobenzyl)pyrimidine-2,4-diamine (7u, ball and stick) in the active site of 
hAChE. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown for clarity. Green: CT; Red: Acyl 
pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry; Turquoise: hydrogen bonding residues. 
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The binding mode of 7u in hAChE (PDB: 1B41) (Fig. 33) indicated that the 2,4-DPR template was 
located midway through the active site gorge (~ 6.5 Å away from the catalytic triad His447 residue at the 
bottom of the active site and ~ 7 Å away from the PAS Trp286). The ring was also equidistantly suspended 
between Tyr124 and Tyr337 allowing for six hydrogen bonding interactions between the tyrosine hydroxyl 
groups and the C-2 NH and pyrimidine N-3 (3 hydrogen bonding interactions per Tyr residue; distances < 
3.5 Å). Hydrophobic interactions with a nearby glycine pocket (Gly121 and 122; ~ 5 Å away) assisted with 
template orientation and C-5/6 of the ring are in close proximity to the catalytic residues (~ 4-6 Å). The 
entire C-4 group (4-fluorobenzylamine) was arched at a 90° angle off of the ligand’s linear conformation to 
orient the fluorine atom in a polar pocket that allowed for two hydrogen bonding interactions to take place 
(Asp74 and Asn87 involved; distance ~ 3.5 Å). This arch conformation was supported by Trp86 that held 
the C-4 phenyl ring in place (distance ~ 4 Å). The donepezil pharmacophore (benzylpiperidine) was 
extended linearly from the C-2 amine group and was nestled by a large aromatic pocket comprised of 
Trp286, Tyr341 and Tyr337. Interestingly, the benzyl component of the pharmacophore was positioned at 
the posterior face of Trp286 and this prevents the C-2 group from fully interacting with the PAS. Overall, 
the ligand mainly exhibited a linear conformation spanning the CAS and PAS simultaneously. The arching 
conformation observed with the C-4 group was interesting as it denotes the unique properties offered by the 
small, yet highly electronegative halogen, fluorine.   
On the other hand, the binding mode of 7u in hBuChE (PDB: 1P0I) (Fig. 34) indicated that the 2,4-
DPR template was located almost midway through the active site gorge (~ 10 Å away from the catalytic 
triad His447 residue at the bottom of the active site and ~ 12 Å away from the entry site residue, Ala277). 
The ring was also stacked against Asp70 (distances ~ 4-5 Å) and perpendicularly suspended between 
Thr120 and Tyr332 (equidistant at ~ 4.5 Å). Similar to its hAChE binding mode, the entire C-4 group (4-
fluorobenzylamine) was arched at a 90° angle off of the template’s linear conformation to orient the 
fluorine atom toward His438 (hydrogen bonding interaction; distance ~ 3.5 Å) and Ser198. This arch 
conformation was supported by perpendicular stacking of the C-4 phenyl ring between Trp82 and Phe329 
(distance ~ 4-6 Å). The donepezil pharmacophore (benzylpiperidine) was also arched at a 90° angle off of 
the template’s linear conformation to run parallel to the orientation of the C-4 group. This placed the entire 
C-2 group in a hydrophobic region running along side Pro285 and the enzyme’s acyl pocket (Leu286, 
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Ser287, Val288; distances ~ 4-5 Å) with the phenyl ring ~ 4 Å away from Trp231 and Phe398. Despite the 
fact that the ligand was oriented in an inverse U-shaped conformation, which is considered unfavourable, it 
was able to interact with various key residues and exhibit a good anti-BuChE profile. 
 
Fig. (34): Docking of N2-(1-Benzylpiperidin-4-yl)-N4-(4-fluorobenzyl)pyrimidine-2,4-diamine (7u, ball and stick) in the active site of 
hBuChE. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown for clarity. Green: CT; Red: 
Acyl pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry; Turquoise: hydrogen bonding residues. 
 
4.2.4. Lead β-secretase inhibitor  
 
 N2-(1-benzylpiperidin-4-yl)-N4-(4-chlorobenzyl)pyrimidin-2,4-diamine 
Designation: 4u  
Cholinesterase Profile: AChE IC50 = 7.70 µM, BuChE IC50 = 2.50 µM; S.I = 3.10 
Amyloid Profile: β-secretase IC50 = 0.60 µM; Aβ1-40-aggreg. (%) = 27.70  
(hAChE-induced); 39.90 (self-induced) 
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Fig. (35): Docking of N2-(1-benzylpiperidin-4-yl)-N4-(4-chlorobenzyl)pyrimidin-2,4-diamine (4u, ball and stick) in the active site of 
hBACE-1. Green lines represent hydrogen bonding (distance < 3.5 Å). Hydrogen atoms are not shown for clarity. Green: Catalytic 
site; Red: Flap; Purple, grey and Blue: Some hydrophobic and hydrophilic residues of the various sub-site pockets in BACE-1; Yellow: 
Other key residues - part of the hydrogen-bond network; Turquoise: hydrogen bonding residues. 
 
The binding mode of 4u in hBACE-1 (PDB: 1FKN) (Fig. 35) indicated that the 2,4-DPR template 
was perpendicularly stacked between the active site Asp228 residue and Thr72 (distance ~ 3.5-5 Å) 
allowing for a hydrogen-bonding interaction between the pyrimidine N-1 and the Thr231 OH (distance < 
2.5 Å). The 4-chlorobenzylamine substituent at the C-4 position was oriented toward a relatively 
hydrophobic pocket comprised of Val69, Pro70, Arg128, Tyr198 and Ile126 (distance ~ 6.5 Å) allowing for 
a strong hydrogen-bonding interaction between the C-4 NH and the backbone C=O of Gly34 (distance = 
2.7 Å). The benzylpiperidine substituent at C-2 exhibited a V-shaped conformation as a result of its 
interactions within a hydrophobic region comprised of Tyr71, Phe108, Ile110 and Trp115 (distances ~ 6 
Å). This conformation however, allowed for C-2 NH to undergo a strong hydrogen-bonding interaction 
with the C=O of Gly230 (distance < 2.3 Å). Overall this derivative exhibited an S-shaped binding mode in 
BACE-1; the balance of hydrogen-bonding and hydrophobic interactions at both the C-2 and C-4 positions 
allowed this derivative to exhibit potent BACE-1 inhibition.  
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4.2.5. Key Superimpositions 
Investigating the binding modes of related ligands by superimposition of docked structures (SODS) 
is a fast and convenient method to correlate their binding modes with the biological profiles. 
 
Fig. (36) – hAChE SODS of:    
  2-(4-Cyclohexylpiperazin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13m):  
AChE IC50 = 8.70 µM 
 N-Benzhydryl-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (14m):  
AChE IC50 = 10.00 µM 
______________________________________________________________________________________ 
The SODS of 13m and 14m elegantly corroborates the biological profiles of these derivatives in terms of 
their similar activity against hAChE  (8.70 and 10.00 µM) and hAChE-induced aggregation of Aβ1-40 
peptide (~ 32% at 100 µM). 
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Fig. (36): SODS of 13m (turquoise, ball and stick) and 14m (fuchsia, ball and stick) in the active site of hBuChE. Hydrogen atoms are 
not shown for clarity. Green: CT; Red: Acyl pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry. 
 
Fig. (37) – hAChE SODS of:    
 N2-(1-Benzylpiperidin-4-yl)-N4-(4-methoxybenzyl)pyrimidine-2,4-diamine (9u):  
AChE IC50 = 9.40 µM 
 
 N2-(1-Benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)pyrimidine-2,4-diamine (10u): 
AChE IC50 = 9.90 µM 
 
 N2-(1-Benzylpiperidin-4-yl)-N4-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine (11u):  
AChE IC50 = 10.30 µM 
 
With donepezil for comparative purposes 
______________________________________________________________________________________ 
The SODS of 9-11u along with donepezil show how the 2,4-DPR derivatives extend further toward 
the PAS compared to donepezil correlating with the enhanced inhibition of hAChE-induced aggregation of 
Aβ1-40 peptide. Interestingly, 10u was completely blocking access to Trp286 compared to all the other 
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ligands shown. At the active site, the donepezil and 2,4-DPR derivative benzylpiperidine pharmacophores 
are all oriented toward Trp86 at varying angles.  
 
 
Fig. (37): SODS of 9u (turquoise, ball and stick), 10u (fuchsia, ball and stick) and 12u (orange, ball and stick) in the active site of 
hAChE. Donepezil (black, stick) is shown for comparison. Hydrogen atoms are not shown for clarity. Green: CT; Red: Acyl pocket; 
Blue: Hydrophobic stabilizing residues; Yellow: gorge entry. 
 
Fig. (38) – hBuChE SODS of:    
 2-(4-Methylpiperazin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13f):  
BuChE IC50 = 2.60 µM 
 2-(4-Methylpiperidin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13g):  
BuChE IC50 = 2.20 µM 
 N-Benzyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (2g):  
BuChE IC50 = 3.40 µM 
______________________________________________________________________________________ 
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The SODS of 2g, 13f and 13g corroborated the very similar anti-BuChE activities of these 
derivatives, regardless of the bioisosteric variances at either or both of the C-2 and C-4 positions. By 
interacting with Trp82 and the acyl pocket residues, these derivatives were able to provide potent BuChEI 
(IC50 < 4 µM).  
 
Fig. (38): SODS of 2g (grey, ball and stick), 13f (fuchsia, ball and stick) and 13g (turquoise, ball and stick) in the active site of 
hBuChE. Hydrogen atoms are not shown for clarity. Green: CT; Red: Acyl pocket; Blue: Hydrophobic stabilizing residues; Yellow: 
gorge entry. 
 
Fig. (39) – hBuChE SODS of:    
  N-(2-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (3h):  
BuChE IC50 = 4.70 µM 
  N-(3-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (4h):  
BuChE IC50 = 5.90 µM 
  N-(4-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (5h): 
 BuChE IC50 = 6.70 µM 
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The SODS of 3-5h corroborated the very similar anti-BuChE activities of these derivatives, 
regardless of the bioisosteric placement of the chlorine atom (2-, 3- or 4-position; respectively) on the C-4 
benzylamine group. Interestingly, 3h and 4h were overlapping for most of their binding conformations (C-
4 groups ran along side the acyl pocket), but 5h was rotated 180° along the x-axis (C-4 group ran between 
Trp82 and Phe329).  
 
Fig. (39): SODS of 3-5h (fuchsia, turquoise and grey, ball and stick; respectively) in the active site of hBuChE. Hydrogen atoms are 
not shown for clarity. Green: CT; Red: Acyl pocket; Blue: Hydrophobic stabilizing residues; Yellow: gorge entry. 
 
Fig. (40) – hBACE-1 SODS of:    
  N-(2-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (3m):  
hBACE-1 IC50 = 13.30 µM 
  N-(3-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (4m):  
hBACE-1 IC50 = 2.60 µM 
  N-(4-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (5m): 
 hBACE-1 IC50 = 1.30 µM 
______________________________________________________________________________________ 
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The SODS of 3-5m corroborated the anti-BACE-1 inhibitory pattern of these derivatives, where the 
placement of the chlorine atom (2-, 3- or 4-position; respectively) impacted BACE-1 inhibition drastically. 
Interestingly, 3m and 4m had similar binding modes and orientation while 5m was oriented in an opposite 
fashion with its C-4 group near the enzyme’s mouth, allowing for the pyrimidine ring to lie suspended over 
the active site aspartic acid residues. 
 
 
Fig. (40): SODS of 3-5m (turquoise, fuchsia and orange, ball and stick; respectively) in the active site of hBACE-1. Hydrogen atoms 
are not shown for clarity. Green: Catalytic site; Red: Flap; Purple, turquoise and Blue: Some hydrophobic and hydrophilic residues of 
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CHAPTER V 
  Conclusion and Future Outlook   
 
Over the course of the research program, a chemical library of 112 derivatives (series 2–12) based 
on a 2,4-DPR template were designed and synthesized using simple and efficient synthetic methods (2 or 3 
step reactions) and screened against multiple pathways of AD (AChE, BuChE, AChE-induced Aβ1-40-
aggregation, self-induced Aβ1-40-aggregation and β-secretase).  
The design aspect of the project relied on the review of recent literature and preliminary molecular 
modeling studies to assess the potential of a 2,4-DPR template. The synthetic methods utilized (N.A.S, 
oxidation and hydrolysis) were successful and provided yields ranging from 45-90%. Biological screening 
was accomplished using previously established methods or commercially available assay kits to obtain 
SAR data. Molecular modeling studies were conducted to investigate the docking of lead derivatives within 
the target enzymes and to corroborate their biological profiles. A collective summary of the various 
parameters for library characterization is presented below: 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
o Molecular Weights (MWs): 254.33 – 463.57 gmol-1 
o Molecular Volumes: 174.90 – 319.30 Å3 
o Partition Coefficients (ClogPs): 1.18 – 6.32 
o AChE Inhibition Range (IC50): 5.50 – > 100 µM  
o BuChE Inhibition Range (IC50): 1.70 – > 100 µM  
o Aβ1-40 Aggregation Inhibition (AChE-induced): 0 – 59% 
o Aβ1-40 Aggregation Inhibition (Self-induced): 0 – 48% 
o BACE-1 Inhibition Range (IC50): 0.60 – > 50 µM  
o Neuroblastoma Cell Viability (at 40 µM): 0 – 100% 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
The majority of 2,4-DPR derivatives (94 out of 112 or 84%) were classified as dual ChEI (Fig. 25). With 
respect to AChE inhibition, the derivatives were not as potent as Aricept ® (donepezil; AChE IC50 of 32 
nM) but the most potent derivative (13a, N-(Naphthalen-1-ylmethyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine; 
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AChE IC50 of 5.5 µM) exhibited an IC50 close to that of Reminyl ® (galantamine; AChE IC50 of 3.2 µM). A 
small fraction of 2,4-DPR derivatives (39 out of 112 or 35%) exhibited good activity ranging from 1-15 µM 
(Fig. 26) and this highlights the challenge in designing potent AChE inhibitors with dual ChE activity. On 
the other hand, 60 out of 112 derivatives (~ 54%) exhibited good BuChEI ranging from 1-15 µM, despite 
the enzyme’s larger and more open active site. Of those 60 derivatives, 13 exhibited better or equipotent 
activity compared to both Aricept ® (donepezil; BuChE IC50 of 3.2 µM) and Reminyl ® (galantamine; 
AChE IC50 of 13.2 µM) including the most potent BuChEI, 8m (2-(4-cyclohexylpiperazin-1-yl)-N-(4-
methylbenzyl)pyrimidin-4-amine; IC50 = 1.70 µM). 
In an effort to identify novel and multifunctional candidates for the potential treatment of AD, select 
derivatives were screened for their ability to target some amyloid pathways of AD. In regards to Aβ1-40 
peptide aggregation, 2,4-DPR derivatives exhibited a wide range of activity toward both mechanisms of 
aggregation (AChE-induced – from 0 up to 59% and self-induced – from 0 up to 48%). With the first 
mechanism, derivatives that interacted with the PAS of AChE demonstrated good activity against peptide 
aggregation when compared to Aricept ® (donepezil; % inhibition at 100 µM = 17%) and Reminyl ® 
(galantamine; % inhibition at 100 µM = 0%). Top candidates included 2f (N-benzyl-2-(4-methylpiperazin-
1-yl)pyrimidin-4-amine) and 10u (N2-(1-Benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)pyrimidine-2,4-
diamine) that exhibited equipotent reduction in peptide aggregation (59%; ~ 3.5-fold more active compared 
to Aricept ® and ~ 1.4-fold less active compared to propidium) and of the derivatives tested, 23 out of 68 (~ 
34%) surpassed the activity of Aricept ®. With the second mechanism, derivatives that disrupted β-sheet 
formation demonstrated good activity against peptide aggregation when compared to Reminyl ® 
(galantamine; % inhibition at 100 µM = 48%). Derivative 6u (N2-(1-benzylpiperidin-4-yl)-N4-(4-
bromobenzyl)pyrimidine-2,4-diamine) was the only equipotent inhibitor of self-induced Aβ1-40 aggregates 
compared to Reminyl ® (% inhibition at 100 µM = 48%). To halt the generation of pro-Aβ peptides and to 
offer a degree of a DME, select derivatives were also screened for their ability to inhibit BACE-1. Of the 
38 derivatives tested, 32 (~ 84%) exhibited superior activity toward BACE-1 compared to the peptide-like 
inhibitor (N-Benzyloxycarbonyl-Val-Leu-Leucinal; BACE-1 IC50 = 14 µM). Derivatives 4u, 7u, 9u, 10g 
and 12m were the top candidate with a BACE-1 IC50 of 600-700 nM.  
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The neuroblastoma cell viability measurements in the presence and absence of test compounds was 
ranged from 0 to 100%. The data implied a relationship between lipophilicity parameters, bioisosteres and 
their impact on cell viability.  
The SAR data acquired for dual ChE, Aβ1-40 aggregation and BACE-1 inhibition supports the 
hypothesis that a 2,4-DPR can serve as a suitable template to develop multifunctional candidates for the 
potential treatment of AD. In this regard, a lead candidate from the chemical library generated (10u) was 
identified that fits the criteria of exhibiting multifunctional activity as shown below: 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
 N2-(1-benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)pyrimidine-2,4-diamine 
Designation: 10u  
Cholinesterase Profile: AChE IC50 = 9.90 µM, BuChE IC50 = 11.40 
µM; S.I = 0.90 
Amyloid Profile: β-secretase IC50 = 34% inhibition at 10 µM; Aβ1-40-
aggreg. (%) = 59.30 (hAChE-induced); 17.10 (self-induced) 
SH-SY5Y Neuroblastoma Cell Viability (% at 40 µM): 81.00 
Other Aspects: MW = 433.55 gmol-1; MV = 240.10 Å3; ClogP = 4.26 
 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Future studies regarding this research program can be outlined as follows: 
o Further examine lead derivatives such 10u in other pathological parameters of AD such as metal 
chelation, anti-oxidant properties, inflammation and ability to prevent NFT formation. 
o Modifications to structure could lead to an enhanced biological profile. 
o Examine lead candidates in an AD animal model to assess in vivo potential. 
 
Overall, the outcome of the research program was successful in providing some key insights into the 
development of novel pyrimidine-based templates as multifunctional small molecules to potentially treat 
AD. Current evidence supports the need to develop a multi-pronged approach to achieve the desired DMEs 
and potentially halt/reverse the rapid onset of AD as compared to the traditional “one drug, one target” 
approach.  
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CHAPTER VI 
  Experimental   
 
6.1. Chemistry 
All necessary solvents and reagents were obtained from various vendors (Acros Organics ®, Sigma-
Aldrich ® and Alfa Aesar ®) with a minimum purity of 95% and were used without further purification. 
Melting points were determined on a Fisher-Johns apparatus and are uncorrected. Infrared (IR) spectra 
were obtained from microfilms on NaCl plates using a Perkin Elmer FT-IR spectrometer. 1H-NMR spectra 
were recorded on a Bruker ® Avance 300 MHz series spectrometer using CDCl3 or MeOD4 as the solvent). 
Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were used for 
multiplicity of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. High-resolution 
electron ionization mass spectral (HREIMS) analysis was obtained using a JEOL HX110 double focusing 
mass spectrometer. Residue purification was accomplished using i) SGCC using Merck 230-400 mesh 
silica gel 60 and, if necessary ii) HPLC. Combustion analysis was carried out by Midwest Microlab, LLC 
(Indianapolis, IN) and the % C, H, N of select compounds were within ± 0.4% of theoretical values for all 
elements listed indicating a purity of > 95%. All test derivatives showed single spot on thin-layer 
chromatography (TLC) performed on Merck 60F254 silica gel plates (0.2 mm) using three different solvent 
systems (9:1 EtOAc: MeOH; 3:1 EtOAc: hexanes and 3:1 EtOAc: DCM) and spots were visualized with 
UV 254 nm or stained with iodine or potassium permanganate (KMnO4).  
 
6.1.1. General Method to Prepare Intermediates 2-15 
To a mixture of 2,4-dichloropyrimidine (1, Fig. 11) (5.00 g, 33.60 mmol) and primary amines (R1 = 
benzylamine, 2-, 3-, 4-chloro, 4-bromo, 4-fluoro, 4-methyl, 4-methoxy, 3,4-dimethoxy, 3,4,5-trimethoxy 
benzylamines, benzo[d][1,3]dioxol-5-methylamine, naphthalen-1ylmethylamine, diphenylmethylamine or 
phenylethylamine; respectively, 33.60 mmol) in 50-60 mL of EtOH, kept at 0 °C (ice-bath), DIPEA (6.08 
mL, 36.80 mmol) was added. The reaction was stirred on the ice-bath for 5 minutes then refluxed at 80-85 
°C for 4 hrs. After cooling to r.t, 15-20 mL of EtOAc was added and solution was neutralized with drop-
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wise addition of ~ 6M HCl (pH = 7-7.5), washed with a saturated NaHCO3 and NaCl solution (1:3, 1 x 50 
mL). Aqueous layer was re-washed with EtOAc (2 x 25 mL) and the combined organic layer was dried 
over anhydrous MgSO4 and filtered. The organic layer was evaporated in vacuo and the resulting residue 
was further purified using either one or both of the following methods: 1) Method A:  SGCC using EtOAc: 
hexanes twice (3:1 and 1:3, respectively) or 9:1 DCM: EtOAc to afford solid products (60-65%) or 2) 
Method B: Differential melting point separation – The collected organic layers are evaporated in vacuo and 
the oily residue is vigorously mixed with a solution of hexanes to afford a precipitate that was filtered, 
washed with hexanes and dried on filter paper at 75-80 °C for ~ 2-3 hrs to afford solid products (60–89%). 
Some physical and spectroscopy data are provided below.  
 
N-Benzyl-2-chloropyrimidin-4-amine (2): The product was obtained as a white/light yellow solid after 
coupling with benzylamine (3.67 mL, 33.60 mmol). Method A – 4.78 g, 65%; Method B – 5.31 g, 72%. 
mp: 130-132 °C. IR (film, CH2Cl2): 3434 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J = 6.0 Hz, 
1H), δ 7.28-7.34 (m, 5H), δ 6.20 (d, J = 6.0 Hz, 1H), δ 4.53 (br s, 2H). HREIMS Calcd for C11H10ClN3 
(M+) m/z 219.6702, observed 219.0498. Anal. Calcd for: C11H10ClN30.32 H2O; C, 58.55; H, 4.43; N, 
18.63. Found: C, 58.61; H, 4.76; N, 18.64.  
 
2-Chloro-N-(2-chlorobenzyl)pyrimidin-4-amine (3): The product was obtained as a light yellow solid 
after coupling with 2-chlorobenzylamine (4.10 mL, 33.60 mmol). Method B – 5.97 g, 70%. mp: 95-97 °C. 
1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J = 6.0 Hz, 1H), δ 7.30-7.36 (m, 2H), δ 7.16-7.22 (m, 2H), δ 6.26 
(d, J = 6.0 Hz, 1H), δ 5.80 (br s, 1H), δ 4.51 (br s, 2H). HREIMS Calcd for C11H9Cl2N3 254.1153, observed 
253.0196. 
 
2-Chloro-N-(3-chlorobenzyl)pyrimidin-4-amine (4): The product was obtained as a yellow solid after 
coupling with 3-chlorobenzylamine (4.10 mL, 33.60 mmol). Method B – 5.98 g, 70%. mp: 128-130 °C. 1H-
NMR (300 MHz, CDCl3) δ 7.99 (d, J = 6.0 Hz, 1H), δ 7.24-7.28 (m, 3H), δ 7.08-7.19 (m, 1H), δ 6.27 (d, J 
= 6.0 Hz, 1H), δ 5.81 (br s, 1H), δ 4.53 (br s, 2H). HREIMS Calcd for C11H9Cl2N3 254.1153, observed 
253.0168. 
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2-Chloro-N-(4-chlorobenzyl)pyrimidin-4-amine (5): The product was obtained as an off-white solid after 
coupling with 4-chlorobenzylamine (4.10 mL, 33.60 mmol). Method B – 5.13 g, 68%. mp: 138-140 °C. 1H-
NMR (300 MHz, CDCl3) δ 8.00 (d, J = 6.0 Hz, 1H), δ 7.30-7.34 (m, 2H), δ 7.21-7.25 (m, 2H), δ 6.20 (d, J 
= 6.0 Hz, 1H), δ 5.54 (br s, 1H), δ 4.52 (br s, 2H). HREIMS Calcd for C11H9Cl2N3 254.1153, observed 
253.0176. 
 
N-(4-bromobenzyl)-2-chloropyrimidin-4-amine (6): The product was obtained as a yellow solid after 
coupling with 4-bromobenzylamine (5.39 mL, 33.60 mmol). Method B – 4.85 g, 66%. mp: 115-117 °C. 1H-
NMR (300 MHz, CDCl3) δ 7.99 (d, J = 6.0 Hz, 1H), δ 7.45-7.48 (m, 2H), δ 7.17-7.20 (m, 2H), δ 6.25 (d, J 
= 6.0 Hz, 1H), δ 5.73 (br s, 1H), δ 4.51 (br s, 2H). HREIMS Calcd for C11H9BrClN3 298.5663, observed 
296.9669. 
 
2-Chloro-N-(4-fluorobenzyl)pyrimidin-4-amine (7): The product was obtained as an off-white solid after 
coupling with 4-fluorobenzylamine (3.86 mL, 33.60 mmol). Method B – 5.62 g, 71%. mp: 150-152 °C. 1H-
NMR (300 MHz, CDCl3) δ 8.02 (d, J = 6.0 Hz, 1H), δ 7.25-7.30 (m, 2H), δ 7.00-7.05 (m, 2H), δ 6.22 (d, J 
= 6.0 Hz, 1H), δ 5.49 (br s, 1H), δ 4.51 (br s, 2H). HREIMS Calcd for C11H9ClFN3 237.6607, observed 
237.0474. 
 
2-Chloro-N-(4-methylbenzyl)pyrimidin-4-amine (8): The product was obtained as a yellow solid after 
coupling with 4-methylbenzylamine (4.29 mL, 33.60 mmol). Method B – 6.95 g, 88%. mp: 97-99 °C. 1H-
NMR (300 MHz, CDCl3) δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.16-7.22 (m, 2H), δ 7.10-7.15 (m, 2H), δ 6.21 (d, J 
= 6.0 Hz, 1H), δ 5.57 (s, 1H), δ 4.47 (br s, 2H), δ 2.33 (s, 3H). HREIMS Calcd for C12H12ClN3 233.6968, 
observed 233.0715. 
 
2-Chloro-N-(4-methoxybenzyl)pyrimidin-4-amine (9): The product was obtained as a yellow solid after 
coupling with 4-methoxybenzylamine (4.39 mL, 33.60 mmol). Method B – 7.45 g, 89%. mp: 89-91 °C. 1H-
NMR (300 MHz, CDCl3) δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.23-7.26 (m, 2H), δ 6.86-6.89 (m, 2H), δ 6.23 (d, J 
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= 6.0 Hz, 1H), δ 5.64 (s, 1H), δ 4.45 (br s, 2H), δ 3.78 (s, 3H). HREIMS Calcd for C12H12ClN3O 249.6962, 
observed 249.0675. 
 
2-Chloro-N-(3,4-dimethoxybenzyl)pyrimidin-4-amine (10): The product was obtained as a yellow solid 
after coupling with 3,4-dimethoxybenzylamine (5.11 mL, 33.60 mmol). Method B – 6.95 g, 88%. mp: 79-
81 °C. 1H-NMR (300 MHz, CDCl3) δ 8.00 (d, J = 6.0 Hz, 1H), δ 6.79-6.84 (m, 3H), δ 6.21 (d, J = 6.0 Hz, 
1H), δ 5.51 (s, 1H), δ 4.45 (br s, 2H), δ 3.86 (s, 3H), δ 3.85 (s, 3H). HREIMS Calcd for C13H14ClN3O2 
279.7222, observed 279.0778. 
 
2-Chloro-N-(3,4,5-trimethoxybenzyl)pyrimidin-4-amine (11): The product was obtained as a beige solid 
after coupling with 3,4,5-trimethoxybenzylamine (5.71 mL, 33.60 mmol). Method B – 4.33 g, 60%. mp: 
93-95 °C. 1H-NMR (300 MHz, CDCl3) δ 8.00 (d, J = 6.0 Hz, 1H), δ 6.53 (br s, 2H), δ 6.29 (d, J = 6.0 Hz, 
1H), δ 5.78 (br s, 1H), δ 4.46 (br s, 2H), δ 3.84 (s, 6H), δ 3.82 (s, 3H). HREIMS Calcd for C14H16ClN3O3 
309.7481, observed 309.0880. 
 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-chloropyrimidin-4-amine (12): The product was obtained as a 
light orange/brown solid after coupling with benzo[d][1,3]dioxol-5-ylmethylamine (4.23 mL, 33.60 mmol). 
Method B – 7.07 g, 80%. mp: 110-112 °C. 1H-NMR (300 MHz, CDCl3) δ 7.99 (d, J = 6.0 Hz, 1H), δ 6.81 
(br s, 1H), δ 6.76 (br s, 2H), δ 6.20 (d, J = 6.0 Hz, 1H), δ 5.94 (s, 2H), δ 4.42 (br s, 2H). HREIMS Calcd for 
C12H10ClN3O2 263.6797 , observed 263.0462.  
 
2-Chloro-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13): The product was obtained after coupling 
with naphthalen-1-ylmethylamine (4.95 mL, 33.60 mmol) and was a light orange/brown solid (Method A – 
5.43 g, 60%; Method B – 6.83 g, 75%): mp: 158-160 °C. IR (film, CH2Cl2): 3432 cm-1 (NH). 1H-NMR (300 
MHz, CDCl3): δ 8.01 (d, J = 6.0 Hz, 1H), δ 7.82-7.96 (m, 3H), δ 7.40-7.56 (m, 4H), δ 6.23 (d, J = 6.0 Hz, 
1H) δ 4.70 (br s, 2H). HREIMS Calcd for C15H12ClN3 (M+) m/z 269.7289, observed 269.0737. Anal. Calcd 
for: C15H12ClN30.17 H2O: C, 66.79; H, 4.48; N, 15.58. Found: C, 66.04; H, 4.56; N, 15.40. 
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N-Benzhydryl-2-chloropyrimidin-4-amine (14): The product was obtained after coupling with 
diphenylmethylamine (5.81 mL, 33.60 mmol) and was a light yellow solid (Method A using 9:1 DCM: 
EtOAc followed by Method B – 5.46 g, 55%): mp: 133-135 °C. IR (film, CDCl3): 3412 cm-1 (NH). 1H-
NMR (300 MHz, CDCl3) δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.27-7.36 (m, 10H), δ 6.12 (d, J = 6.0 Hz, 1H), δ 
5.78 (br s, 2H). HREIMS Calcd for C17H14ClN3 (M+) m/z 295.7662, found 295.0871. 
 
2-Chloro-N-phenethylpyrimidin-4-amine (15): The product was synthesized after coupling with 2-
phenylethylamine (4.35 mL, 33.60 mmol). The residue was re-dissolved in a solvent mixture of EtOAc, 
DCM and MeOH in ~ 4:2:1 ratio. The resulting oily residue was further purified by SGCC (Method A) to 
afford a white/off-white solid (4.70 g, 60%): mp: 75-77 °C. IR (film, CH2Cl2): 3433 cm-1 (NH). 1H-NMR 
(300 MHz, CDCl3): δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.17-7.33 (m, 5H), δ 6.16 (d, J = 6.0 Hz, 1H), δ 3.60 (br s, 
2H), δ 2.88-2.92 (m, 2H). HREIMS Calcd for C12H12ClN3 (M+) m/z 233.6968, observed 233.0606. 
 
6.1.2. General Method to Prepare Derivatives 2a-c,f-o,q-t, 3-12a,f-h,m, 13a-c,f-o, 14f-o, 15a-c,f,g,n 
To a solution of 2-15 (0.20 g, 0.65-0.91 mmol) in 3 mL of n-BuOH kept in a PV with stirring, a 
cyclic amine (R2 = pyrrolidine, morpholine, thiomorpholine, methylpiperazine, methylpiperidine, isopropyl 
piperazine, isopropylpiperidine, propyl-, hydroxyethyl-, methoxyethyl-, cyclohexyl-, acetyl-, Boc- 
piperazine, 4-chloro, 4-bromo, 4-fluoro or 4-trifluoromethylbenzylpiperazine – 0.85-1.18 mmol) was 
added. The sealed PV was placed in an oil bath at 150-155 °C and stirred for 1 hr. n-BuOH was evaporated 
in vacuo and the residue was re-dissolved in 3:1 EtOAc: DCM (15 mL) and washed successively with 
saturated NaHCO3 and NaCl solution (1:2, 1 x 15 mL). The aqueous layer was washed with EtOAc (2 x 5 
mL) and the organic layer was dried over anhydrous MgSO4 then filtered. The solution was evaporated in 
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6.1.2.1. Benzylamines (2a-c,f-o,q-t) 
N-Benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine (2a): The product was obtained after coupling 2 with 
pyrrolidine (0.10 mL, 1.18 mmol) to afford a light brown solid (0.15 g, 65%). mp: 103-105 °C. IR (film, 
CH2Cl2): 3435 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.87 (d, J = 6.0 Hz, 1H), δ 7.26-7.32 (m, 5H), δ 
5.62 (d, J = 6.0 Hz, 1H), δ 4.86 (br s, 1H), δ 4.51 (d, J = 6.0 Hz, 2H), δ 3.49-3.53 (m, 4H), δ 1.90-1.94 (m, 
4H). HREIMS Calcd for C15H18N4 (M+) m/z 254.3302, observed 254.1964. Anal. Calcd for: 
C15H18N4H2O; C, 66.15; H, 7.40; N, 20.57. Found: C, 66.15; H, 7.40; N, 20.57.  
 
N-Benzyl-2-morpholinopyrimidin-4-amine (2b): The product was obtained after 2 coupling with 
morpholine (0.11 mL, 1.18 mmol) to afford an orange/light brown solid (0.20 g, 80%). mp: 93-95 °C. IR 
(film, CH2Cl2): 3434 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.87 (d, J = 6.0 Hz, 1H), δ 7.29-7.31 (m, 
5H), δ 5.69 (d, J = 6.0 Hz, 1H), δ 4.91 (br s, 1H), δ 4.50 (d, J = 6.0 Hz, 2H), δ 3.70-3.75 (m, 8H). HREIMS 
Calcd for C15H18N4O (M+) m/z 270.3296, observed 270.1605. Anal. Calcd for C15H18N4O: C, 66.64; H, 
6.71; N, 20.73. Found: C, 66.45; H, 6.72; N, 20.46. 
 
N-Benzyl-2-thiomorpholinopyrimidin-4-amine (2c): The product was obtained after 2 coupling with 
thiomorpholine (0.12 mL, 1.18 mmol) to afford a light brown solid (0.20 g, 77%). mp 85–87 °C. IR (film, 
CDCl3): 3258 (NH) cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 1H), δ 7.24-7.33 (m, 
5H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 5.03 (br s, 1H), δ 4.47 (d, J = 6.0 Hz, 2H), δ 4.03-4.07 (m, 4H), δ 2.54-
2.58 (m, 4H). HREIMS Calcd for C15H18N4S (M+) m/z 286.3952, found m/z 286.1872. Anal. Calcd for 
C15H18N4S: C, 62.91; H, 6.33; N, 19.56. Found: C, 62.62; H, 6.33; N, 19.31. 
 
N-Benzyl-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (2f): The product was obtained after coupling 2 
with methylpiperazine (0.14 mL, 1.18 mmol) to afford a light yellow solid (0.22 g, 85%). mp: 150-153 °C. 
IR (film, CH2Cl2): 3454 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.86 (d, J = 6.0 Hz, 1H), δ 7.27-7.32 
(m, 5H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.87 (br s, 1H), δ 4.50 (d, J = 6.0 Hz, 2H), δ 3.77 (t, J = 6.0 Hz, 4H), 
δ 2.42 (t, J = 6.0 Hz, 4H), δ 2.31 (s, 3H). HREIMS calcd for C16H21N5 (M+) m/z 283.3714, found 283.1804. 
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Anal. Calcd for C16H21N50.6 EtOAc: C, 65.74; H, 7.74; N, 20.83. Found: C, 65.64; H, 7.75; N, 20.67. 
 
N-Benzyl-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (2g): The product was obtained after coupling 2 
with methylpiperidine (0.14 mL, 1.18 mmol) to afford a light pink solid (0.22 g, 85%). mp: 83-85 °C. IR 
(film, CH2Cl2): 3433 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.28-7.32 (m, 
5H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 4.84 (br s, 1H), δ 4.63-4.67 (m, 2H), δ 4.50 (d, J = 6.0 Hz, 2H), δ 2.73-
2.81 (m, 2H), δ 1.62-1.66 (m, 2H), δ 1.22-1.26 (m, 1H), δ 1.10-1.18 (m, 2H), δ 0.91 (d, J = 6.0 Hz, 3H). 
HREIMS Calcd for C17H22N4 (M+) m/z 282.3834, found 282.2376. Anal. Calcd for C17H22N4; C, 72.31; H, 
7.85; N, 19.84. Found: C, 72.18; H, 7.85; N, 19.60. 
 
N-Benzyl-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (2h): The product was obtained after 
coupling 2 with isopropylpiperazine (0.18 mL, 1.18 mmol) and was purified using a 3:1 EtOAc: hexanes 
SGCC to afford a white solid (0.14 g, 50%). mp: 103-105 °C. IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR 
(300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.24-7.34 (m, 5H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.93 (br s, 
1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.73-3.76 (m, 4H), δ 2.62-2.71 (m, 1H), δ 2.50-2.53 (m, 4H), δ 1.03 (d, J 
= 6.0 Hz, 6H). HREIMS Calcd for C18H25N5 (M+) m/z 311.4246, found 311.2552. Anal. Calcd for 
C18H25N5; C, 69.42; H, 8.09; N, 22.49. Found: C, 69.69; H, 8.31; N, 22.15. 
 
N-Benzyl-2-(4-isopropylpiperidin-1-yl)pyrimidin-4-amine (2i): The product was obtained after coupling 
2 with isopropylpiperidine (0.18 mL, 1.18 mmol) and was purified using  3:1 ether: hexanes SGCC to 
afford a yellow solid (0.16 g, 55%). mp: 58-60 °C. IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, 
CDCl3): δ 7.86 (d, J = 6.0 Hz, 1H), δ 7.22-7.32 (m, 5H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 4.84 (br s, 1H), δ 
4.71-4.75 (m, 2H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 2.66-2.74 (m, 2H), δ 1.65-1.69 (m, 2H), δ 1.38-1.48 (m, 
1H), δ 1.06-1.21 (m, 3H), δ 0.85-0.88 (m, 6H). HREIMS Calcd for C19H26N4 (M+) m/z 310.4365, found 
310.3086. Anal. Calcd for C19H26N4; C, 73.51; H, 8.44; N, 18.05. Found: C, 73.51; H, 8.57; N, 17.91. 
 
N-Benzyl-2-(4-propylpiperazin-1-yl)pyrimidin-4-amine (2j): The product was obtained after coupling 2 
with n-propylpiperazine.2HBr (0.35 g, 1.18 mmol) and was purified using a 3:1 EtOAc: hexanes SGCC to 
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afford a light orange solid (0.16 g, 55%). mp: 93-95 °C. IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 
MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.21-7.30 (m, 5H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.93 (br s, 1H), 
δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.71-3.75 (m, 4H), δ 2.39-2.42 (m, 4H), δ 2.27-2.30 (m, 2H), δ 1.49-1.56 (m, 
2H), δ 0.87-0.91 (m, 3H). HREIMS Calcd for C18H25N5 (M+) m/z 311.4246, observed 311.2008. Anal. 
Calcd for C18H25N5•0.6 H2O; C, 67.09; H, 8.20; N, 21.73. Found: C, 67.11; H, 7.85; N, 21.55. 
 
2-[4-(4-(Benzylamino)pyrimidin-2-yl)piperazin-1-yl]ethanol (2k): The product was obtained after 
coupling 2 with hydroxyethylpiperazine (0.15 mL, 1.18 mmol). Residue was re-dissolved in 1:1 EtOAc: 
DCM and was purified using a 3:1 EtOAc: hexanes SGCC to afford a brownish yellow solid (0.14 g, 50%). 
mp: 103-105 °C. IR (film, CH2Cl2): 3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 
1H), δ 7.24-7.34 (m, 5H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 5.01 (br s, 1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.73-
3.76 (m, 4H), δ 3.60-3.64 (m, 2H), δ 2.94 (s, 1H), δ 2.51-2.55 (m, 2H), δ 2.47-2.50 (m, 4H). HREIMS 
Calcd for C17H23N5O (M+) m/z 313.3974, found 313.1637. Anal. Calcd for C17H23N5O•0.3 DCM; C, 60.20; 
H, 6.78; N, 20.65. Found: C, 60.03; H, 6.89; N, 20.10. 
 
N-Benzyl-2-[4-(2-methoxyethyl)piperazin-1-yl]pyrimidin-4-amine (2l): The product was obtained after 
coupling 2 with methoxyethylpiperazine (0.18 mL, 1.18 mmol) to afford an orange semi-solid (0.17 g, 
57%). mp: 63-65 °C. IR (film, CH2Cl2): 3433 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.82 (d, J = 6.0 
Hz, 1H), δ 7.21-7.31 (m, 5H), δ 5.62 (d, J = 6.0 Hz, 1H), δ 5.06 (br s, 1H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 
3.74-3.77 (m, 4H), δ 3.48-3.52 (m, 2H), δ 3.32 (s, 3H), δ 2.54-2.58 (m, 2H), δ 2.45-2.48 (m, 4H). HREIMS 
Calcd for C18H25N5O (M+) m/z 327.4240, found 327.2040.  
 
N-Benzyl-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (2m): The product was obtained after 
coupling 2 with cyclohexylpiperazine (0.21 g, 1.18 mmol) and was purified using a 3:1 EtOAc: hexanes 
SGCC to afford an orange solid (0.21 g, 66%). mp: 60-62 °C. IR (film, CH2Cl2): 3435 cm-1 (NH). 1H-NMR 
(300 MHz, CDCl3): δ 7.82 (d, J = 6.0 Hz, 1H), δ 7.21-7.32 (m, 5H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 5.07 (br s, 
1H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 3.72-3.75 (m, 4H), δ 2.54-2.57 (m, 4H), δ 2.25 (s, 1H), δ 1.86 (br s, 2H), 
δ 1.75 (br s, 2H), δ 1.58-1.61 (m, 1H), δ 1.13-1.19 (m, 5H). HREIMS Calcd for C21H29N5 (M+) m/z 
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351.4885, found 351.2259. Anal. Calcd for C21H29N5•0.5 DCM; C, 65.55; H, 7.68; N, 17.78. Found: C, 
65.77; H, 7.70; N, 17.85. 
 
1-[4-(4-(Benzylamino)pyrimidin-2-yl)piperazin-1-yl]ethanone (2n): The product was obtained after 
coupling 2 with acetylpiperazine (0.16 g, 1.18 mmol) to afford a yellowish white solid (0.25 g, 86%). mp: 
150-153 °C. IR (film, CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.87 (d, J = 6.0 Hz, 1H), δ 
7.28-7.31 (m, 5H), δ 5.70 (d, J = 6.0 Hz, 1H), δ 4.93 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 3.72-3.79 (m, 
4H), δ 3.61-3.64 (m, 2H), δ 3.44-3.48 (m, 2H), δ 2.11 (s, 3H). HREIMS Calcd for C17H21N5O (M+) m/z 
311.3815, found 311.1746. Anal. Calcd for C17H21N5O•0.4 EtOAc; C, 64.46; H, 7.04; N, 20.21. Found: C, 
64.43; H, 7.04; N, 20.15. 
 
 Tert-butyl 4-[4-(Benzylamino)pyrimidin-2-yl]piperazine-1-carboxylate (2o): The product was obtained 
after coupling 7 with tert-butyl piperazine-1-carboxylate (0.23 g, 1.18 mmol). Product was purified using a 
3:1 EtOAc: hexanes SGCC to afford a light yellowish solid (0.31 g, 90%). mp: 115-117 °C. IR (film, 
CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.80 (d, J = 6.0 Hz, 1H), δ 7.21-7.30 (m, 5H), δ 
5.65 (d, J = 6.0 Hz, 1H), δ 4.91 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 3.66-3.69 (m, 4H), δ 3.37-3.40 (m, 
4H), δ 1.43 (s, 9H). HREIMS Calcd for C20H27N5O (M+) m/z 369.4607, found 369.2163. Anal. Calcd for 
C20H27N5O2; C, 65.02; H, 7.37; N, 18.96. Found: C, 65.54; H, 7.33; N, 18.76.  
 
N-Benzyl-2-[4-(4-chlorobenzyl)piperazin-1-yl]pyrimidin-4-amine (2q): The product was obtained after 
coupling 2 with 4-chlorobenzylpiperazine (0.23 mL, 1.18 mmol). The sample was purified using a 9:1 
EtOAc:DCM SGCC to afford a yellowish solid (0.20 g, 55%). mp: 88-90 °C. IR (film, CH2Cl2): 3437 cm-1 
(NH). 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.24-7.30 (m, 9H), δ 5.65 (d, J = 6.0 Hz, 
1H), δ 4.87 (br s, 1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.73-3.76 (m, 4H), δ 3.47 (s, 2H), δ 2.41-2.44 (m, 4H). 
HREIMS Calcd for C22H24ClN5 (M+) m/z 393.9125, found 393.2443. Anal. Calcd for C22H24ClN5; C, 67.08; 
H, 6.14; N, 17.78. Found: C, 67.44; H, 6.13; N, 17.68. 
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N-Benzyl-2-[4-(4-bromobenzyl)piperazin-1-yl]pyrimidin-4-amine (2r): The product was obtained after 
coupling 2 with 4-bromobenzylpiperazine (0.30 g, 1.18 mmol) to afford a yellowish solid (0.20 g, 50%). 
mp: 90-93 °C. IR (film, CH2Cl2): 3434 cm-1 (NH). 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), 
δ 7.41-7.44 (m, 2H), δ 7.24-7.34 (m, 5H), δ 7.19-7.22 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.87 (br s, 1H), 
δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.73-3.76 (m, 4H), δ 3.45 (s, 2H), δ 2.41-2.44 (m, 4H). HREIMS Calcd 
C22H24BrN5 (M+) m/z 438.3635, found 438.2430. Anal. Calcd for C22H24BrN5•0.2 EtOAc; C, 60.06; H, 
5.66; N, 15.36. Found: C, 60.07; H, 5.65; N, 15.39. 
 
N-Benzyl-2-[4-(4-fluorobenzyl)piperazin-1-yl]pyrimidin-4-amine (2s): The product was obtained after 
coupling 2 with 4-fluorobenzylpiperazine (0.23 g, 1.18 mmol) to afford an orange semi-solid (0.22 g, 65%). 
IR (film, CH2Cl2): 3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 1H), δ 7.26-7.29 
(m, 7H), δ 6.96-7.02 (m, 2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 5.17 (br s, 1H), δ 4.47 (d, J = 6.0 Hz, 2H), δ 
3.74-3.76 (m, 4H), δ 3.46 (s, 2H), δ 2.40 (t, J = 6.0 Hz, 4H). HREIMS Calcd for C22H24FN5 (M+) m/z 
377.4579, found 377.1980. Anal. Calcd for C22H24FN5•0.5 DCM; C, 64.36; H, 6.00; N, 16.68. Found: C, 
63.95; H, 5.97; N, 16.54. 
 
N-Benzyl-2-[4-(4-trifluoromethylbenzyl)piperazin-1-yl]pyrimidin-4-amine (2t): The product was 
obtained after coupling 2 with 4-trifluoromethylbenzylpiperazine (0.25 mL, 1.18 mmol) to afford a 
yellowish orange solid (0.25 g, 64%). mp: 88-90 °C. IR (film, CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 
MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.55-7.58 (m, 2H), δ 7.44-7.47 (m, 2H), δ 7.24-7.34 (m, 5H), δ 
5.65 (d, J = 6.0 Hz, 1H), δ 5.00 (br s, 1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.75-3.78 (m, 4H), δ 3.55 (s, 2H), δ 
2.43-2.46 (m, 4H). HREIMS Calcd C23H24F3N5 (M+) m/z 427.4654, found 427.2203. Anal. Calcd for 
C23H24F3N5; C, 64.62; H, 5.66; N, 16.38. Found: C, 64.39; H, 5.64; N, 16.12. 
 
6.1.2.2. 2-Chlorobenzylamines (3a,f-h,m) 
N-(2-Chlorobenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (3a): The product was obtained after coupling 
3 with pyrrolidine (0.08 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to afford a 
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light brown semi-solid (0.16 g, 70%). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.34-7.41 
(m, 2H), δ 7.17-7.23 (m, 2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.98 (br s, 1H), δ 4.61 (d, J = 6.0 Hz, 2H), δ 
3.50-3.53 (m, 4H), δ 1.91-1.94 (m, 4H). HREIMS Calcd for C15H17ClN4 (M+) m/z 288.7753, observed 
288.1145. 
 
N-(2-Chlorobenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (3f): The product was obtained after 
coupling 3 with methylpiperazine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a beige solid (0.18 g, 72%). mp: 105-107 °C. 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 
6.0 Hz, 1H), δ 7.33-7.38 (m, 2H), δ 7.17-7.22 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.98 (br s, 1H), δ 4.59 
(d, J = 6.0 Hz, 2H), δ 3.74-3.77 (m, 4H), δ 2.39-2.42 (m, 4H), δ 2.30 (s, 3H). HREIMS calcd for 
C16H20ClN5 (M+) m/z 317.8165, found 317.1403. 
 
N-(2-Chlorobenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (3g): The product was obtained after 
coupling 3 with methylpiperidine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a light orange/yellow semi-solid (0.12 g, 50%). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 
6.0 Hz, 1H), δ 7.35-7.39 (m, 2H), δ 7.18-7.23 (m, 2H), δ 5.60 (d, J = 6.0 Hz, 1H), δ 4.95 (br s, 1H), δ 4.63-
4.67 (m, 2H), δ 4.59 (d, J = 6.0 Hz, 2H), δ 2.73-2.81 (m, 2H), δ 1.62-1.66 (m, 2H), δ 1.22-1.26 (m, 1H), δ 
1.10-1.18 (m, 2H), δ 0.91 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C17H21ClN4 (M+) m/z 316.8284, found 
316.1452. 
 
N-(2-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (3h): The product was obtained 
after coupling 3 with isopropylpiperazine (0.16 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford a light brown solid (0.18 g, 65%). mp: 97-99 °C. 1H-NMR (300 MHz, CDCl3): δ 
7.85 (d, J = 6.0 Hz, 1H), δ 7.32-7.38 (m, 2H), δ 7.16-7.21 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.97 (br s, 
1H), δ 4.59 (d, J = 6.0 Hz, 2H), δ 3.74-3.77 (m, 4H), δ 2.66-2.72 (m, 1H), δ 2.50-2.54 (m, 4H), δ 1.02 (d, J 
= 6.0 Hz, 6H). HREIMS Calcd for C18H24ClN5 (M+) m/z 345.8697, found 345.1729. 
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N-(2-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (3m): The product was obtained 
after coupling 3 with cyclohexylpiperazine (0.18 g, 1.02 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford an orange solid (0.21 g, 70%). mp: 56-58 °C. 1H-NMR (300 MHz, CDCl3): δ 7.85 
(d, J = 6.0 Hz, 1H), δ 7.32-7.38 (m, 2H), δ 7.16-7.21 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.97 (br s, 1H), 
δ 4.59 (d, J = 6.0 Hz, 2H), δ 3.72-3.76 (m, 4H), δ 2.55-2.59 (m, 4H), δ 2.26 (s, 1H), δ 1.88 (br s, 2H), δ 
1.77 (br s, 2H), δ 1.58-1.61 (m, 1H), δ 1.13-1.19 (m, 5H). HREIMS Calcd for C21H29N5 (M+) m/z 385.9335, 
found 385.2027. 
 
6.1.2.3. 3-Chlorobenzylamines (4a,f-h,m) 
N-(3-Chlorobenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (4a): The product was obtained after coupling 
4 with pyrrolidine (0.08 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to afford a 
light orange/brown solid (0.14 g, 61%). mp: 90-92 °C. 1H-NMR (300 MHz, CDCl3) δ 7.82 (d, J = 6.0 Hz, 
1H), δ 7.27-7.31 (m, 1H), δ 7.13-7.21 (m, 3H), δ 5.69 (d, J = 6.0 Hz, 1H), δ 5.35 (br s, 1H), δ 4.50 (d, J = 
6.0 Hz, 2H), δ 3.49-3.53 (m, 4H), δ 1.90-1.95 (m, 4H). HREIMS Calcd for C15H17ClN4 288.7753, observed 
288.1134. 
 
N-(3-Chlorobenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (4f): The product was obtained after 
coupling 4 with methylpiperazine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford an off-white solid (0.20 g, 80%). mp: 98-100 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J 
= 6.0 Hz, 1H), δ 7.26-7.30 (m, 1H), δ 7.16-7.23 (m, 3H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.94 (br s, 1H), δ 
4.48 (d, J = 6.0 Hz, 2H), δ 3.75-3.78 (m, 4H), δ 2.41-2.44 (m, 4H), δ 2.31 (s, 3H). HREIMS Calcd for 
C16H20ClN5 317.8165, observed 317.1404. 
 
N-(3-Chlorobenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (4g): The product was obtained after 
coupling 4 with methylpiperidine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford an off-white solid (0.20 g, 80%). mp: 88-90 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 
6.0 Hz, 1H), δ 7.27-7.30 (m, 1H), δ 7.19-7.26 (m, 3H), δ 5.62 (d, J = 6.0 Hz, 1H), δ 5.00 (br s, 1H), δ 4.60-
4.64 (m, 2H),δ 4.48 (d, J = 6.0 Hz, 2H), δ 2.72-2.77 (m, 2H), δ 1.58-1.62 (m, 2H), δ 1.53-1.57 (m, 1H), δ 
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1.05-1.17 (m, 2H), δ 0.91 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C17H21ClN4 316.8284, observed 
316.1452.  
 
N-(3-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (4h): The product was obtained 
after coupling 4 with isopropylpiperazine (0.16 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford a beige solid (0.15 g, 55%). mp: 105-107 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 
(d, J = 6.0 Hz, 1H), δ 7.27-7.31 (m, 1H), δ 7.19-7.24 (m, 3H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 1H), 
δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.74-3.80 (m, 4H), δ 2.69-2.73 (m, 1H), δ 2.50-2.56 (m, 4H), δ 1.05 (d, J = 6.0 
Hz, 6H). HREIMS Calcd for C18H24ClN5 345.8697, observed 345.1724. 
 
N-(3-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (4m): The product was obtained 
after coupling 4 with cyclohexylpiperazine (0.18 g, 1.02 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford a whitish solid (0.15 g, 59%). mp: 90-92 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 
(d, J = 6.0 Hz, 1H), δ 7.28-7.32 (m, 1H), δ 7.19-7.24 (m, 3H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 1H), 
δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.74-3.79 (m, 4H), δ 2.57-2.62 (m, 4H), δ 2.30 (br s, 1H), δ 1.89 (br s, 2H), δ 
1.78 (br s, 2H), δ 1.59-1.60 (m, 1H), δ 1.15-1.22 (m, 5H). HREIMS Calcd for C21H28ClN5 385.9335, 
observed 385.2022. 
 
6.1.2.4. 4-Chlorobenzylamines (5a,f-h,m) 
N-(4-Chlorobenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (5a): The product was obtained after coupling 
5 with pyrrolidine (0.08 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to afford a 
light orange/brown solid (0.15 g, 64%). mp: 129-131 °C. 1H-NMR (300 MHz, CDCl3) δ 7.84 (d, J = 6.0 
Hz, 1H), δ 7.24-7.33 (m, 4H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 5.12 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 
3.50-3.54 (m, 4H), δ 1.90-1.94 (m, 4H). HREIMS Calcd for C15H17ClN4 288.7753, observed 288.1136. 
 
N-(4-Chlorobenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (5f): The product was obtained after 
coupling 5 with methylpiperazine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
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SGCC to afford an off-white solid (0.22 g, 88%). mp: 135-137 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, 
J = 6.0 Hz, 1H), δ 7.26-7.33 (m, 2H), δ 7.21-7.25 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 1H), δ 
4.47 (d, J = 6.0 Hz, 2H), δ 3.76-3.79 (m, 4H), δ 2.43-2.46 (m, 4H), δ 2.33 (s, 3H). HREIMS Calcd for 
C16H20ClN5 317.8165 , observed 317.1410. 
 
N-(4-Chlorobenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (5g): The product was obtained after 
coupling 5 with methylpiperidine (0.12 mL, 1.02 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a light orange solid (0.20 g, 80%). mp: 86-88 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J 
= 6.0 Hz, 1H), δ 7.26-7.33 (m, 2H), δ 7.22-7.26 (m, 2H), δ 5.60 (d, J = 6.0 Hz, 1H), δ 4.89 (br s, 1H), δ 
4.60-4.65 (m, 2H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 2.72-2.80 (m, 2H), δ 1.62-1.66 (m, 2H), δ 1.56-1.61 (m, 
1H), δ 1.03-1.09 (m, 2H), δ 0.91 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C16H20ClN5 316.8284, observed 
316.1449.  
 
N-(4-Chlorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (5h): The product was obtained 
after coupling 5 with isopropylpiperazine (0.16 mL, 1.02 mmol) to afford a beige solid (0.25 g, 93%). mp: 
120-122 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.26-7.33 (m, 2H), δ 7.21-7.26 (m, 
2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.89 (br s, 1H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 3.74-3.77 (m, 4H), δ 2.70-
2.74 (m, 1H), δ 2.52-2.55 (m, 4H), δ 1.05 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C18H24ClN5 345.8697, 
observed 345.1724. 
 
N-(4-Chlorobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (5m): The product was obtained 
after coupling 5 with cyclohexylpiperazine (0.18 g, 1.02 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford an orange/brown solid (0.26 g, 86%). mp: 55-57 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.86 (d, J = 6.0 Hz, 1H), δ 7.26-7.30 (m, 2H), δ 7.21-7.25 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.88 (br s, 
1H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 3.74-3.80 (m, 4H), δ 2.58-2.64 (m, 4H), δ 2.29-2.36 (m, 1H), δ 1.90 (br s, 
2H), δ 1.79 (br s, 2H), δ 1.61-1.65 (m, 1H), δ 1.20-1.26 (m, 5H). HREIMS Calcd for C21H28ClN5 385.9335, 
observed 385.2035. 
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6.1.2.5. 2-Bromobenzylamines (6a,f-h,m) 
N-(4-Bromobenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (6a): The product was obtained after coupling 
6 with pyrrolidine (0.07 mL, 0.87 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to afford a 
light yellow solid (0.12 g, 54%). mp: 122-124 °C. 1H-NMR (300 MHz, CDCl3) δ 7.78 (d, J = 6.0 Hz, 1H), 
δ 7.39-7.43 (m, 2H), δ 7.17-7.22 (m, 2H), δ 5.77 (d, J = 6.0 Hz, 1H), δ 5.06 (br s, 1H), δ 4.49 (d, J = 6.0 
Hz, 2H), δ 3.46-3.53 (m, 4H), δ 1.91-1.98 (m, 4H). HREIMS Calcd for C15H17BrN4 333.2263, observed 
332.0640. 
 
N-(4-Bromobenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (6f): The product was obtained after 
coupling 6 with methylpiperazine (0.10 mL, 0.87 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford an orange/brown solid (0.17 g, 70%). mp: 65-67 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 
(d, J = 6.0 Hz, 1H), δ 7.40-7.45 (m, 2H), δ 7.15-7.23 (m, 2H), δ 5.70 (d, J = 6.0 Hz, 1H), δ 5.05 (br s, 1H), 
δ 4.45 (d, J = 6.0 Hz, 2H), δ 3.90-3.95 (m, 4H), δ 2.61-2.66 (m, 4H), δ 2.47 (s, 3H). HREIMS Calcd for 
C16H20BrN5 362.2675, observed 361.0903. 
 
N-(4-Bromobenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (6g): The product was obtained after 
coupling 6 with methylpiperidine (0.10 mL, 0.87 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a light orange solid (0.12 g, 50%). mp: 85-87 °C. 1H-NMR (300 MHz, CDCl3) δ 7.82 (d, J 
= 6.0 Hz, 1H), δ 7.40-7.44 (m, 2H), δ 7.17-7.24 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 5.03 (br s, 1H), δ 
4.60-4.64 (m, 2H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 2.75-2.83 (m, 2H), δ 1.63-1.71 (m, 2H), δ 1.57-1.61 (m, 
1H), δ 1.07-1.12 (m, 2H), δ 0.91 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C17H21BrN4 361.2794, observed 
360.0953. 
 
N-(4-Bromobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (6h): The product was obtained 
after coupling 6 with isopropylpiperazine (0.10 mL, 0.87 mmol) to afford an orangey/brown solid (0.18 g, 
69%). mp: 115-117 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.39-7.44 (m, 2H), δ 
7.16-7.24 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 1H), δ 4.45 (d, J = 6.0 Hz, 2H), δ 3.60-3.66 (m, 
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4H), δ 2.59-2.66 (m, 4H), δ 2.30-2.37 (m, 1H), δ 1.06 (d, J = 6.0 Hz, 6H). HRMS Calcd for C18H24BrN5 
390.3207, observed 389.1213. 
 
N-(4-Bromobenzyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (6m): The product was obtained 
after coupling 6 with cyclohexylpiperazine (0.15 g, 0.87 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford an orange/brown solid (0.15 g, 60%). mp: 51-53 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.85 (d, J = 6.0 Hz, 1H), δ 7.39-7.44 (m, 2H), δ 7.16-7.24 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 
1H), δ 4.45 (d, J = 6.0 Hz, 2H), δ 3.60-3.66 (m, 4H), δ 2.59-2.66 (m, 4H), δ 2.30-2.37 (m, 1H), δ 1.91 (br s, 
2H), δ 1.79 (br s, 2H), δ 1.60-1.64 (m, 1H), δ 1.20-1.26 (m, 5H). HREIMS Calcd for C21H28BrN5 430.3845, 
observed 429.1529.  
 
6.1.2.6. 4-Fluorobenzylamines (7a,f-h,m) 
N-(4-Fluorobenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (7a): The product was obtained after coupling 
7 with pyrrolidine (0.09 mL, 1.09 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to afford a 
white solid (0.14 g, 60%). mp: 120-122 °C. 1H-NMR (300 MHz, CDCl3) δ 7.81 (d, J = 6.0 Hz, 1H), δ 7.26-
7.31 (m, 2H), δ 6.96-7.02 (m, 2H), δ 5.76 (d, J = 6.0 Hz, 1H), δ 5.43 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), 
δ 3.51-3.55 (m, 4H), δ 1.91-1.95 (m, 4H). HREIMS Calcd for C11H17FN3 272.3207, observed 272.1437. 
 
N-(4-Fluorobenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (7f): The product was obtained after 
coupling 7 with methylpiperazine (0.12 mL, 1.09 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a light yellow solid (0.18 g, 71%). mp: 152-154 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, 
J = 6.0 Hz, 1H), δ 7.24-7.29 (m, 2H), δ 6.96-7.02 (m, 2H), δ 5.68 (d, J = 6.0 Hz, 1H), δ 4.94 (br s, 1H), δ 
4.48 (d, J = 6.0 Hz, 2H), δ 3.85-3.88 (m, 4H), δ 2.53-2.56 (m, 4H), δ 2.32 (s, 3H). HREIMS Calcd for 
C16H20FN5 301.3619, observed 301.1701. 
 
N-(4-Fluorobenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (7g): The product was obtained after 
coupling 7 with methylpiperidine (0.12 mL, 1.09 mmol) and was purified using a 9:1 EtOAc: MeOH 
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SGCC to afford a light orange solid (0.17 g, 69%). mp: 90-92 °C. 1H-NMR (300 MHz, CDCl3) δ 7.53 (d, J 
= 6.0 Hz, 1H), δ 7.24-7.30 (m, 2H), δ 6.89-6.98 (m, 2H), δ 6.22 (d, J = 6.0 Hz, 1H), δ 5.07 (br s, 1H), δ 
4.55-4.61 (m, 2H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 2.90-2.98 (m, 2H), δ 1.71-1.76 (m, 2H), δ 1.09-1.23 (m, 
3H), δ 0.93 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C17H21FN4 300.3738, observed 300.1748. 
 
N-(4-Fluorobenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (7h): The product was obtained 
after coupling 7 with isopropylpiperazine (0.12 mL, 1.09 mmol) to afford an orangey/brown solid (0.22 g, 
85%). mp: 85-87 °C. 1H-NMR (300 MHz, CDCl3) δ 7.84 (d, J = 6.0 Hz, 1H), δ 7.23-7.28 (m, 2H), δ 6.96-
7.02 (m, 2H), δ 5.68 (d, J = 6.0 Hz, 1H), δ 5.01 (br s, 1H), δ 4.45 (d, J = 6.0 Hz, 2H), δ 3.60-3.64 (m, 4H), 
δ 2.89-2.93 (m, 1H), δ 2.65-2.69 (m, 4H), δ 1.17 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C18H24FN5 
329.4151, observed 329.2025.  
 
2-(4-Cyclohexylpiperazin-1-yl)-N-(4-fluorobenzyl)pyrimidin-4-amine (7m): The product was obtained 
after coupling 7 with cyclohexylpiperazine (0.18 g, 1.09 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford an orange/brown solid (0.25 g, 80%). mp: 50-52 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.85 (d, J = 6.0 Hz, 1H), δ 7.24-7.39 (m, 2H), δ 6.94-7.02 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 
1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.80-3.84 (m, 4H), δ 2.62-2.66 (m, 4H), δ 2.34-2.39 (m, 1H), δ 2.02 (br s, 
2H), δ 1.92  (br s, 2H), δ 1.60-1.64 (m, 1H), δ 1.14-1.18 (m, 5H). HREIMS Calcd for C21H28FN5 369.4789, 
observed 369.2341. 
 
6.1.2.7. 4-Methylbenzylamines (8a,f-h,m) 
N-(4-Methylbenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (8a): The product was obtained after 
coupling 8 with pyrrolidine (0.09 mL, 1.11 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to 
afford a yellow solid (0.11 g, 50%). mp: 90-92 °C. 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, J = 6.0 Hz, 1H), 
δ 7.16-7.22 (m, 2H), δ 7.07-7.15 (m, 2H), δ 5.78 (d, J = 6.0 Hz, 1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.54-3.58 
(m, 4H), δ 2.31 (s, 3H), δ 1.91-1.95 (m, 4H). HREIMS Calcd for C16H20N4 268.3568, observed 268.1688. 
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N-(4-Methylbenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (8f): The product was obtained after 
coupling 8 with methylpiperazine (0.12 mL, 1.11 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a yellow solid (0.16 g, 63%). mp: 95-97 °C. 1H-NMR (300 MHz, CDCl3) δ 7.87 (d, J = 6.0 
Hz, 1H), δ 7.18-7.23 (m, 2H), δ 7.05-7.11 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.86 (br s, 1H), δ 4.44 (d, J 
= 6.0 Hz, 2H), δ 3.76-3.80 (m, 4H), δ 2.41-2.45 (m, 4H), δ 2.32 (s, 3H), δ 2.31 (s, 3H). HREIMS Calcd for 
C17H23N5 297.3980, observed 297.1949. 
 
N-(4-Methylbenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (8g): The product was obtained after 
coupling 8 with methylpiperidine (0.12 mL, 1.11 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a light yellow solid (0.12 g, 49%). mp: 96-98 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J 
= 6.0 Hz, 1H), δ 7.18-7.22 (m, 2H), δ 7.11-7.15 (m, 2H), δ 5.62 (d, J = 6.0 Hz, 1H), δ 4.80 (br s, 1H), δ 
4.64-4.68 (m, 2H), δ 4.44 (d, J = 6.0 Hz, 2H), δ 2.72-2.80 (m, 2H), δ 2.32 (s, 3H), δ 1.62-1.66 (m, 2H), δ 
1.52-1.59 (m, 1H), δ 1.10-1.17 (m, 2H), δ 0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C18H24N4 296.4100, 
observed 296.1997.  
 
2-(4-Isopropylpiperazin-1-yl)-N-(4-methylbenzyl)pyrimidin-4-amine (8h): The product was obtained 
after coupling 8 with isopropylpiperazine (0.12 mL, 1.11 mmol) to afford an orangey/brown semi-solid 
(0.18 g, 65%). 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.16-7.21 (m, 2H), δ 7.09-7.14 
(m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.85 (br s, 1H), δ 4.44 (d, J = 6.0 Hz, 2H), δ 3.79-3.83 (m, 4H), δ 
2.71-2.75 (m, 1H), δ 2.52-2.56 (m, 4H), δ 2.31 (s, 3H), δ 1.03 (d, J = 6.0 Hz, 6H). HREIMS Calcd for 
C19H27N5 325.4512, observed 325.2271.  
 
2-(4-Cyclohexylpiperazin-1-yl)-N-(4-methylbenzyl)-pyrimidin-4-amine (8m): The product was obtained 
after coupling 8 with cyclohexylpiperazine (0.18 g, 1.11 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford a light orange solid (0.21 g, 67%). mp: 55-57 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.85 (d, J = 6.0 Hz, 1H), δ 7.16-7.21 (m, 2H), δ 7.10-7.15 (m, 2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.84 (br s, 
1H), δ 4.43 (d, J = 6.0 Hz, 2H), δ 3.74-3.78 (m, 4H), δ 2.57-2.61 (m, 4H), δ 2.32 (s, 3H), δ 2.25-2.31 (m, 
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1H), δ 1.88 (br s, 2H), δ 1.78 (br s, 2H), δ 1.60-1.64 (m, 1H), δ 1.19-1.24 (m, 5H). HRMS Calcd for 
C22H31N5 365.5150, observed 365.2570.  
 
6.1.2.8. 4-Methoxybenzylamines (9a,f-h,m) 
N-(4-Methoxybenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (9a): The product was obtained after 
coupling 9 with pyrrolidine (0.08 mL, 1.04 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to 
afford a yellow solid (0.14 g, 61%). mp: 96-98 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 6.0 Hz, 1H), 
δ 7.22-7.27 (m, 2H), δ 6.81-6.86 (m, 2H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 4.85 (br s, 1H), δ 4.42 (d, J = 6.0 
Hz, 2H), δ 3.77 (s, 3H), δ 3.49-3.53 (m, 4H), δ 1.90-1.94 (m, 4H). HREIMS Calcd for C16H20N4O 
284.3562, observed 284.1646. 
 
N-(4-Methoxybenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (9f): The product was obtained 
after coupling 9 with methylpiperazine (0.11 mL, 1.04 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a yellow solid (0.18 g, 71%). mp: 105-107 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 
6.0 Hz, 1H), δ 7.21-7.26 (m, 2H), δ 6.82-6.87 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.83 (br s, 1H), δ 4.41 
(d, J = 6.0 Hz, 2H), δ 3.75-3.81 (m, 7H), δ 2.43-2.47 (m, 4H), δ 2.32 (s, 3H). HREIMS Calcd for 
C17H23N5O 313.3974, observed 313.1895.  
 
N-(4-Methoxybenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (9g): The product was obtained 
after coupling 9 with methylpiperidine (0.11 mL, 1.04 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford an off-white solid (0.11 g, 45%). mp: 84-86 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 
6.0 Hz, 1H), δ 7.20-7.23 (m, 2H), δ 6.83-6.86 (m, 2H), δ 5.60 (d, J = 6.0 Hz, 1H), δ 4.78 (br s, 1H), δ 4.64-
4.68 (m, 2H), δ 4.41 (d, J = 6.0 Hz, 2H), δ 3.78 (s, 3H), δ 2.73-2.80 (m, 2H), δ 1.62-1.66 (m, 2H), δ 1.56-
1.62 (m, 1H), δ 1.11-1.19 (m, 2H), δ 0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C18H24N4O 312.4094, 
observed 312.1944. 
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2-(4-Isopropylpiperazin-1-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (9h): The product was obtained 
after coupling 9 with isopropylpiperazine (0.11 mL, 1.04 mmol) to afford a beige solid (0.13 g, 49%). mp: 
128-130 °C. 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.21-7.26 (m, 2H), δ 6.83-6.86 (m, 
2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.82 (br s, 1H), δ 4.41 (d, J = 6.0 Hz, 2H), δ 3.74-3.78 (m, 7H), δ 2.67-
2.73 (m, 1H), δ 2.51-2.55 (m, 4H), δ 1.03 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C19H27N5O 341.4506, 
observed 341.2221.  
 
2-(4-Cyclohexylpiperazin-1-yl)-N-(4-methoxybenzyl)pyrimidin-4-amine (9m): The product was 
obtained after coupling 9 with cyclohexylpiperazine (0.17 g, 1.04 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford an orange brown solid (0.20 g, 60%). mp: 51-53 °C. 1H-NMR (300 MHz, 
CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.21-7.26 (m, 2H), δ 6.83-6.86 (m, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 
4.81 (br s, 1H), δ 4.41 (d, J = 6.0 Hz, 2H), δ 3.71-3.78 (m, 7H), δ 2.58-2.62 (m, 4H), δ 2.28-2.32 (m, 1H), δ 
1.89 (br s, 2H), δ 1.77 (br s, 2H), δ 1.60-1.64 (m, 1H), δ 1.16-1.23 (m, 5H). HREIMS Calcd for C22H31N5O 
381.5144, observed 381.2533. 
 
6.1.2.9. 3,4-Dimethoxybenzylamines (10a,f-h,m) 
N-(3,4-Dimethoxybenzyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (10a): The product was obtained after 
coupling 10 with pyrrolidine (0.07 mL, 0.93 mmol) and was purified using a 9:1 EtOAc: MeOH SGCC to 
afford a beige solid (0.12 g, 55%). mp: 68-70 °C. 1H-NMR (300 MHz, CDCl3) δ 7.88 (d, J = 6.0 Hz, 1H), δ 
6.78-6.88 (m, 3H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.82 (br s, 1H), δ 4.43 (d, J = 6.0 Hz, 2H), δ 3.85 (s, 3H), δ 
3.84 (s, 3H), δ 3.46-3.51 (m, 4H), δ 1.90-1.95 (m, 4H). HREIMS Calcd for C17H22N4O2 314.3822, observed 
314.1736.  
 
N-(3,4-Dimethoxybenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (10f): The product was 
obtained after coupling 10 with methylpiperazine (0.10 mL, 0.93 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a yellow solid (0.12 g, 50%). mp: 75-77 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.87 (d, J = 6.0 Hz, 1H), δ 6.79-6.88 (m, 3H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.82 (br s, 1H), δ 4.44 (d, J = 
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6.0 Hz, 2H), δ 3.85 (s, 3H), δ 3.84 (s, 3H), δ 3.76-3.80 (m, 4H), δ 2.40-2.44 (m, 4H), δ 2.30 (s, 3H). 
HREIMS Calcd for C18H25N5O2 343.4234, observed 343.2011. 
 
N-(3,4-Dimethoxybenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (10g): The product was 
obtained after coupling 10 with methylpiperidine (0.10 mL, 0.93 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a beige semi-solid (0.11 g, 46%). 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J 
= 6.0 Hz, 1H), δ 6.79-6.88 (m, 3H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 4.79 (br s, 1H), δ 4.64-4.68 (m, 2H), δ 
4.41 (d, J = 6.0 Hz, 2H), δ 3.85 (s, 3H), δ 3.84 (s, 3H), δ 2.72-2.79 (m, 2H), δ 1.63-1.67 (m, 2H), δ 1.55-
1.61 (m, 1H), δ 1.10-1.19 (m, 2H), δ 0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C19H26N4O2 342.4353, 
observed 342.2043.  
 
N-(3,4-Dimethoxybenzyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (10h): The product was 
obtained after coupling 10 with isopropylpiperazine (0.10 mL, 0.93 mmol) to afford a light brown semi-
solid (0.16 g, 60%). 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 6.0 Hz, 1H), δ 6.79-6.89 (m, 3H), δ 5.65 (d, 
J = 6.0 Hz, 1H), δ 4.83 (br s, 1H), δ 4.43 (d, J = 6.0 Hz, 2H), δ 3.85 (s, 3H), δ 3.84 (s, 3H), δ 3.76-3.80 (m, 
4H), δ 2.64-2.70 (m, 1H), δ 2.51-2.56 (m, 4H), δ 1.04 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C20H29N5O2 
371.4766, observed 371.2318. 
 
2-(4-Cyclohexylpiperazin-1-yl)-N-(3,4-dimethoxybenzyl)pyrimidin-4-amine (10m): The product was 
obtained after coupling 10 with cyclohexylpiperazine (0.15 g, 0.93 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford an orangey brown solid (0.21 g, 71%). mp: 56-58 °C. 1H-NMR (300 MHz, 
CDCl3) δ 7.83 (d, J = 6.0 Hz, 1H), δ 6.79-6.89 (m, 3H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.82 (br s, 1H), δ 4.42 
(d, J = 6.0 Hz, 2H), δ 3.85 (s, 3H), δ 3.84 (s, 3H), δ 3.76-3.81 (m, 4H), δ 2.56-2.61 (m, 4H), δ 2.27-2.32 
(m, 1H), δ 1.90 (br s, 2H), δ 1.78 (br s, 2H), δ 1.59-1.63 (m, 1H), δ 1.17-1.24 (m, 5H). HREIMS Calcd for 
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6.1.2.10. 3,4,5-Trimethoxybenzylamines (11a,f-h,m) 
2-(Pyrrolidin-1-yl)-N-(3,4,5-trimethoxybenzyl)pyrimidin-4-amine (11a): The product was obtained 
after coupling 11 with pyrrolidine (0.06 mL, 0.84 mmol) and was purified using a 9:1 EtOAc: MeOH 
SGCC to afford a beige solid (0.15 g, 67%). mp: 66-68 °C. 1H-NMR (300 MHz, CDCl3) δ 7.89 (d, J = 6.0 
Hz, 1H), δ 6.55 (s, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.85 (br s, 1H), δ 4.43 (d, J = 6.0 Hz, 2H), δ 3.82 (s, 
6H), δ 3.81 (s, 3H), δ 3.50-3.55 (m, 4H), δ 1.90-1.95 (m, 4H). HREIMS Calcd for C18H24N4O3 344.4082, 
observed 344.1847. 
 
N-(3,4,5-Trimethoxybenzyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (11f): The product was 
obtained after coupling 11 with methylpiperazine (0.09 mL, 0.84 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a yellow solid (0.13 g, 54%). mp: 55-57 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.87 (d, J = 6.0 Hz, 1H), δ 6.54 (s, 2H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.84 (br s, 1H), δ 4.42 (d, J = 6.0 Hz, 
2H), δ 3.82 (s, 6H), δ 3.81 (s, 3H), δ 3.76-3.80 (m, 4H), δ 2.40-2.44 (m, 4H), δ 2.31 (s, 3H). HREIMS 
Calcd for C19H27N5O3 373.4494, observed 373.2124. 
 
N-(3,4,5-Trimethoxybenzyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (11g): The product was 
obtained after coupling 11 with methylpiperidine (0.09 mL, 0.84 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a beige solid (0.12 g, 48%). mp: 65-67 °C. 1H-NMR (300 MHz, CDCl3) δ 
7.85 (d, J = 6.0 Hz, 1H), δ 6.54 (s, 2H), δ 5.71 (d, J = 6.0 Hz, 1H), δ 4.78 (br s, 1H), δ 4.65-4.69 (m, 2H), δ 
4.43 (d, J = 6.0 Hz, 2H), δ 3.83 (s, 6H), δ 3.82 (s, 3H), δ 2.78-2.86 (m, 2H), δ 1.64-1.70 (m, 2H), δ 1.58-
1.63 (m, 1H), δ 1.07-1.16 (m, 2H), δ 0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C20H28N4O3 372.4613, 
observed 372.2162.  
 
2-(4-Isopropylpiperazin-1-yl)-N-(3,4,5-trimethoxybenzyl)pyrimidin-4-amine (11h): The product was 
obtained after coupling 11 with isopropylpiperazine (0.09 mL, 0.84 mmol) to afford a light orange solid 
(0.14 g, 54%). mp: 100-102 °C. 1H-NMR (300 MHz, CDCl3) δ 7.87 (d, J = 6.0 Hz, 1H), δ 6.45 (m, 2H), δ 
5.65 (d, J = 6.0 Hz, 1H), δ 4.83 (br s, 1H), δ 4.42 (d, J = 6.0 Hz, 2H), δ 3.83 (s, 6H), δ 3.82 (s, 3H), δ 3.76-
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3.80 (m, 4H), δ 2.64-2.70 (m, 1H), δ 2.53-2.57 (m, 4H), δ 1.03 (d, J = 6.0 Hz, 6H). HREIMS Calcd for 
C21H31N5O3 401.5025, observed 401.2429.  
 
2-(4-Cyclohexylpiperazin-1-yl)-N-(3,4,5-trimethoxybenzyl)pyrimidin-4-amine (11m): The product was 
obtained after coupling 11 with cyclohexylpiperazine (0.14 g, 0.84 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford an orange brown solid (0.20 g, 70%). mp: 56-58 °C. 1H-NMR (300 MHz, 
CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 6.54 (s, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.83 (br s, 1H), δ 4.41 (d, J 
= 6.0 Hz, 2H), δ 3.83 (s, 6H), δ 3.82 (s, 3H), δ 3.75-3.80 (m, 4H), δ 2.58-2.62 (m, 4H), δ 2.24-2.29 (m, 
1H), δ 1.89 (br s, 2H), δ 1.77 (br s, 2H), δ 1.59-1.63 (m, 1H), δ 1.15-1.22 (m, 5H). HREIMS Calcd for 
C24H35N5O3 441.5664, observed 441.2744. 
 
6.1.2.11. Benzo[d][1,3]dioxol-5-methylamines (12a,f-h,m) 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(pyrrolidin-1-yl)pyrimidin-4-amine (12a): The product was 
obtained after coupling 12 with pyrrolidine (0.07 mL, 0.99 mmol) and was purified using a 9:1 EtOAc: 
MeOH SGCC to afford a beige solid (0.11 g, 48%). mp: 60-62 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J 
= 6.0 Hz, 1H), δ 6.76-6.85 (m, 3H), δ 5.86 (s, 2H), δ 5.60 (d, J = 6.0 Hz, 1H), δ 4.82 (br s, 1H), δ 4.47 (d, J 
= 6.0 Hz, 2H), δ 3.49-3.53 (m, 4H), δ 1.91-1.95 (m, 4H). HREIMS Calcd for C16H18N4O2 298.3397, 
observed 298.1436. 
 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine (12f): The product 
was obtained after coupling 12 with methylpiperazine (0.11 mL, 0.99 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a light yellow solid (0.15 g, 60%). mp: 75-77 °C. 1H-NMR (300 MHz, 
CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 6.80-6.89 (m, 3H), δ 5.92 (s, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.80 
(br s, 1H), δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.72-3.77 (m, 4H), δ 2.40-2.45 (m, 4H), δ 2.31 (s, 3H). HREIMS 
Calcd for C17H21N5O2 327.3809, observed 327.1700. 
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N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(4-methylpiperidin-1-yl)pyrimidin-4-amine (12g): The product 
was obtained after coupling 12 with methylpiperidine (0.11 mL, 0.99 mmol) and was purified using a 9:1 
EtOAc: MeOH SGCC to afford a beige semi-solid (0.11 g, 46%). 1H-NMR (300 MHz, CDCl3) δ 7.85 (d, J 
= 6.0 Hz, 1H), δ 6.72-6.80 (m, 3H), δ 5.91 (s, 2H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.78 (br s, 1H), δ 4.63-4.67 
(m, 2H), δ 4.39 (d, J = 6.0 Hz, 2H), δ 2.73-2.80 (m, 2H), δ 1.62-1.67 (m, 2H), δ 1.56-1.61 (m, 1H), δ 1.08-
1.18 (m, 2H), δ 0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C18H22N4O2 326.3929, observed 326.1742.  
 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (12h): The 
product was obtained after coupling 12 with isopropylpiperazine (0.11 mL, 0.99 mmol) to afford a beige 
solid (0.12 g, 45%). mp: 119-121 °C. 1H-NMR (300 MHz, CDCl3) δ 7.86 (d, J = 6.0 Hz, 1H), δ 6.74-6.84 
(m, 3H), δ 5.91 (s, 2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.80 (br s, 1H), δ 4.39 (d, J = 6.0 Hz, 2H), δ 3.74-3.79 
(m, 4H), δ 2.67-2.71 (m, 1H), δ 2.50-2.55 (m, 4H), δ 1.04 (d, J = 6.0 Hz, 6H). HREIMS Calcd for 
C19H25N5O2 355.4341, observed 355.2007. 
 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (12m): The 
product was obtained after coupling 12 with cyclohexylpiperazine (0.17 g, 0.99 mmol) and was purified 
using a 9:1 EtOAc: MeOH SGCC to afford an orangey brown solid (0.19 g, 63%). mp: 52-54 °C. 1H-NMR 
(300 MHz, CDCl3) δ 7.85 (d, J = 6.0 Hz, 1H), δ 6.72-6.80 (m, 3H), δ 5.90 (s, 2H), δ 5.62 (d, J = 6.0 Hz, 
1H), δ 4.80 (br s, 1H), δ 4.39 (d, J = 6.0 Hz, 2H), δ 3.72-3.77 (m, 4H), δ 2.55-2.60 (m, 4H), δ 2.25-2.30 (m, 
1H), δ 1.88 (br s, 2H), δ 1.77 (br s, 2H), δ 1.60-1.64 (m, 1H), δ 1.15-1.22 (m, 5H). HREIMS Calcd for 
C22H29N5O2 395.4980, observed 395.2311. 
 
6.1.2.12. Naphthalen-1ylmethylamines (13a-c,f-o)  
N-(Naphthalen-1-ylmethyl)-2-(pyrrolidine)pyrimidin-4-amines (13a): The product was obtained after 
coupling 13 with pyrrolidine (0.08 mL, 0.96 mmol) to afford a light brown solid (0.16 g, 70%). mp: 105-
107 °C. IR (film, CH2Cl2): 3433 cm-1 (NH). 1H-NMR (300 MHz, CDCl3) δ 8.05 (d, J = 6.0 Hz, 1H), δ 7.78-
7.91 (m, 3H), δ 7.38-7.51 (m, 4H), δ 5.64 (d, J = 6.0 Hz, 1H), δ 4.96 (d, J = 6.0 Hz, 2H), δ 4.79 (br s, 1H), 
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δ 3.53-3.57 (m, 4H), δ 1.91-1.95 (m, 4H). HREIMS Calcd C19H20N4 (M+) m/z 304.3889, found 304.2086. 
Anal. Calcd for C19H20N40.2 H2O; C, 74.02; H, 6.49; N, 18.18. Found: C, 74.09; H, 6.68; N, 18.19. 
 
2-Morpholino-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13b): The product was obtained after 
coupling 13 with morpholine (0.08 mL, 0.96 mmol) to afford a light yellow solid (0.18 g, 75%). mp: 170-
172 °C. IR (film, CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.01 (d, J = 6.0 Hz, 1H), δ 
7.79-7.90 (m, 3H), δ 7.39-7.52 (m, 4H), δ 5.71 (d, J = 6.0 Hz, 1H), δ 4.92 (d, J = 6.0 Hz, 2H), δ 4.77 (br s, 
1H), δ 3.69-3.77 (m, 8H). HREIMS Calcd C19H20N4O (M+) m/z 320.3883, found 320.1825. Anal. Calcd for 
C19H20N4O; C, 71.23; H, 6.29; N, 17.49. Found: C, 71.28; H, 6.37; N, 17.08. 
 
N-(Naphthalen-1-ylmethyl)-2-thiomorpholinopyrimidin-4-amine (13c): The product was obtained after 
coupling 13 thiomorpholine (0.10 mL, 0.96 mmol) to afford a yellowish brown solid (0.19 g, 76%). mp: 
105-107 °C. IR (film, CH2Cl2): 3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.01 (d, J = 6.0 Hz, 1H), δ 
7.73-7.87 (m, 3H), δ 7.39-7.51 (m, 4H), δ 5.68 (d, J = 6.0 Hz, 1H), δ 4.93 (d, J = 6.0 Hz, 2H), δ 4.82 (br s, 
1H), δ 4.05-4.12 (m, 4H), δ 2.59-2.65 (m, 4H). HREIMS Calcd C19H20N4S (M+) m/z 336.4539, found 
336.2171. Anal. Calcd for C19H20N4S; C, 67.83; H, 5.99; N, 16.65. Found: C, 67.78; H, 5.86; N, 16.50. 
 
2-(4-Methylpiperazin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13f): The product was 
obtained after coupling 13 with methylpiperazine (0.11 mL, 0.96 mmol) to afford a yellow solid (0.23 g, 
80%). mp: 118-120 °C. IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.03 (d, J = 6.0 
Hz, 1H), δ 7.78-7.90 (m, 3H), δ 7.39-7.52 (m, 4H), δ 5.67 (d, J = 6.0 Hz, 1H), δ 4.94 (d, J = 6.0 Hz, 2H), δ 
4.80 (br s, 1H), δ 3.81-3.85 (m, 4H), δ 2.41-2.45 (m, 4H), δ 2.32 (s, 3H). HREIMS Calcd C20H23N5 (M+) 
m/z 333.4301, found 333.1961. Anal. Calcd for C20H23N5•0.5 EtOAc; C, 70.01; H, 7.21; N, 18.55. Found: 
C, 69.72; H, 7.25; N, 18.21. 
 
2-(4-Methylpiperidin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13g): The product was 
obtained after coupling 13 with methylpiperidine (0.11 mL, 0.96 mmol). The residue was purified using a 
3:1 ether: hexanes column to afford an off-white/light yellow semi-solid (0.14 g, 55%). IR (film, CH2Cl2): 
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3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.03 (d, J = 6.0 Hz, 1H), δ 7.78-7.91 (m, 3H), δ 7.38-7.53 
(m, 4H), δ 5.62 (d, J = 6.0 Hz, 1H), δ 4.94 (d, J = 6.0 Hz, 2H), δ 4.75 (br s, 1H), δ 4.68-4.72 (m, 3H), δ 
2.76-2.84 (m, 2H), δ 1.64-1.68 (m, 2H), 1.57-1.60 (m, 1H), 1.10-1.14 (m, 4H), 0.92 (d, J = 6.0 Hz, 3H). 
HREIMS Calcd C21H24N4 (M+) m/z 332.4421, found 332.2246. Anal. Calcd for C21H24N4•0.5 EtOAc; C, 
73.38; H, 7.50; N, 14.88. Found: C, 73.07; H, 7.52; N, 14.64. 
 
2-(4-Isopropylpiperazin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13h): The product was 
obtained after coupling 13 with isopropylpiperazine (0.14 mL, 0.96 mmol). The residue was purified using 
a 3:1 EtOAc: hexanes column to afford a yellow semi-solid (0.16 g, 60%). IR (film, CH2Cl2): 3437 cm-1 
(NH). 1H-NMR (300 MHz, CDCl3): δ 7.89 (d, J = 6.0 Hz, 1H), δ 7.78-7.87 (m, 3H), δ 7.41-7.53 (m, 4H), δ 
5.66 (d, J = 6.0 Hz, 1H), δ 4.94 (d, J = 6.0 Hz, 2H), δ 4.79 (br s, 1H), δ 3.78-3.81 (m, 4H), δ 2.65-2.74 (m, 
1H), δ 2.53-2.56 (m, 4H), δ 1.04 (d, J = 6.0 Hz, 6H). HREIMS Calcd C22H27N5 (M+) m/z 361.4833, found 
361.2267. Anal. Calcd for: C22H27N5•0.5 DCM; C, 66.90; H, 6.99; N, 17.34. Found: C, 66.68; H, 6.97; N, 
17.26.  
	  
2-(4-Isopropylpiperidin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13i): The product was 
obtained after coupling 13 with isopropylpiperidine (0.14 mL, 0.96 mmol) to afford a light orange semi-
solid (0.20 g, 75%). IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.02 (d, J = 6.0 Hz, 
1H), δ 7.78-7.95 (m, 3H), δ 7.38-7.53 (m, 4H), δ 5.61 (d, J = 6.0 Hz, 1H), δ 4.92 (br s, 3H), δ 4.75-4.80 (m, 
2H), δ 2.69-2.77 (m, 2H), δ 1.66-1.70 (m, 2H), δ 1.41-1.47 (m, 1H), δ 1.07-1.24 (m, 3H), δ 0.87-0.89 (d, J 
= 6.0 Hz, 6H). HREIMS Calcd for C23H28N4 (M+) m/z 360.4952, found 360.2317. Anal. Calcd for: 
C23H28N4; C, 76.63; H, 7.83; N, 15.54. Found: C, 76.34; H, 7.80; N, 15.47. 
 
N-(Naphthalen-1-ylmethyl)-2-(4-propylpiperazin-1-yl)-pyrimidin-4-amine (13j): The product was 
obtained after coupling 13 with n-propylpiperazine.2HBr (0.29 g, 0.96 mmol) to afford a light brown solid 
(0.19 g, 70%). mp: 100-102 °C. IR (film, CH2Cl2): 3435 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.88 
(d, J = 6.0 Hz, 1H), δ 7.75-7.85 (m, 3H), δ 7.40-7.52 (m, 4H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.93 (d, J = 6.0 
Hz, 2H), δ 4.80 (br s, 1H), δ 3.77-3.81 (m, 4H), δ 2.42-2.46 (m, 4H), δ 2.27-2.32 (m, 2H), δ 1.46-1.52 (m, 
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2H), δ 0.87-0.96 (m, 3H). HREIMS Calcd for C22H27N5 (M+) m/z 361.4833, found 361.2275. 
 
2-[4-(4-[(Naphthalen-1-ylmethyl)amino]pyrimidin-2-yl)piperazin-1-yl]ethanol (13k): The product was 
obtained after coupling 13 with hydroxyethylpiperazine (0.12 mL, 0.96 mmol) to afford a brown solid (0.21 
g, 78%). mp: 53-55 oC. IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J = 6.0 
Hz, 1H), δ 7.77-7.88 (m, 3H), δ 7.37-7.51 (m, 4H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.93 (br s, 3H), δ 3.77-3.80 
(m, 4H), δ 3.60-3.64 (m, 2H), δ 2.50-2.56 (m, 6H). HREIMS Calcd for C21H25N5O (M+) m/z 363.4561, 
found 363.2045. 
 
2-[4-(2-Methoxyethyl)piperazin-1-yl]-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13l): The product 
was obtained after coupling 13 with methoxyethylpiperazine (0.14mL, 0.96 mmol) to afford a dark brown 
semi-solid (0.20 g, 70%). IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J = 
6.0 Hz, 1H), δ 7.77-7.87 (m, 3H), δ 7.37- 7.50 (m, 4H), δ 5.64 (d, J = 5.7 Hz, 1H), δ 4.92 (br s, 3H), δ 3.81-
3.85 (m, 4H), δ 3.49-3.53 (m, 2H), δ 3.34 (s, 3H), δ 2.56-2.60 (m, 2H), δ 2.51-2.55 (m, 4H). HREIMS 
Calcd for C22H27N5O (M+) m/z 377.4827, found 377.2214. 
	  
2-(4-Cyclohexylpiperazin-1-yl)-N-(naphthalen-1-ylmethyl)pyrimidin-4-amine (13m): The product was 
obtained after coupling 13 with cyclohexylpiperazine (0.16 g, 0.96 mmol) to afford a yellow solid (0.24 g, 
80%). mp: 53-55 °C. IR (film, CH2Cl2): 3435 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J = 6.0 
Hz, 1H), δ 7.74-7.87 (m, 3H), δ 7.37-7.51 (m, 4H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 4.92 (br s, 3H), δ 3.76-3.80 
(m, 4H), δ 2.56-2.60 (m, 4H), δ 2.26-2.31 (m, 1H), δ 1.80-1.90 (m, 2H), δ 1.67-1.77 (m, 2H), δ 1.59-1.63 
(m, 1H), δ 1.17-1.23 (m, 5H). HREIMS Calcd for C25H31N5 (M+) m/z 401.5471, found 401.2948. 
 
1-[4-(4-[(Naphthalen-1-ylmethyl)amino]pyrimidin-2-yl)piperazin-1-yl]ethanone (13n): The product 
was obtained after coupling 13 with acetylpiperazine (0.13 g, 0.96 mmol) to afford a light orange solid 
(0.18 g, 68%). mp: 70-72 °C. IR (film, CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 8.00 (d, J 
= 6.0 Hz, 1H), δ 7.77-7.88 (m, 3H), δ 7.37-7.53 (m, 4H), δ 5.71 (d, J = 6.0 Hz, 1H), δ 4.94 (d, J = 6.0 Hz, 
2H), δ 4.88 (br s, 1H), δ 3.72-3.78 (m, 4H), δ 3.58-3.62 (m, 2H), δ 3.40-3.44 (m, 2H), δ 2.07 (s, 3H). 
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HREIMS Calcd for C21H23N5O (M+) m/z 361.4402, found 361.1899. 
 
Tert-butyl 4-[4-([Naphthalen-1-ylmethyl]amino)pyrimidin-2-yl]piperazine-1-carboxylate (13o): The 
product was obtained after coupling 13 with tert-butyl piperazine-1-carboxylate (0.18 g, 0.96 mmol). The 
residue was purified using a 3:1 EtOAc: hexanes column to afford a yellow solid (0.21 g, 68%). mp: 70-72 
°C. IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.84-
7.76 (m, 3H), δ 7.36-7.50 (m, 4H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 5.05 (br s, 1H), δ 4.91 (d, J = 6.0 Hz, 2H), 
δ 3.71-3.74 (m, 4H), δ 3.41-3.44 (m, 4H), δ1.45 (s, 9H). HREIMS Calcd for C24H29N5O2 (M+) m/z 
419.5194, observed 419.2325. 
 
6.1.2.13. Diphenylmethylamines (14f-o) 
N-Benzhydryl-2-(methylpiperazin-1-yl)pyrimidin-4-amine (14f): The product was obtained after 
coupling 14 with methylpiperazine (0.17 mL, 1.14 mmol). The residue was purified using a 9:1 EtOAc: 
MeOH column to afford a yellow solid (0.17 g, 70%). mp: 128-130 °C. IR (film, CDCl3): 3431 cm-1 (NH). 
1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 1H), δ 7.27-7.36 (m, 10H), δ 5.93 (br s, 1H), δ 5.62 (d, 
J = 6.0 Hz, 1H), δ 5.15 (br s, 1H), δ 3.73-3.77 (m, 4H), δ 2.41-2.45 (m, 4H), δ 2.33 (s, 3H). HREIMS 
Calcd for C22H25N5 (M+) m/z 359.4674, found 359.2105. 
 
N-Benzhydryl-2-(methylpiperidin-1-yl)pyrimidin-4-amine (14g): The product was obtained after 
coupling 14 with methylpiperidine (0.17 mL, 1.14 mmol). The residue was purified using a 9:1 EtOAc: 
MeOH column to afford a light orange/yellow semi-solid (0.12 g, 50%). IR (film, CDCl3): 3432 cm-1 (NH). 
1H-NMR (300 MHz, CDCl3): δ 7.82 (d, J = 6.0 Hz, 1H), δ 7.26-7.35 (m, 10H), δ 5.94 (br s, 1H), δ 5.58 (d, 
J = 6.0 Hz, 1H), δ 5.17 (br s, 1H), δ 4.51-4.56 (m, 2H), δ 2.68-2.76 (m, 2H), δ 1.50-1.56 (m, 3H), δ 1.02-
1.09 (m, 2H), δ 0.89 (d, J = 6.0 Hz, 3H). HREIMS Calcd for C22H26N5 (M+) m/z 358.4793, found 358.2155. 
 
N-Benzhydryl-2-(4-isopropylpiperazin-1-yl)pyrimidin-4-amine (14h): The product was obtained after 
coupling 14 with isopropylpiperazine (0.17 mL, 1.14 mmol). The residue was purified using a 9:1 EtOAc: 
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MeOH column to afford an off-white solid (0.16 g, 60%). mp: 103-105 °C. IR (film, CDCl3): 3429 cm-1 
(NH). 1H-NMR (300 MHz, CDCl3): δ 7.81 (d, J = 6.0 Hz, 1H), δ 7.24-7.34 (m, 10H), δ 5.94 (br s, 1H), δ 
5.59 (d, J = 6.0 Hz, 1H), δ 5.22 (d, J = 6.0 Hz, 1H), δ 3.66-3.70 (m, 4H), δ 2.62-2.70 (m, 1H), δ 2.43-2.47 
(m, 4H), δ 1.02 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C24H29N5 (M+) m/z 387.5206, found 387.2414. 
 
N-Benzhydryl-2-(4-isopropylpiperidin-1-yl)pyrimidin-4-amine (14i): The product was obtained after 
coupling 14 with isopropylpiperidine (0.17 mL, 1.15 mmol). The residue was purified using a 3:1 EtOAc: 
DCM column to afford an orange semi-solid (0.13 g, 50%). IR (film, CDCl3): 3427 cm-1 (NH). 1H-NMR 
(300 MHz, CDCl3δ 7.82 (d, J = 6.0 Hz, 1H), δ 7.27-7.36 (m, 10H), δ 5.96 (br s, 1H), δ 5.74 (br s, 1H), δ 
5.60 (br s, 1H) δ 4.60-4.64 (m, 2H), δ 2.62-2.70 (m, 2H), δ 1.60-1.64 (m, 2H), δ 1.40-1.45 (m, 1H), δ 1.14-
1.24 (m, 3H), δ 0.87 (d, J = 6.0 Hz, 6H). HREIMS Calcd for C25H30N4 (M+) m/z 386.5325, found 386.2462. 
 
N-Benzhydryl-2-(4-propylpiperazin-1-yl)pyrimidin-4-amine (14j): The product was obtained after 
coupling 14 with n-propylpiperazine.2HBr (0.34 g, 1.15 mmol). The residue was purified using a 9:1 
EtOAc: MeOH column to afford an off-white semi-solid (0.15 g, 57%). IR (film, CDCl3) 3423 cm-1 (NH). 
1H-NMR (300 MHz, CDCl3): δ 7.83 (d, J = 6.0 Hz, 1H), δ 7.24-7.32 (m, 10H), δ 5.92 (br s, 1H), δ 5.61 (d, 
J = 6.0 Hz, 1H), δ 5.13 (d, J = 6.0 Hz, 1H), δ 3.68-3.72 (m, 4H), δ 2.39-2.42 (m, 4H), δ 2.29-2.34 (m, 2H), 
δ 1.50-1.55 (m, 2H), δ 0.87-0.92 (m, 3H). HREIMS Calcd for C24H29N5 (M+) m/z 387.5206, found 
387.2434. 
 
2-[4-(4-[Benzhydrylamino]pyrimidin-2-yl)piperazin-1-yl]ethanol (14k): The product was obtained after 
coupling 14 with hydroxyethylpiperazine (0.15 mL, 1.15 mmol) to afford a light yellow solid (0.17 g, 
65%). mp: 155-157 °C. IR (film, CDCl3): 3421 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 
Hz, 1H), δ 7.27-7.34 (m, 10H), δ 5.93 (br s, 1H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 5.19 (br s, 1H), δ 3.76-3.80 
(m, 4H), δ 3.68 (t, J = 6.0 Hz, 2H), δ 2.62 (t, J = 6.0 Hz, 2H), δ 2.56-2.60 (m, 4H). HREIMS Calcd for 
C23H27N5O (M+) m/z 389.4934, found 389.2217. 
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N-Benzhydryl-2-[4-(2-methoxyethyl)piperazin-1-yl]pyrimidin-4-amine (14l): The product was obtained 
after coupling 14 with methoxyethylpiperazine (0.17 mL, 1.15 mmol) to afford a light orange/yellow semi-
solid (0.18 g, 65%). IR (film, CDCl3): 3428 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.79 (d, J = 6.0 Hz, 
1H), δ 7.25-7.30 (m, 10H), δ 5.93 (br s, 1H), δ 5.58 (d, J = 6.0 Hz, 1H), δ 5.28 (d, J = 6.0 Hz, 1H), δ 3.65-
3.68 (m, 4H), δ 3.47-3.51 (m, 2H), δ 3.32 (s, 3H), δ 2.51-2.55 (m 2H), δ 2.40-2.43 (m, 4H). HREIMS 
Calcd for C24H29N5O (M+) m/z 403.5200, found 403.2378. Anal. Calcd for: C24H29N5O; C, 71.44; H, 7.24; 
N, 17.36. Found: C, 71.31; H, 7.15; N, 17.14.  
 
N-Benzhydryl-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine (14m): The product was obtained after 
coupling 14 with cyclohexylpiperazine (0.19 g, 1.15 mmol). The residue was purified using a 3:1 EtOAc: 
DCM column to afford a light yellow solid (0.17 g, 60%). mp: 53-55 °C. IR (film, CDCl3): 3424 cm-1 
(NH). H-NMR (300 MHz, CDCl3) δ 7.83 (d, J = 6.0 Hz, 1H), δ 7.24-7.33 (m, 10H), δ 5.92 (br s, 1H), δ 
5.61 (d, J = 6.0 Hz, 1H), δ 5.14 (br s, 1H), δ 3.64-3.68 (m, 4H), δ 2.49-2.52 (m, 4H), δ 2.27-2.32 (m, 1H), δ 
1.81-1.86 (m, 2H), δ 1.75-1.80 (m, 2H) δ 1.60-1.64 (m, 1H), δ 1.21-1.27 (m, 5H). HREIMS Calcd for 
C27H33N5 (M+) m/z 427.5844, found 427.2733. 
 
1-[4-(4-[Benzhydrylamino]pyrimidin-2-yl)piperazin-1-yl]ethanone (14n): The product was obtained 
after coupling 14 with acetylpiperazine (0.16 g, 1.15 mmol) to afford a light yellow solid (0.2 g, 76%). mp: 
182-184 °C. IR (film, CDCl3): 3429 cm-1 (NH). 1H-NMR (300 MHz, CDCl3) δ 7.81 (d, J = 6.0 Hz, 1H), δ 
7.21-7.28 (m, 10H), δ 5.96 (br s, 1H), δ 5.68 (d, J = 6.0 Hz, 1H), δ 5.46 (d, J = 6.0 Hz, 1H), δ 3.64 (d, J = 
6.0 Hz, 2H), δ 3.59 (d, J = 6.0 Hz, 2H), δ 3.49 (d, J = 6.0 Hz, 2H), δ 3.33 (d, J = 6.0 Hz, 2H), δ 2.04 (s, 3H) 
HREIMS Calcd for C23H25N5O (M+) m/z 387.4775, found 387.2059. Anal. Calcd for: C23H25N5O; C, 71.29; 
H, 6.50; N, 18.07. Found: C, 71.11; H, 6.52; N, 18.02. 
	  
Tert-butyl 4-[4-(Benzhydrylamino)pyrimidin-2-yl]piperazine-1-carboxylate (14o): The product was 
obtained after coupling 14 with tert-butyl piperazine-1-carboxylate (0.21 g, 1.15 mmol). The residue was 
purified using a 3:1 EtOAc: DCM column to afford an off-white solid (0.18 g, 60%). mp: 68-70 °C. IR 
(film, CDCl3): 3442 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.81 (d, J = 6.0 Hz, 1H), δ 7.22-7.32 (m, 
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10H), δ 5.95 (br s, 1H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 5.30 (d, J = 6.0 Hz, 1H), δ 3.58-3.62 (m, 4H), δ 3.31-
3.35 (m, 4H), δ 1.45 (s, 9H). HREIMS Calcd for C26H31N5O2 (M+) m/z 445.5566, found 445.2489. Anal. 
Calcd for: C26H31N5O2; C, 70.09; H, 7.01; N, 15.72. Found: C, 70.17; H, 7.02; N, 15.71. 
	  
6.1.2.14. Phenylethylamines (15a-c,f,g,n) 
N-Phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amines (15a): The product was obtained by coupling 15 
with pyrrolidine (0.09 mL, 1.11 mmol) to afford a light yellowish brown solid (0.15 g, 65%). mp: 85-87 
°C. IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.86 (d, J = 6.0 Hz, 1H), δ 7.18-
7.32 (m, 5H), δ 5.59 (d, J = 6.0 Hz, 1H), δ 4.56 (br s, 1H), δ 3.55 (t, J = 6.0 Hz, 2H), δ 3.50 (t, J = 6.0 Hz, 
4H), δ 2.86-2.91 (m, 2H), δ 1.90-1.93 (m, 4H). HREIMS C16H20N4 (M+) m/z 268.3568, found 268.2125. 
Anal. Calcd for C16H20N4•0.5 H2O; C, 69.29; H, 7.63; N, 20.2. Found: C, 69.51; H, 7.32; N, 20.11. 
 
2-Morpholino-N-phenethylpyrimidin-4-amine (15b): The product was obtained after coupling 15 with 
morpholine (0.10 mL, 1.11 mmol) to afford a light brown solid (0.21 g, 86%). mp: 93-95 °C. IR (film, 
CH2Cl2): 3433 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.18-7.32 (m, 5H), δ 
5.65 (d, J = 6.0 Hz, 1H), δ 4.59 (br s, 1H), δ 3.68-3.75 (m, 8H), δ 3.55-3.59 (m, 2H), δ 2.86-2.90 (m, 2H). 
HREIMS Calcd C16H20N4O (M+) m/z 284.3562, found 284.1725. Anal. Calcd for C16H20N4O; C, 67.58; H, 
7.09; N, 19.70. Found: C, 67.71; H, 7.14; N, 19.42.  
 
N-Phenethyl-2-thiomorpholinopyrimidin-4-amine (15c): The product was obtained after coupling 15 
with thiomorpholine (0.11 mL, 1.11 mmol) to afford a brown solid (0.21 g, 81%). mp: 60-62 °C. IR (film, 
CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 MHz, CDCl3) δ 7.84 (d, J = 6.0 Hz, 1H), δ 7.18-7.30 (m, 5H), δ 
5.61 (d, J = 6.0 Hz, 1H), δ 4.58 (br s, 1H), δ 3.98 (t, J = 6.0 Hz, 4H), δ 3.54 (t, J = 6.0 Hz, 2H), δ 2.86-2.90 
(m, 2H), δ 2.61 (t, J = 6.0 Hz, 4H). HREIMS Calcd C16H20N4S (M+) m/z 284.3562, found 284.1725. Anal. 
Calcd for C16H20N4S; C, 63.97; H, 6.71; N, 18.65. Found: C, 64.12; H, 6.85; N, 18.46. 
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2-(4-Methylpiperazin-1-yl)-N-phenethylpyrimidin-4-amine (15f): The product was obtained after 
coupling 15 with methylpiperazine (0.12 mL, 1.11 mmol) to afford a light yellow solid (0.18 g, 69%). mp: 
58-60 °C IR (film, CH2Cl2): 3436 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 
7.18-7.30 (m, 5H), δ 5.62 (d, J = 6.0 Hz, 1H), δ 4.57 (br s, 1H), δ 3.76-3.79 (m, 4H), δ 3.52-3.56 (m, 2H), δ 
2.86-2.90 (m, 2H), δ 2.41-2.44 (m, 4H), δ 2.31 (s, 3H). HREIMS Calcd C17H23N5 (M+) m/z 297.3980, 
found 297.1958. Anal. Calcd for C17H23N5•1.3 H2O; C, 68.05; H, 7.67; N, 23.35. Found: C, 68.12; H, 7.82; 
N, 23.36.  
 
2-(4-Methylpiperidin-1-yl)-N-phenethylpyrimidin-4-amine (15g): The product was obtained after 
coupling 15 with methylpiperidine (0.12 mL, 1.11 mmol) to afford a light brown solid (0.20 g, 79%). mp: 
65-67 °C. IR (film, CH2Cl2): 3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 1H), δ 
7.18-7.33 (m, 5H), δ 5.57 (d, J = 6.0 Hz, 1H), δ 4.64-4.69 (m, 2H), δ 4.53 (br s, 1H), δ 3.52-3.56 (m, 2H), δ 
2.86-2.90 (m, 2H), δ 2.73-2.82 (m, 2H), δ 1.63-1.68 (m, 3H), δ 1.33-1.40 (m, 1H), δ 1.08-1.16 (m, 3H), δ 
0.92 (d, J = 6.0 Hz, 3H). HREIMS Calcd C18H24N4 (M+) m/z 296.4100, found 296.2380.  
 
1-[4-(4-(Phenethylamino)pyrimidin-2-yl)piperazin-1-yl]ethanone (15n): The product was obtained after 
coupling 15 with acetylpiperazine (0.14 g, 1.11 mmol) to afford a yellow solid (0.24 g, 86%). mp: 150-152 
°C. IR (film, CH2Cl2): 3437 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.85 (d, J = 6.0 Hz, 1H), δ 7.19-
7.33 (m, 5H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.61 (br s, 1H), δ 3.73-3.80 (m, 4H), δ 3.65 (t, J = 6.0 Hz, 2H), δ 
3.55 (t, J = 6.0 Hz, 2H), δ 3.46-3.50 (m, 2H), δ 2.86-2.90 (m, 2H), δ 2.12 (s, 3H). HREIMS Calcd 
C18H23N5O (M+) m/z 325.4081, found 325.1913. Anal. Calcd for C18H23N5•0.6 EtOAc; C, 64.78; H, 7.41; 
N, 18.52. Found: C, 64.66; H, 7.43; N, 18.30. 
 
6.1.3. General method to prepare derivatives 2-12u. 
To a solution of 4-aminobenzylpiperidine and DIPEA (2.58-3.64 mmol, each) in 1 mL of n-BuOH 
kept in a PV with stirring, an intermediate 2-15 (0.20 g, 0.65-0.91 mmol) was added. The sealed PV was 
placed in an oil bath at 185-195 °C and stirred overnight (~ 14-16 hrs). Solution was neutralized with 6M 
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HCl, diluted with 15 mL EtOAc and washed successively with saturated NaHCO3 and NaCl solution (1:3, 
1 x 15 mL). The aqueous layer was washed with EtOAc (2 x 5 mL) and the organic layer was dried over 
anhydrous MgSO4 then filtered. The solution was evaporated in vacuo and purified using 9:1 Acetone: 
MeOH SGCC and (if necessary) de-greased by boiling in hexanes for 5 min. then decanting the 
contaminated solvent and re-dried to afford either solid or semisolid orange/light brown products. Some 
physical and spectroscopy data are provided below. 
 
N4-Benzyl-N2-(1-benzylpiperidin-4-yl)pyrimidine-2,4-diamine (2u): The product was obtained after 
coupling 2 with 4-aminobenzylpiperidine (0.74 mL, 3.64 mmol) (0.20 g, 59%). mp: 88-90 °C. IR (film, 
CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.78 (d, J = 6.0 Hz, 1H), δ 7.21-7.34 (m, 10H), δ 
5.66 (d, J = 6.0 Hz, 1H), δ 4.92 (br s, 2H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 3.76-3.82 (m, 1H), δ 3.48 (s, 2H), δ 
2.76-2.80 (m, 2H), 2.09-2.16 (m, 2H), 1.95-1.99 (m, 2H), 1.42-1.55 (m, 2H). HREIMS Calcd C23H27N5 
(M+) m/z 373.4940, found 373.2008. Anal. Calcd for C23H27N5•DCM; C, 62.88; H, 6.38; N, 15.28. Found: 
C, 62.88; H, 6.38; N, 15.28. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(2-chlorobenzyl)pyrimidine-2,4-diamine (3u): The product was 
obtained after coupling 3 with 4-aminobenzylpiperidine (0.64 mL, 3.15 mmol) (0.16 g, 51%). mp: 65-67 
°C. 1H-NMR (300 MHz, CDCl3): δ 7.78 (d, J = 6.0 Hz, 1H), δ 7.17-7.36 (m, 9H), δ 5.67 (d, J = 6.0 Hz, 
1H), δ 4.99 (br s, 1H), δ 4.73 (br s, 1H) δ 4.57 (d, J = 6.0 Hz, 2H), δ 3.75-3.79 (m, 1H), δ 3.48 (s, 2H), δ 
2.76-2.80 (m, 2H), 2.09-2.16 (m, 2H), 1.95-1.99 (m, 2H), 1.42-1.55 (m, 2H). HREIMS Calcd C23H26ClN5 
(M+) m/z 407.9390, found 407.1872.  
 
N2-(1-Benzylpiperidin-4-yl)-N4-(3-chlorobenzyl)pyrimidine-2,4-diamine (4u): The product was 
obtained after coupling 4 with 4-aminobenzylpiperidine (0.64 mL, 3.15 mmol) (0.16 g, 51%). mp: 62-63 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.77 (d, J = 6.0 Hz, 1H), δ 7.17-7.30 (m, 9H), δ 5.68 (d, J = 6.0 Hz, 
1H), δ 5.00 (br s, 1H), δ 4.81 (br s, 1H), δ 4.46 (d, J = 6.0 Hz, 2H), δ 3.73-3.79 (m, 1H), δ 3.49 (s, 2H), δ 
2.77-2.81 (m, 2H), δ 2.09-2.16 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.44-1.54 (m, 2H). HREIMS Calcd 
C23H26ClN5 (M+) m/z 407.9390, found 407.1877. 
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N2-(1-Benzylpiperidin-4-yl)-N4-(4-chlorobenzyl)pyrimidine-2,4-diamine (5u): The product was 
obtained after coupling 5 with 4-aminobenzylpiperidine (0.64 mL, 3.15 mmol) (0.17 g, 54%). mp: 64-66 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.77 (d, J = 6.0 Hz, 1H), δ 7.25-7.30 (m, 5H), δ 7.16-7.23 (m, 4H), δ 
5.66 (d, J = 6.0 Hz, 1H), δ 5.00 (br s, 1H), δ 4.87 (br s, 1H), δ 4.44 (d, J = 6.0 Hz, 2H), δ 3.73-3.79 (m, 
1H), δ 3.50 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.09-2.16 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.44-1.54 (m, 2H). 
HREIMS Calcd C23H26ClN5 (M+) m/z 407.9390, found 407.1879. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(4-bromobenzyl)pyrimidine-2,4-diamine (6u): The product was 
obtained after coupling 6 with 4-aminobenzylpiperidine (0.54 mL, 2.68 mmol) (0.14 g, 48%). mp: 59-61 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.76 (d, J = 6.0 Hz, 1H), δ 7.55-7.58 (m, 2H), δ 7.21-7.26 (m, 5H), δ 
7.14-7.17 (m, 2H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.99 (br s, 2H), δ 4.43 (d, J = 6.0 Hz, 2H), δ 3.74-3.80 (m, 
1H), δ 3.50 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.09-2.16 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.44-1.54 (m, 2H). 
 HREIMS Calcd C23H26BrN5 (M+) m/z 452.3900, found 451.1361. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(4-fluorobenzyl)pyrimidine-2,4-diamine (7u): The product was obtained 
after coupling 7 with 4-aminobenzylpiperidine (0.68 mL, 3.37 mmol) (0.15 g, 45%). mp: 61-63 °C. 1H-
NMR (300 MHz, CDCl3) δ 7.79 (d, J = 6.0 Hz, 1H), δ 7.28-7.31 (m, 2H), δ 7.21-7.27 (m, 5H), δ 6.96-7.02 
(m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.90 (br s, 1H), δ 4.71 (d, J = 6.0 Hz, 1H), δ 4.43 (d, J = 6.0 Hz, 2H), 
δ 3.75-3.80 (m, 1H), δ 3.49 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.09-2.16 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.44-
1.54 (m, 2H). HREIMS Calcd C23H26FN5 (M+) m/z 391.4844, found 391.2165. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(4-methylbenzyl)pyrimidine-2,4-diamine (8u): The product was 
obtained after coupling 8 with 4-aminobenzylpiperidine (0.69 mL, 3.42 mmol) (0.17 g, 50%). mp: 60-62 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.77 (d, J = 6.0 Hz, 1H), δ 7.25-7.30 (m, 5H), δ 7.19-7.23 (m, 2H), δ 
7.10-7.15 (m, 2H), δ 5.65 (d, J = 6.0 Hz, 1H), δ 4.88 (br s, 2H), δ 4.42 (d, J = 6.0 Hz, 2H), δ 3.76-3.82 (m, 
1H), δ 3.49 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.31 (s, 3H), δ 2.09-2.16 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.44-
1.54 (m, 2H). HREIMS Calcd C24H29N5 (M+) m/z 387.5206, observed 387.2415. 
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N2-(1-Benzylpiperidin-4-yl)-N4-(4-methoxybenzyl)pyrimidine-2,4-diamine (9u): The product was 
obtained after coupling 9 with 4-aminobenzylpiperidine (0.65 mL, 3.20 mmol) (0.15 g, 45%). mp: 55-57 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.79 (d, J = 6.0 Hz, 1H), δ 7.21-7.30 (m, 7H), δ 6.83-6.86 (m, 2H), δ 
5.65 (d, J = 6.0 Hz, 1H), δ 4.81 (br s, 1H), δ 4.68 (d, J = 6.0 Hz, 1H), δ 4.38 (d, J = 6.0 Hz, 2H), δ 3.77 (s, 
3H), δ 3.49 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.10-2.17 (m, 2H), δ 1.96-2.00 (m, 2H), δ 1.66-1.72 (m, 1H), δ 
1.42-1.52 (m, 2H). HRMS Calcd for C24H29N5O 403.5200 , observed 403.2361. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)pyrimidine-2,4-diamine (10u): The product was 
obtained after coupling 10 with 4-aminobenzylpiperidine (0.58 mL, 2.86 mmol) (0.14 g, 45%). mp: 52-54 
°C. 1H-NMR (300 MHz, CDCl3) δ 7.80 (d, J = 6.0 Hz, 1H), δ 7.27-7.31 (m, 5H), δ 6.79-6.86 (m, 3H), δ 
5.67 (d, J = 6.0 Hz, 1H), δ 4.83 (br s, 1H), δ 4.76 (br s, 1H), δ 4.39 (d, J = 6.0 Hz, 2H), δ δ 3.85 (s, 3H), δ 
3.84 (s, 3H), δ 3.49 (s, 2H), δ 2.77-2.81 (m, 2H), δ 2.11-2.18 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.55-1.62 (m, 
1H), δ 1.44-1.51 (m, 2H). HRMS Calcd for C25H31N5O2 433.5459, observed 433.2472. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine (11u): The product 
was obtained after coupling 11 with 4-aminobenzylpiperidine (0.52 mL, 2.58 mmol) (0.14 g, 45%). mp: 63-
65 °C. 1H-NMR (300 MHz, CDCl3) δ 7.80 (d, J = 6.0 Hz, 1H), δ 7.29-7.34 (m, 5H), δ 6.51 (s, 2H), δ 5.67 
(d, J = 6.0 Hz, 1H), δ 4.84 (br s, 1H), δ 4.77 (br s, 1H), δ 4.40 (d, J = 6.0 Hz, 2H), δ 3.83 (s, 6H), δ 3.82 (s, 
3H), δ 3.49 (s, 2H), δ 2.78-2.82 (m, 2H), δ 2.11-2.18 (m, 2H), δ 1.97-2.01 (m, 2H), δ 1.55-1.62 (m, 1H), δ 
1.45-1.52 (m, 2H). HRMS Calcd for C26H33N5O3 463.5719, observed 463.2578. 
 
N4-(Benzo[d][1,3]dioxol-5-ylmethyl)-N2-(1-benzylpiperidin-4-yl)pyrimidine-2,4-diamine (12u): The 
product was obtained after coupling 12 with 4-aminobenzylpiperidine (0.61 mL, 3.03 mmol) (0.14 g, 45%). 
mp: 56-58 °C. 1H-NMR (300 MHz, CDCl3) δ 7.77 (d, J = 6.0 Hz, 1H), δ 7.22-7.30 (m, 5H), δ 6.70-6.77 
(m, 3H), δ 5.90 (s, 2H), δ 5.63 (d, J = 6.0 Hz, 1H), δ 5.01 (br s, 1H), δ 4.78 (d, J = 6.0 Hz, 1H), δ 4.35 (d, J 
= 6.0 Hz, 2H), δ 3.47 (s, 2H), δ 2.76-2.80 (m, 2H), δ 2.09-2.15 (m, 2H), δ 1.95-1.99 (m, 2H), δ 1.74-1.79 
(m, 1H), δ 1.44-1.54 (m, 2H). HRMS Calcd for C24H27N5O2 417.5035, observed 417.2175. 
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6.1.4. General method to prepare derivative 2d 
 4-(4-(benzylamino)pyrimidin-2-yl)thiomorpholine-1-oxide 
To a mixture of N-benzyl-2-thiomorpholinopyrimidin-4-amine (2c) (0.20 g, 0.70 mmol) in 3 mL of 
1,4-dioxane, kept at 0 °C (ice-bath), mCPBA (0.19 g, 1.12 mmol) in 1 mL 1,4-dioxane was added 
dropwise. The reaction is allowed to stir on the ice-bath for 5 minutes and then was kept at r.t for 3 hrs. 
DCM was added to the mixture to aid in the 1,4-dioxane in vacuo evaporation. The residue was re-
dissolved in a 3:1 EtOAc and DCM and successfully washed with a concentrated NaHCO3 and NaCl 
solution (1:2, 1 x 15 mL). Aqueous layer was washed with EtOAc (3 x 15 mL) and the combined organic 
layer was dried over anhydrous MgSO4 and filtered. The organic layer was evaporated in vacuo and the 
resulting solid residue was further purified using 3:1 EtOAc: hexanes SGCC to afford a light yellow solid 
(0.16 g, 75%). mp: 78-80 °C. IR (film, CH2Cl2): 3439 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.87 (d, J 
= 6.0 Hz, 1H), δ 7.24-7.35 (m, 5H), δ 5.74 (d, J = 6.0 Hz, 1H), δ 4.99 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), 
δ 4.37 (t, J = 6.0 Hz, 1H), δ 4.32 (t, J = 6.0 Hz, 1H), 4.10-4.19 (m, 2H), 2.69-2.73 (m, 4H). HREIMS Calcd 
C15H18N4OS (M+) m/z 302.3946, found 302.1259. Anal. Calcd for C15H18N4OS•0.3 DCM; C, 56.05; H, 
5.72; N, 17.09. Found: C, 56.38; H, 5.74; N, 17.22.  
 
6.1.5. General method to prepare derivative 2e 
4-(4-(benzylamino)pyrimidin-2-yl)thiomorpholine 1,1-dioxide 
To a mixture of N-benzyl-2-thiomorpholinopyrimidin-4-amine (7c) (0.20 g, 0.70 mmol) in 5 mL of 
MeOH, kept at 0 °C (ice-bath), potassium peroxymonosulphate (0.23 g, 1.54 mmol) in 0.5 mL of H2O was 
added dropwise. The reaction was allowed to stir on the ice-bath for 5 minutes, then heated at 70-75 °C for 
1hr and finally moved to r.t for 4hrs. MeOH was evaporated in vacuo and the residue was re-dissolved in 
3:1 EtOAc: DCM and successfully washed with a concentrated NaHCO3 and NaCl solution (1:2, 1 x 15 
mL). Aqueous layer was washed with EtOAc (3 x 15 mL) and the combined organic layer was dried over 
anhydrous MgSO4 and filtered. The organic layer was evaporated in vacuo and the resulting solid residue 
was further purified using 3:1 EtOAc: hexanes SGCC to afford a light orange solid (0.17 g, 75%). mp: 65-
67 °C. IR (film, CH2Cl2): 3464 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.87 (d, J = 6.0 Hz, 1H), δ 7.25-
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7.35 (m, 5H), δ 5.79 (d, J = 6.0 Hz, 1H), δ 5.14 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 4.21-4.25 (m, 4H), 
δ 2.88-2.92 (m, 4H). HREIMS Calcd C15H10N4O2S (M+) m/z 318.3946, found 318.1310. Anal. Calcd for 
C15H18N4O2S•0.2 DCM; C, 51.95; H, 5.28; N, 15.94. Found: C, 52.04; H, 5.34; N, 15.71. 
 
6.1.6. General method to prepare derivatives 2p, 13p and 14p 
To a mixture of 2o, 13o or 14o (0.20 g, 0.45-0.54 mmol) in 4 mL of DCM, kept at 0 oC (ice-bath), 
TFA (4 mL, 53.83 mmol) was added dropwise. The reaction was allowed to stir on the ice-bath for 5 
minutes and then was kept at r.t for 2 hrs. DCM and TFA were evaporated in vacuo with the aid of toluene 
and the residue was re-dissolved in 3:1 EtOAc: DCM and successfully washed with a concentrated 
NaHCO3 and NaCl solution (1:1, 1 x 15 mL). Aqueous layer was washed with EtOAc (3 x 15 mL) and the 
combined organic layer was dried over anhydrous MgSO4 and filtered. The organic layer was evaporated in 
vacuo to afford a solid or semi-solid product. Some physical and spectroscopy data are provided below. 
 
N-benzyl-2-(piperazin-1-yl)pyrimidin-4-amine (2p): The product was a light yellow solid (0.11 g, 75%). 
mp: 70-72 °C. IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.86 (d, J = 6.0 Hz, 1H), 
δ 7.24-7.34 (m, 5H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 4.91 (br s, 1H), δ 4.49 (d, J = 6.0 Hz, 2H), δ 3.73-3.76 
(m, 4H), 3.09 (s, 1H), δ 2.88-2.91 (m, 4H). HREIMS Calcd C15H19N5 (M+) m/z 269.3449, found 269.1953.  
 
N-(naphthalen-1-ylmethyl)-2-(piperazin-1-yl)pyrimidin-4-amine (13p): The product was a yellow semi-
solid (0.06 g, 60%). IR (film, CH2Cl2): 3438 cm-1 (NH). 1H-NMR (300 MHz, CDCl3) δ 7.98 (d, J = 6.0 Hz, 
1H), δ 7.84-7.87 (m, 3H), δ 7.36-7.50 (m, 4H), δ 5.66 (d, J = 6.0 Hz, 1H), δ 5.05 (d, J = 6.0 Hz, 1H), δ 4.90 
(d, J = 6.0 Hz, 2H), δ 3.95-4.01 (m, 4H), δ 3.07-3.13 (m, 4H). HREIMS Calcd for C19H21N5 (M+) m/z 
319.4035, found 319.1785.  
 
N-Benzhydryl-2-(piperazin-1-yl)pyrimidin-4-amine (14p): The product was an orange/yellow semi-solid 
(0.07 g, 60%). IR (film, CDCl3): 3426 cm-1 (NH). 1H-NMR (300 MHz, CDCl3): δ 7.84 (d, J = 6.0 Hz, 1H), 
δ 7.25-7.32 (m, 10H), δ 5.90 (br s, 1H), δ 5.80 (br s, 1H), δ 5.41 (br s, 1H), δ 3.94-3.98 (m, 4H), δ 2.98-
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3.02 (m, 4H). HREIMS Calcd for C21H23N5 (M+) m/z 345.4408, found 345.1954. 
 
6.2. Biochemistry 
6.2.1. Cholinesterase Assay 
The assay utilizes hAChE (product number C3389; Sigma-Aldrich, St. Louis, MO) and equine 
serum BuChE (product number C1057; Sigma-Aldrich, St. Louis, MO) along with tacrine.HCl (item 
number 70240; Cayman Chemical, Ann Arbor, MI), bis(7)-tacrine (item number 10005836; Cayman 
Chemical, Ann Arbor, MI), donepezil.HCl.H2O (product number D6821; Sigma-Aldrich, St. Louis, MO) 
and galanthamine.HBr (product number G1660; Sigma, St. Louis, MO) as reference agents. Derivative 
stock solutions were dissolved in a minimum volume of DMSO (1%) and diluted using a 50 mM Tris–HCl, 
pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O buffer solution. In a standard 96-well plate, 160 µL 5,5’-
dithiobis(2-nitrobenzoic acid) (1.5 mM DTNB prepared in buffer), 50 µL of hAChE (0.22 U/mL prepared 
in 50 mM Tris–HCl, pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of BuChE (0.06 U/mL 
prepared in 50 mM Tris–HCl, pH 8.0, 0.1% w/v BSA) were incubated with the various concentrations of 
test compounds (0.001–100 µM, 10 µL) at r.t for 5 min followed by the addition of 30 µL of the respective 
substrates (15 mM AThC or BuThC). The absorbance was measured at different time intervals (0-3 min) at 
a wavelength of 405 nm using a BioTek ELx800 microplate reader and percent inhibition was calculated by 
the comparison of compound treated to various control incubations that included 1% DMSO. The 
concentration of the test compound causing 50% inhibition (IC50, µM) was calculated from the 
concentration-inhibition response curve on logarithmic scale (duplicate to quadruplicate determinations). 
 
6.2.2. Aβ1-40 Aggregation Assay  
The hAChE-induced aggregation assay from Dr. Yang’s group was previously reported in Ref. 121. 
The HFIP salt of Aβ1-40 was purchased from Anaspec, Inc. (Cat. 64128-1), human recombinant AChE 
lyophilized powder and ThT were purchased from Sigma Aldrich (Cat. C1682 and T3516; respectively) 
and the hAChE-induced assay was run using propidium iodide (Cat. P4170; Sigma Aldrich) as a control. 
Aβ1-40 was dissolved in DMSO (1 mL/mg) and sonicated for 30 min to obtain a 232 µM solution. hAChE 
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was dissolved in 215 mM sodium phosphate buffer (pH 8.0) to obtain a 4.69 µM solution.  For the hAChE-
induced assay, 4 µL of Aβ1-40 were incubated with 20 µL of hAChE to give a final concentration of 23.2 
µM of Aβ1-40 and 2.35 µM of hAChE (10:1 ratio).  For co-incubation experiments, 16 µL of test samples in 
215 mM sodium phosphate buffer pH 8.0 solution (6% DMSO) (final concentration 100 µM) were used. 
For the self-induced assay, 4 µL of Aβ1-40 was incubated with 16 µL of test samples in 215 mM sodium 
phosphate buffer pH 8.0 solution (6% DMSO) (final concentration 100 µM). The black Costar ®, clear 
bottom 96-well plates were incubated at room temperature for 24 hrs followed by the addition of 150 µL of 
15 µM of thioflavin T in 50 mM glycine-NaOH buffer (pH 8.5). The plate was gently rocked for 2 min. and 
the fluorescence was monitored at 446 nm (excitation) and 490 nm (emission) using a Molecular Devices 
SpectraMax spectrofluorometer. The fluorescence intensities in the presence and absence of inhibitors 
before and after the incubation period were compared and the percentage of inhibition was calculated with 
equation: 100% control value (i.e. no inhibitor) - [(IFi - IFo)] where IFi and IFo are the fluorescence 
intensities in the presence of ThT and absence of ThT before 24 hrs incubation, respectively. 
 
6.2.3. β-secretase Assay  
The instructions outlined in the PanVera ® BACE-1 screening kit (part # P2985; Madison, WI) were 
followed as directed with no deviations. Test samples were screened at various concentrations (0.1, 1, 10, 
50 and 100 µM) to obtain an IC50 value along with donepezil (product number D6821; Sigma-Aldrich, St. 
Louis, MO) and a peptidic derivative (product number 565749; EMD-Merck) as reference agents. The 
results were an average of duplicate readings (n = 2).  
 
6.2.4. MTT Assay  
The cell viability assay from Dr. Yang’s group (UCSD) was previously reported in Ref. 121 and the 
proceeding method was carried out Dr. Beazely’s group (UW). The SH-SY5Y neuroblastoma cells were 
plated at density of 4 x 105 per mL in 96-well plates with complete growth media consisting of DMEM and 
Ham’s F12 in a 1:1 ratio, supplemented with 2.5 mM glutamate and 10% fetal bovine serum at 37 °C in 5% 
CO2. The cells were incubated overnight and treated with the test samples at a 40 µM concentration, for 24 
hr at 37 °C (n = 4). The MTT in an amount equal to 10% of the culture medium volume was added to each 
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well and the cells were cultured for additional 3 hr at 37 °C in 5% CO2. After incubation, the resulting 
formazan crystals were solubilized with MTT reagent solution (10% Triton X-100 and 0.1 N HCl in 
anhydrous isopropanol) in each well and the absorbance was recorded at 570 nm. All results were 
expressed as a percent reduction of MTT relative to untreated controls. 
 
6.3. Computational Chemistry  
Docking experiments were performed using Discovery Studio Client v2.5.0.9164 (2005-09), 
Accelrys Software Inc. The X-ray crystal structure coordinates for hAChE, hBuChE and hBACE-1 were 
obtained from the RCSB Protein Data Bank (PDB: 1B41, 1P0I, 1FKN) and hydrogens were added. The 
ligand molecules were constructed using the Build Fragment tool and energy minimized for 1000 iterations 
reaching a convergence of 0.01 kcal/mol Å. Docking experiments were carried out using the Libdock 
command in the receptor-ligand interactions protocol of Discovery Studio and the energy-minimized 
ligands after defining a 10-12 Å sphere radius subset within the enzyme. The Chemistry at HARvard 
Macromolecular Mechanics (CHARMM) force field, was employed for all docking purposes. The ligand-
enzyme assembly was then subjected to a molecular dynamics (MD) simulation using Simulation protocol 
at a constant temperature of 300 K with a 100 step equilibration for over 1000 iterations and a time step of 
1 fs using a distance dependent dielectric constant 4r. The optimal binding orientation of the ligand-enzyme 
assembly obtained after docking was further minimized for 1000 iterations using the conjugate gradient 
method until a convergence of 0.001 kcal/mol Å was reached after which Eintermolecular (kcal/mol) of the 
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